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Summary
The incidence of fungal infections and particularly infections caused by non- 
albicans Candida species has increased considerably in the past two decades. The 
azole antifimgal drugs are central to the management of fungal infections and like the 
use of other antibiotics drug resistance has emerged. Factors associated with 
antifimgal resistance were investigated including azole susceptibility, drug 
accumulation and membrane sterol composition. Intracellular drug accumulation in 
Candida strains and species was examined and a clear correlation to microbial 
sensitivity was not observed. Also the membrane sterol profiles of some resistant 
strains were also altered with an increase in intermediates sterols, but no clear 
evidence of new mutants of sterol biosynthetic enzymes was uncovered. Some clinical 
strains were found to be resistant to specific azoles where other strains were resistant 
to a broad spectrum of azoles. The fimgal cell wall and its biosynthesis are essential 
for cell viability and as such are potential targets for novel antifimgal agents. CYP56 
in S. cerevisiae encodes a cytochrome P450 enzyme that catalyses the biosynthesis of 
dityrosine during spore wall biogenesis. The role of the C. albicans CYP56 gene in 
growth and drug susceptibility was investigated. The full-length CYP56 DNA 
sequence was determined and the gene disrupted using the SAT 1-flipper technique. 
The cyp56E mutant exhibited increased susceptibility to caspofungin and nikkomycin 
compared to the wild-type parental strain, whereas susceptibility to azoles and other 
metabolic inhibitors tested was unaffected. Phenotypically, the wild-type and mutant 
strains were morphologically similar on rich media, however in minimal media the 
cyp56A mutant exhibits hyphal growth in contrast to the yeast only form of the 
parental wild-type strain. Also the mutant failed to form chlamydospores. Over­
expression of CYP56 protein in E. coli produced a membrane-associated cytochrome 
P450 enzyme that catalysed the conversion of A-formyl tyrosine to A-formyl 
dityrosine when reconstituted with a fungal cytochrome P450 reductase in liposomes. 
The present study aimed to further the understanding of the biological, genetic and 
physiological aspects azole effect on clinical strains, on fungal CYPs (including 
CYP56) and for sterol biology associated with fungi, particularly in Candida species.
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Chapter 1
Introduction
1
1.1 Introduction
In recent years, fungal infections have increased markedly and one of the main agents 
is the opportunistic pathogen Candida albicans (Colombo et al., 2006, Capoor et al., 
2005). The first class of antifungal agents used in the medical field were polyenes 
reported in the 1950s (Holt, 1980). For about 30 years, amphotericin B was the one 
drug available to control severe systemic fungal infections. Although the first reports 
of the antifungal properties of N-substituted imidazoles were published in the late 
1960s, only in the 1980s was the imidazole ketoconazole and then the triazole 
fluconazole approved for use in the clinic that allowed further advances in fungal 
chemotherapy (Beck-Sague and Jarvis, 1993, Holt, 1980). However, the widespread 
use of the azoles resulted in resistance emerging. Consequently new antifungal drugs 
are now required (Kelly et al., 1993, Sanglard and Odds, 2002, Howard et al., 2006). 
Triazoles and their newer derivatives derive their antifungal activity through the 
inhibition of cytochrome P450-dependent 14a-sterol demethylation, an essential step 
in fungal sterol biosynthesis. Furthermore, combined therapies including azoles and 
non-azoles antifimgal drugs have been examined as an alternative treatment to 
overcome resistance (Steinbach et a l , 2003). The development of new antifimgal 
drugs with novel modes of action is required to combat the mortality rate associated 
with fungal infection and overcome resistance. The present work examines the 
prevalence of resistance mechanisms in Candida spp. and investigates the biology of a 
novel C. albicans cytochrome P450 as a new potential antifungal drug target.
2
1.1.1. Nomenclature of Cytochromes P450
Cytochrome P450 (CYP) is a generic term for a haem-containing superfamily of 
related, but distinct, oxidative enzymes important in biology. CYP was first described 
in 1958 (Klingenberg, 1958). The name refers to "pigment at 450 nm", so named for 
the characteristic Soret peak formed by absorbance of light at wavelengths near 450 
nm when the haem iron is reduced (e.g. with sodium dithionite) and complexed to 
carbon monoxide. CYP nomenclature, based on divergent evolution of the P450 
superfamily, was proposed and developed by Nebert and coworkers (Nelson et al., 
1996). Specifically, CYPs are classified into the same family (e.g. CYP1, 2, 3 etc) if 
they have >40% amino acid identity and the same subfamily if they share >55% 
amino acid identity (e.g. CYP1A, 2A, 3A etc). The rules can be more flexible if 
CYPs have the same function. (Gotoh, 1993, Roberts et al., 2002). Genes encoding 
for the CYP enzymes are designated with the abbreviation CYP, followed by an 
Arabic numeral indicating the gene family, a capital letter indicating the subfamily, 
and another numerals for the individual gene. The convention is to italicise when 
referring to the gene, but not the protein. For example, CYP2E1 is the gene that 
encodes for the enzyme CYP2E1 -  one of the enzymes involved in ethanol 
metabolism.
1.1.2. CYP function and properties
CYPs represent a great of phylogenetically diverse enzymes performing an array of 
endogenous and exogenous metabolism (Kelly et al., 2003, Nelson, 2003). CYPs 
play key roles in steroid hormone and sterol biosynthesis, the activation and
3
detoxification of many xenobiotics, the metabolism of polyunsaturated fatty acids 
(such as arachidonic acid and prostaglandins), activation of vitamins A and D3 to 
biologically active molecules, the synthesis of a vast array of secondary metabolites in 
plants, insects and microorganisms as well as the metabolism of contaminating 
environmental chemicals and carcinogens (Szczebara et al., 2003, Smith et al., 1993). 
CYP mixed-fimction monooxygenase systems are probably the most important 
element of metabolism of xenobiotics in animals. To metabolize such diverse 
substrates, CYP shows considerable molecular multiplicity. CYP sequence 
homologues have been determined in all lineages of life, including mammals, birds, 
fish, insects, worms, sea squirts, sea urchins, plants, fungi, slime moulds, bacteria and 
archaea (Gonzalez and Nebert, 1990, Nelson, 2003). However, many bacteria lack 
CYPs. It is believed that the multiple forms of CYPs may have been derived from a 
common ancestor by gene duplication and mutation during evolution (Kelly et al., 
2001).
1.1.3. CYP Localization
Most eukaryotic CYPs are membrane-associated proteins, either in the inner 
membrane of mitochondria or in the endoplasmic reticulum (ER) of cells. 
Endoplasmic reticulum located CYPs metabolise thousands of endogenous and 
exogenous compounds (Kelly et al., 2003) whilst mitochondrial CYPs are mostly 
involved in steroid biosynthesis. In humans the liver has the highest concentration of, 
CYPs and their substrates include drugs and toxic compounds as well as metabolic 
biproducts such as bilirubin (a breakdown product of hemoglobin). In contrast, 
bacterial cytochromes P450 are usually soluble and are involved in the production of
4
energy as well as participating in secondary metabolite pathways. Mitochondrial and 
bacterial CYP systems combine with NADPH-ferredoxin-dependent reductase and 
ferredoxin to form an electron transport chain. In contrast endoplasmic reticulum 
CYPs use NADPH dependent cyochrome P450 reductase (CPR) to transport electrons 
to allow completion of the catalytic cycle (Fig. 1.1). Reducing equivalents in the form 
of electrons are required for the molecular splitting of atmospheric dioxygen, with one 
atom being inserted into the substrate molecule and the secod atom being reduced to a 
water molecule. Due to their membrane-binding properties, eukaryotic CYPs have 
been difficult to purify and crystallize, but this has been achieved recently (Williams 
et al., 2000).
1.1.4. CYP structural architecture
The resolved crystal structures of many CYPs have now been reported beginning with 
P450cam (CYP101) from Psuedomonasputida (Poulos and Howard, 1987, Xiao et al., 
2004). The CYP molecule is a protein shaped like a triangular prism (Fig. 1.2). The 
number of CYP structures solved has increased considerably (Poulos et al., 1987, 
Podust et al., 2001, Lepesheva et al., 2006). The structure of CYPs is conserved 
however the position of various structural elements differs considerably contributing 
to their substrate specificity and stereo- and region-selectivity. Although the sequence 
identity between any two CYPs with resolved crystal structure may be only < 20%, 
the overall topology of the proteins has general similarity, with some differences in 
the orientations of various helices and protein domains. The most dramatic variations 
observed between CYP structures are found in regions responsible for substrate access, 
binding and catalysis.
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1.1.5. Molecular biology of CYPs
CYPs are mono-oxygenases and consisting of approximately 500 amino acids and 
containing a haem group at the active site. Many can metabolise multiple substrates 
as well as catalysing multiple reaction types (eg. Hydroxylation, epoxidation, 
demethylation, desaturation, dehalogenation) which accounts for their central 
importance in metabolising the potentially endless variety of endogenous and 
exogenous molecules. Generally, CYPs with endogenous biosynthetic functions 
seemingly have restricted substrate ranges and dedicated roles (eg CYPs involved in 
steroid biosynthesis).
Table 1.1. A list of organisms with CYPs in the database (October 2006) 
(http://dmelson.utmem.edu/CytochromeP450.htmlT The gene sequences for CYP 
enzymes deposited include approximately 6422 genes between the 708 families.
CYPs genes Families
Animals 2279 99
Plants 2311 94
Fungi 1001 282
Bacteria 621 177
Protists 210 51
Archaebacteria 8 5
Total 6422 708
8
1.1.6. Fungal CYP diversity
Fungal CYP was first identified in Saccharomyces cerevisiae (Lindenmayer and 
Smith, 1964) and this yeast system was extensively characterized by Yoshida and 
colleagues (eg. Yoshida and Aoyama, 1984). The P450 identified in this 
characterization was sterol 14a-demethylase and subsequently named CYP51 when 
the gene was cloned in the Loper laboratory (Kalb et al., 1987). CYP51 is the target 
for azole antifungal agents. In late 1970s, azole antifungal agents were shown to 
inhibit sterol 14a-demethylase in Ustilago maydis and C. albicans (Henry and Sisler, 
1978, Van den Bossche et al., 1978). Various azole compounds have been developed 
as potent antifungal agents (Sanati et al., 1997, Walsh et al., 2000, Wolff et al., 2006). 
Knowledge of fungal CYP51 has become indispensable in our understanding of the 
mechanism of action of azole antifungal compounds and for the development of more 
effective and safe azole derivatives. Since initial isolation of the CYP51 gene in 
yeast, CYP51 has been found to be widespread in eukaryotes and in some bacteria 
and hence is the only CYP family found in all the Kingdoms of Life (Fig. 1.3) 
(Stromstedt et al., 1996, Bak et al., 1997).
Although S. cerevisiae contained only three CYPs, it was anticipated that filamentous 
fungi would contain many more CYPs considering their abitility to produce diverse 
secondary metabolites and their capability in biotransformation. However, it was still 
very surprising when it was found that Aspergillus spp. contained over 100 CYPs, 
more than the 57 found in humans (Nelson, 2003, Mellado et al., 2002). Besides 
CYP51, fungal genome sequences also contain another CYP, CYP61, required to 
form the C-22(23) double bond in the sterol side chain in ergosterol biosynthesis 
(Kelly et al., 1995, Hata et al., 1981).
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Other characterised fungal CYPs include CYP52 (responsible for the terminal 
hydroxylation in the metabolism of alkanes and fatty acids, Sanglard and Loper, 
1989), CYP53 (responsible for benzoate hydroxylation), CYP54 (unknown function, 
van Gorcom et al., 1990), and CYP56 (a CYP catalysing dityrosine biosynthesis in the 
spore wall of S. cerevisiae, Briza et al., 1994, Smail et al., 1995). It was also 
suprising that a second CYP51 gene was discovery in the genome of A. fumigatus 
(Gollapudy et al., 2004, Mellado et al., 2001).
Infections caused by A. fumigatus have increased substantially in recent years, 
particularly with high mortality and morbidity in the immunocompromised host 
(Latge, 1999, Howard et al., 2006). A. fumigatus is intrinsically resistant to 
fluconazole which is used to treat C. albicans infections. However, the newer 
triazoles such as itraconazole, voriconazole and posaconazole are potent inhibitors in 
vitro and in vivo of this species (Mellado et al., 2004). Unfortunately, a number of A. 
fumigatus itraconazole resistant isolates have now been reported (Alcazar-Fuoli et al., 
2006, Denning et al., 1997). This may be due to the multiplicity of CYP51 in A. 
fumigatus due to their being two distinct and related CYP51 genes (Mellado et al., 
2001). Ergosterol depletion, coupled with the accumulation of methylated sterol 
precursors, has been indicated to affect both membrane integrity and the function of 
some membrane-bound proteins, including chitin synthase (Vanden Bossche et al., 
1987). This leads to an inhibition of fungal cell growth. In A. fumigatus azole 
resistance has been associated with reduced intracellular accumulation due to either 
increased expression of drug transporters as well as mutation of the cellular target 
CYP51, which decreases the affinity of the enzyme for azoles compounds (Alcazar- 
Fuoli et al., 2006, Mellado et al., 2004).
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1.1.6.1. The role of CYP56 in fungal biology
The cell wall is the outermost structure of yeast cells and it confers substantial 
mechanical strength with a dynamic plasticity, thus guaranteeing cell survival in a 
fluctuating environment. The yeast cell wall also constitutes a permeability barrier 
that has dramatic influence on the tolerance of yeast cells to damaging environmental 
agents. The combination of both characteristics requires a very complex cell wall 
whose biosynthesis and composition is only relatively recently beginning to be 
understood (Ram et al., 1998).
The C. albicans cell wall is composed mainly of mannan (linked with protein to form 
mannoprotein), a-glucan, P-glucan, and chitin, which are complex polymers of 
mannose, glucose, and 7V-acetylglucosamine, respectively. The content and 
distribution of these components vary with cell age, culture conditions, and 
morphology (Brown et al., 2000, Bogengruber et al., 1998, Ruiz-Herrera et al., 2006). 
The linkages between the glucan, chitin, and mannoprotein components are poorly 
understood but presumably play a critical role in maintaining the integrity of the cell 
wall and hence the viability of the organism.
Yeast cells have a thick cell wall that maintains cell shape, protects against osmotic 
stress and requires modification for both oval and dimorphic cell growth. The 
polysaccharide scaffold that strengthens the cell wall consists of a flexible network of 
branched 1,3-P-glucan, to which 1,6-P glucan and chitin are attached by their reducing 
ends, with some chitin attached directly to 1,6-P-glucan (Ruiz-Herrera et al., 2006). 
The fate of proteins targeted for extracellular localization is varied, as are the changes
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associated with modification of the cell wall in the dimorphic yeast C. albicans during 
morphogenesis (Nombela et al., 2006). The evidence accumulated during the past 
decade, using the two current yeast models S. cerevisiae and C. albicans, clearly 
shows that many proteins that lack an N-terminal signal peptide also reach the cell 
surface. The initial discovery of these proteins outside the plasma membrane was 
totally unexpected. Recent evidence suggests that these peptides may be involved in 
several processes, including cell-wall dynamics and interactions with host 
components. Due to the data not being consistent with the classical export route, 
which is based on canonical N-terminal signal peptides, it can only be interpreted in 
terms of other mechanisms.
As a response to nitrogen starvation, in the presence of a poor carbon source, 
MATsJMAT-alpha diploid cells of the baker’s yeast S. cerevisiae exit the cell cycle, 
undergo meiosis, and form haploid spores (Coluccio and Neiman, 2004). These spores 
are a quiescent, stress-resistant cell type that can survive until nutrients become 
available. The spore wall is a stratified extracellular matrix that is more complex than 
the normal vegetative cell wall (Klis et al., 2006, Smits et al., 2001). The vegetative 
wall consists primarily of an inner layer (closest to the plasma membrane) of P- 
glucans interspersed with a small amount of chitin and an outer layer of heavily 
mannosylated proteins (mannans) (Smits et al., 1999, Klis et al., 2006). By contrast, 
the spore wall consists of four distinct layers. The first two strata consist of an 
innermost layer composed primarily of mannan and a second layer of P-1-3-linked 
glucans, which are similar in composition to the vegetative wall but are reversed in 
position with respect to the spore plasma membrane (Kreger-Van Rij, 1978). The 
outer portion of the spore wall is comprised of two polymers that are unique to the
13
spore and confer much of the spore’s resistance to environmental damage (Pammer et 
al., 1992, Briza et al., 1994). Immediately outside of the p-glucan is a layer composed 
primarily of chitosan, a glucosamine polymer synthesized by the deacetylation of 
chitin (Mishra et al., 1997, Pammer et al., 1992). Outside of the chitosan is a layer that 
consists largely of cross-linked dityrosine molecules (Briza et al., 1988, Briza et al., 
1990a, Briza et al., 1994). In addition to being more complex than the vegetative cell 
wall, the spore wall is also unique in that it is constructed without a preexisting matrix 
to act as a template.
Studies of the Candida cell surface (Shepherd, 1987) have been of particular interest 
for a number of reasons including its importance in antigenicity (Calderone and Braun, 
1991, Smail and Jones, 1984), in adherence to epithelial and endothelial cells 
(Calderone and Braun, 1991), and in interactions with the host immune system (Smail 
and Jones, 1984, Smail et al., 1988). Furthermore, the mechanisms of cell wall 
biosynthesis are critical for our understanding of cell morphogenesis and may provide 
novel targets for the development of new antifungal agents (Hector, 1993). The 
linkages between the glucan, chitin, and mannoprotein are poorly understood and 
dityrosine is well known as a crosslinking agent that is involved in the resistance of 
several fungal species to adverse environmental conditions. Smail et al. 1995 (Smail 
et al., 1995) described observations which indicated that under certain conditions the 
cell wall of C. albicans contains dityrosine, but this has hitherto not been described 
experimentally.
S. cerevisiae mutants deficient in spore wall dityrosine were isolated by Pammer et al. 
(Pammer et al., 1992). Most of the mutant spores lacked only the outermost,
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dityrosine-rich layer of the spore wall. However, mutant ditlOl was found to be 
lacking the chitosan layer of the spore wall. Chemical measurements showed that this 
mutant does not synthesize chitosan during sporulation. The decrease in the amount of 
chitin in vegetative cells and the absence of chitosan in spores suggested that mutant 
ditlOl could be defective in a chitin synthase. Indeed, a genomic yeast clone 
harboring the gene, CSD2, sharing significant sequence similarity with yeast chitin 
synthases I and II (Bulawa, 1992), complemented their mutant and was shown to 
correspond to the chromosomal locus of ditlOl. S. cerevisiae contains only 2-3% of 
chitin in its cell walls. However, the synthesis of this polymer seems to be essential 
for cell survival (Selvaggini et al., 2004).
The proposed pathway of dityrosine biosynthesis in sporulating S. cerevisiae cells 
indicated that two tyrosine molecules are covalently cross-linked to form dityrosine, 
and the enzyme responsible for this reaction is a member of the cytochrome P450 
superfamily (named Dit2p also CYP56, Briza et al., 1994). CPR was essential for 
dityrosine formation because it provides reducing equivalents to CYP56 which are 
essential for catalysis. The first description of the chemical synthesis of dityrosine 
formation was in 1959 by Gross and Sizer (Gross and Sizer, 1959), who achieved this 
feat by the oxidation of tyrosine with hydrogen peroxide and peroxidase. Dityrosine is 
an intensely fluorescent compound and thought to arise via the cross-linkage of two 
tyrosyl radicals (Briza et al., 1986). Cross-links can be formed between existing 
tyrosine residues in structural and non-structural proteins, and also between soluble 
tyrosine residues (Amado et al., 1984). Dityrosines can also be obtained under a 
variety of laboratory-based conditions. Dimerization of the monomer can occur via 
oxidative coupling with reagents such as VOF3 . Alternatively, dimerization can occur
15
via reductive coupling using potassium hexacyanoferrate (III). These methods can 
dimerize simple tyrosines, however they fail to dimerize full-length peptides.
1.1.7. Mechanism of reaction of CYPs
During typical eukaryotic monooxygenation of substrates, CYP requires NADPH, a 
reductase partner (usually CPR) and molecular oxygen. The CYP catalytic cycle is 
illustrated in Fig. 1.1 The catalytic reaction is initiated by the binding of the substrate 
(AH) with the oxidized form (Fe3+) CYP. Subsequently, the P450(Fe3+)-AH bound 
complex is reduced by the first electron and and the haem can then bind 02 to form the 
P450(Fe2+)-AH-02 ternary complex. Carbon monoxide interferes with binding of 02 
to P450-AH and inhibits the catalytic cycle at this first step. The second electron is 
then transferred into the ternary complex. The oxygen is activated (P450(Fe2+)-AH- 
02'), and one oxygen atom attacks the substrate to form an oxygenated product AOH 
whilst the other is reduced to H20 with P450(Fe3+) being restored. The two electrons 
consumed during the catalytic reaction are usually supplied from NADPH via CPR 
although the cytochrome b5/NADH cytochrome b5 reductase system can replace CPR 
in S. cerevisiae (Venkateswarlu et al., 1998). In the case of CYP51 the catalytic 
reaction was demonstrated previously (Shyadehi et al., 1996) and is illustrated in the 
Fig. 1.4.
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1.1.8. Spectral change of CYPs on substrate binding
Binding of a substrate to oxidized CYP generally causes spectral change as measured 
spectrophotometrically between the wavelengths 500nm -  400nm. A substrate 
spectral change can be classified into two categories, Type I and II, which are based 
on the absorbance minimum and maximum of the resulting spectra. The substrate 
spectral change is originated by the displacement of a sixth ligand water molecule of 
the oxidized CYP and the binding of the substrate to the active site. The type I 
spectral change represents the low to high spin state transition with a spectral 
minimum absorption at approximately 420 nm and spectral maximum absorption at 
approximately 390 nm (Sibbesen et al., 1995). In contrast, a type II spectrum exhibits 
a spectral maximum absorption at approximately 430 nm and a spectral minimum 
absorption at approximately 410 nm corresponding to a ligand-bound low spin 
complex and results from an atom containing a lone electron pair in the binding 
molecule interacting directly with the Fe atom in the haem. Substrate spectral changes 
provide information on the mode of interaction of a substrate/ inhibitor with CYP. 
Usually, potential CYP substrate molecules induce Type I spectra whilst CYP 
inhibitors induce Type II spectra. An example of an azole binding spectrum to P450 is 
illustrated in the Fig. 1.5.
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1.2. The biology of Candida spp.
1.2.1. General aspects
In 1839, Lagenbeck was the first to demonstrate the presence of a yeast-like fungus 
growing as a parasite on oesophageal mucosa in a patient who had died from typhoid 
fever. He also discovered that the fungus was able to cause thrush,. The genus 
Candida, species albicans, was first described by Christine Marie Berkhout. She 
described the fungus in her doctoral thesis at the University of Utrecht in 1923. Over 
the subsequent years the classification of the genus and species has evolved. Obsolete 
names for this genus include Mycotorula and Torulopsis. The species has also been 
known in the past as Monilia albicans and Oidium albicans. The current classification 
is nomen conservandum, which means the name is authorized for use by the 
International Botanical Congress (IBC). The genus Candida includes approximately 
150 different species. Many different Candida spp have been implicated in causing 
human infections. C. albicans is the most significant of these species (Odds, 1984, 
Ruchel, 1989). Other Candida species responsible for human disease include Candida 
tropicalis, Candida glabrata, Candida krusei, Candida parapsilosis, and Candida 
lusitaniae.
In the 1970s and 1980s, C. albicans isolates were shown to exist in a diploid state and 
there was no evidence suggesting a sexual reproductive cycle (Olaiya and Sogin, 1979, 
Whelan et al., 1980, Riggsby et al., 1982). This was surprising given the close 
relationship of C. albicans to other sexually reproducing yeast species such as S. 
cerevisiae and Kluyveromyces lactis. Furthermore, by the mid-1990s several S.
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cerevisiae genes known to function in mating and meiosis were found to have close 
orthologues in C. albicans (Bennett and Johnson, 2005). Some of the C. albicans 
orthologues can even substitute for their disrupted S. cerevisiae counterparts when 
expressed in S. cerevisiae (Magee and Magee, 2000, Weber et al., 2002). In recent 
years, this list has grown much longer owing to the sequencing of the C. albicans 
genome. However, since the discovery of C. albicans mating in 2000 (Magee and 
Magee, 2000, Hull et al., 2000), experiments carried out in several laboratories have 
revealed that C. albicans contains an elaborate mating program that has many 
similarities but also many major differences when compared with those of other fungi.
1.2.2. Candida taxonomic classification
The origin of the fungi is very ancient. They first appeared in the fossil records, 
coincidentally with the appearance of the land plants, in the Devonian period around 
400 million years ago. The early microscopists found that fungi were simple to study 
and they first observed division of cells by observing yeasts grow under the 
microscope. Early biological science was focused with categorizing microrganisms 
and researchers constructed taxonomic systems based solely on structure. However, 
for the fungi this created a polyphyletic group that contained microorganisms which 
had very different ancestors (Schauer and Hanschke, 1999). Fungi are referred to as 
the True Fungi, or Eumycota, and are currently divided into four major phyla on the 
basis of their morphology and sexual reproduction. New information based on the 
presence and type of mitochondria, and DNA sequencing of ribosomal RNA, place 
the members of the fungi into a complex phylogenetic tree. For example, in 
taxonomic terms C. albicans is: Kingdom: Fungi, Phylum: Ascomycota, Subphylum:
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Ascomycotina, Class: Ascomycetes, Order: Saccharomycetales, Family:
Saccharomycetaceae and Genus: Candida. Synonymy: Saccharomyces albicans 
(C.P. Robin) Reess, (1877), Monilia albicans (C.P. Robin) Zopf, (1890), 
Parasaccharomyces albicans (C.P. Robin) Mello & L.G. Fern. (1918), Procandida 
albicans (C.P. Robin) E.K. Novak & Zsolt, Acta Botanica Hungarica 7: 133 (1961), 
today Candida albicans (C.P. Robin) Berkhout 1923 
(http ://www. indexfungorum. org/).
1.2.3. Candida spp. and clinical infections
The genus Candida includes around 154 species (Odds, 1984, Sullivan et al., 1995). 
While Candida albicans is the most abundant and significant infectious species, 
Candida tropicalis, Candida glabrata, Candida parapsilosis, Candida krusei, and 
Candida lusitaniae are also isolated and deemed causative agents of Candida 
infections (Nguyen et al., 1996b). HIV-infected patients often suffer severe forms of 
oropharyngeal candidosis, mainly caused by C. albicans, although over the last 
decade the reported incidence of infections caused by other Candida species has 
increased significantly (Nguyen MH, 1996). C. dubliniensis is a recently identified 
yeast and closely related to Candida albicans phylogenetically, (Schorling et al., 2000, 
Sullivan et al., 1995, Sano et al., 2000) and has been mostly isolated in HIV-infected 
individuals with oral candidosis (Sullivan et al., 1995, Sano et al., 2000). C. 
dubliniensis has also been recovered from the oral cavities of asymptomatic and 
symptomatic immunocompetent individuals, although to a much lesser extent. A 
major obstacle in the treatment of Candida infections is the spread of antifungal drug 
resistance mainly in patients chronically subjected to antimycotic therapy. Patients
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receiving fluconazole prophylaxis are particularly at risk of developing infections. 
Furthermore, the diversity of Candida spp. that are encountered in infections is 
expanding and the emergence of other species that were rarely in play as pathogens in 
the past is now observed (Nguyen et al., 1996a, Melo et al., 2004, Agarwal et al.,
2004).
1.2.4. Candida Macroscopic and Microscopic Features
The colonies of Candida spp. are cream /yellowish coloured and grow rapidly in 2 
days. The texture of the colony may be pasty, smooth, glistening or dry, wrinkled and 
dull, depending on the species. The microscopic features of Candida spp. also show 
species-related variations. All species produce blastoconidia singly or in small clusters 
(Sudbery et al., 2004). Most species produce pseudohyphae which may be long, 
branched or curved. True hyphae and chlamydospores are produced by strains of 
some Candida spp., including C. albicans. Most Candida species are dimorphic, 
showing biochemical and structural as well as morphological differences between the 
different forms.
Environmental regulation of morphology is complex and incompletely understood 
(Calderone and Fonzi, 2001). The yeast form is a spherical or ovoid budding 
unicellular form and can be found living commensally on the body surface or in the 
gastrointestinal tract and/or vagina. Candida spp. can switch to (True) hyphae 
(mycelia filaments), which can be found invading tissue during a disease process and 
in the laboratory under certain conditions of growth, e.g., 37°C, neutral pH, presence 
of serum (approximate conditions during tissue invasion). Considering the association
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of temperature with dimorphism, C. albicans behaves in an opposite manner to the 
systemic dimorphic fungal pathogens (that are hyphal at room temperature and yeast­
like at 37°C). In addition C. albicans can also grow as pseudohyphae, with chains of 
elongated yeasts, generally budding in a polar fashion with occasional branches. Germ 
tubes (extensions) arise from yeast cells (Gow, 1997), and they are different from a 
bud arising from a mother cell, and can extend to form hyphae or pseudohyphae. In 
any particular clinical specimen, a variety of forms may be observed. Yeast cells may 
be associated with normal commensal existence but also with some disease processes. 
The other forms (hyphae, pseudohyphae, and germ tubes) may be grouped together 
and are associated with deep tissue invasion (Gow et al., 2002, Calderone and Fonzi, 
2001).
1.2.5. General aspects of Candidosis
Infections caused by Candida spp. are in general referred to as candidosis. Candida 
exist as a member of the normal flora of skin, mouth, vagina, and stool. As well as 
being pathogens, other Candida species are found in the environment, particularly on 
leaves, flowers, water, and soil.
Systemic fungal infections (fimgaemias) have emerged as important causes of 
morbidity and mortality in immunocompromised patients {e.g., AIDS, cancer 
chemotherapy, organ or bone marrow transplantation) (Campisi et al., 2002, 
Kovacicova and Krcmery, 2001, Krcmery et al., 1999, Krcmery and Barnes, 2002, 
Matsumoto et al., 2002). In addition, hospital-related fungal infections in patients not
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previously considered at risk (e.g. patients in intensive care units) has become a major 
cause of health concern (Collin et al., 1999).
The clinical spectrum of candidosis is extremely diverse (Weinberger et al., 2005). 
Almost any organ or system in the body can be affected. Candidosis may be 
superficial and local or deep-seated and disseminated. Disseminated infections arise 
from the haematogenous spread from the primarily infected locus (Calderone and 
Fonzi, 2001, Cassone et al., 1981). The ability to adhere to host tissues, produce 
secretory aspartyl proteases and phospholipase enzymes, and transform from the yeast 
to hyphal phase are the major determinants of its pathogenicity. Several host factors 
predispose a patient to candidosis such as physiological (pregnancy, age), trauma 
(maceration, bum, infection), haematological (neutropenia, AIDS, immunodeficiency), 
endocrinological (diabetes mellitus, hypoparathyroidism), iatrogenic 
(chemotherapeutics, corticoteroids, oral contraceptive, catheters) (Sobel and Vazquez, 
2003, Matsumoto et al., 2002) and others (intravenous drug addiction, malnutrition) 
(Attia and Zaoutis, 1999). Candidosis is mostly an endogenous infection, arising 
from overgrowth of the fungus inhabiting in the normal flora. However, it may 
occasionally be acquired from exogenous sources (such as catheters or prosthetic 
devices) or by person-to-person transmission (such as oral candidosis in neonates of 
mothers with vaginal candidosis or endophthalmitis following comeal transplantation 
from an infected donor) (Frezzini et al., 2005).
1.2.6. The completed sequence of the G albicans genome
The C. albicans genome was sequenced using the strain SC5314 and results deposited 
in the databases in 2004 (Nantel, 2006, Jones et al., 2004). One of the most
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interesting features of the C. albicans genome was the occurrence of structural 
chromosomal rearrangements as means of generating genetic diversity, chromosome 
length polymorphisms (contraction/expansion of repeats), reciprocal translocations, 
chromosome deletions and trisomy of individual chromosomes (Jones et al., 2004). 
These karyotypic alterations lead to changes in phenotype, which is a survival 
adaptation strategy for this fungus. C. albicans genome sequence confirmed eight 
chromosomes (historically named 1-7 and R) and these constitute a haploid genome 
size of 14,851 kilobases (kb), containing 6,419 open reading frames (ORFs) longer 
than 100 triplets, of which some 20% have no known counterpart in other available 
genome sequences. C. albicans is a diploid organism with no known haploid phase, 
and for a long time it was considered to be asexual. Early assemblies of the C. 
albicans genome sequence revealed a mating-type (MAT-like) locus that led to the 
engineering of mating competent strains (Hull and Johnson, 1999). The assembly of a 
complete C. albicans diploid genome sequence for SC5314 has allowed a reliable 
estimate of the frequency of heterozygosities which occurred 4.21 polymorphisms per 
kb, or 1 polymorphism per 237 bases (Jones et al., 2004). These heterozygosities are 
distributed across the C. albicans genome, with the highest prevalence being found on 
chromosomes 5 and 6. Genome sequencing has altered our understanding of this 
organism and allowed numerous experimental approaches to be undertaken including 
some described in this thesis.
1.4. Candida spp. antifungal resistance
The term “microbial resistance” describes the relative insensitivity of a microbial 
organism to an antimicrobial drug as tested in vitro and when compared with other
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isolates of the same species. In contrast, clinical failure describes the failure of an 
appropriate therapy for a certain indication to result in a clinical response. The reason 
for clinical failure may be, for example, antifungal resistance, an impaired immune 
function, poor bioavailability of the drug given, or an accelerated metabolism of the 
drug (Rex et al., 1997, Rex et al., 2001, Oakley et al., 1998, Verweij et al., 1998, 
Dannaoui et al., 2000).
Different types of antifungal resistance have also been defined. Primary (intrinsic) 
resistance occurs in organisms never previously exposed to the drug of interest. In 
contrast, secondary (acquired) resistance arises only after exposure of the organism to 
the drug.,In addition, the term “clinical resistance” can be used to describe failure of 
therapy or relapse of infection. In vitro and in vivo correlations for microbial 
susceptibility in relation to therapeutic response abound in mycology, which 
emphasise the predictive value of standardized testing (Rex et al., 2001, Pfaller et al., 
2005). The National Committee for Clinical Laboratory Standards has published a 
standardized method (M27-A) for antifungal susceptibility testing of yeast (National 
Commitee for Clinical Laboratory Standard, 2002) and has proposed a standardized 
method for testing filamentous fungi (M38-P). The antifungal therapeutic choice is 
based on criteria such as the immune status of the patient, site of infection, 
characteristics of the infection (the fungal species and its susceptibility to different 
antifungal drugs), and the pharmacokinetic characteristics of the drug (e.g., absorption, 
elimination, and toxicity) (Calderone and Fonzi, 2001, Gonzalez et al., 2005, 
Maertens, 2004). Only a limited number of antimycotic drugs are available for the 
treatment of systemic fimgal infections (Fig. 1.6).
27
O
Nmcoo35=
m
co
l_0)
o
- Ca
E
ro
o - o - o
Xo
X-o
a:
oN
03
C
Qa*iZ
O>
2
a>
oKl(0
c
ooCD
T-
O
0=0
flj
o
N<0cooo*-*<D
00(N
5 /3sO•cfl
o
c«VSm
u
u■+■»
C /3
fl c«
Sa>J=
U
fl
W)
fl
V ©
aW) 
fl
-  <2
.8 ^  & a
m
kk
om
yc
in
The mode of action of the most important antifungal drugs can be divided into five 
classes (Vanden Bossche et al., 1987, Ryder, 1991). These are as follows: (1) polyene 
macrolides that lead to an alteration of membrane functions (e.g. amphotericin B); (2) 
sterol biosynthesis inhibitors; (a) inhibitors of CYP51 (e.g. azole derivatives - 
fluconazole, itraconazole, and voriconazole),) and (b) inhibitors of squalene epoxidase 
(e.g. allylamines - naftifine, terbinafine); (3) DNA and RNA synthesis inhibitors (e.g. 
flucytosine); (4) 1,3-P-glucan synthase inhibitors (e.g. echinocandins) and (5) chitin 
synthase inhibitors (e.g. nikkomycin). Azole antifungals, such as fluconazole and 
itraconazole are most commonly used to treat Candida spp. infections. Due to the 
repeated use of these agents, especially in HIV-positive patients with recurrent 
oropharyngeal candidosis, treatment failures linked to the emergence of azole- 
resistant C. albicans strains are often observed. Additionally, the emergence of 
candidosis caused by non-albicans species and aspergillosis, which exhibits low 
antifungal susceptibility, has also been related to the spread of antifungal resistance 
(Howard et al., 2006, Weinberger et al., 2005).
1.4.2. Antifungal agents
1.4.3. Amphotericin B and other polyenes
Amphotericin B is a polyene antifungal agent, first isolated by Gold et al. from the 
bacterium Streptomyces nodosus in 1955 (Donovick et al., 1955). Amphotericin B is 
active against a wide variety of fungi, including yeasts and moulds such as Candida 
spp., Aspergillus spp., Cryptococcus neoformans, Zygomycetes, dimorphic fungi, and 
some dematiaceous fungi. The interaction between amphotericin B and human cell
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membranes containing cholesterol results in toxic side effects of the drug. The most 
important side effect is an impairment of renal function due to decreased filtration in 
the glomeruli (Holt, 1980, Ernst et al., 2002). This results in limited application of 
amphotericin B as an antifungal and it is commonly used as a drug of last resort.
The NCCLS method is not yet sufficient for the discrimination of amphotericin B- 
resistant isolates from the susceptible ones, primarily due to the narrow range of MICs 
that it generates for all test strains (Johnson et al., 2000). Amphotericin B binds to 
sterols, preferentially to the the fungal cell membrane sterol (ergosterol), resulting in 
the formation of pores in the membrane (Prasad, 1997). Consequently, osmotic 
integrity of the fungal membrane is disrupted resulting in leakage of intracellular 
potassium, magnesium, sugars, and metabolites and ultimately leading to cellular 
death. In higher concentrations, polyenes also inhibit chitin synthase, a cell wall 
synthetic enzyme localized in the membrane. The classic amphotericin B 
deoxycholate formulation has been available since 1960. While efforts to develop a 
novel relevant methodology for amphotericin B susceptibility testing are in progress, 
amphotericin B has proven to be fungicidal against Candida spp. strains.
Reports of amphotericin B resistance are limited. Primary resistance to amphotericin 
B exists in some isolates of Candida lusitaniae (Yoon et al., 1999), C. lipolytica, and 
C. guillermondii (Redding et al., 2000, Krcmery and Barnes, 2002). Secondary 
resistance has occasionally been described in Candida spp. as well as in C. 
neoformans (Kelly et al., 1994). Whether repeated treatment with amphotericin B, or 
other factors such as treatment with immunosuppressive chemotherapy, is responsible 
for polyene resistance remains to be clarified. Reasons for recurrence of infection may
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be poor penetration of the drug, inconsistent compliance with other drug regimens, or 
deterioration of the immune system of the host. It has been hypothesized that 
concurrent or previous therapy with azoles might lead to amphotericin B resistance 
(Johnson et al., 2000).
I.4.3.I. Mechanism of resistance of polyenes
The cause of resistance to polyenes is usually a significant alteration of the sterol 
composition in the fungal plasma membrane (e.g., a reduction in the ergosterol 
content due to a lack of the A(8,7) isomerase) (Hitchcock et al., 1987). This 
circumstance leads to a lower affinity of amphotericin B for the predominant sterols 
other than ergosterol in the membrane. (Joseph-Home et al., 1996, Ghannoum and 
Rice, 1999). Polyene resistance through altered sterol composition in the membrane 
can result from mutations in the enzymes involved in fungal ergosterol biosynthesis. 
Kelly et al. observed cross-resistance to amphotericin B in two fluconazole-resistant 
C. albicans strains isolated from patients with AIDS(Kelly et al., 1996). These strains 
accumulate 14a-methylfecosterol instead of the toxic 14a-methylergosta-8,24-dien- 
3p,6a-diol seen in wild-type and hence can grow. This specific change results from 
mutations in sterol C5-desaturase so that in the absence of azole ergosterol does not 
accumulate (ergosta-7 and ergosta-7,22-dienol does) and thus the strains became 
resistant to amphotericin B. The same group reported two amphotericin B-resistant 
mutants of Ustilago maydis with cross-resistance to nystatin. An alteration of the 
ergosterol biosynthesis was precluded as the cause of polyene resistance in these 
isolates (Kelly et al., 1997b, Sanglard and Odds, 2002). Treatment with amphotericin 
B is often guided by toxicity rather than by therapeutic efficacy, whereas lipsosomal
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formulations have reduced toxicity, thus allowing higher doses to be administered 
(Gokhale et al., 1993, Walsh et al., 2004).
Besides altered ergosterol content other mechanisms of resistance to amphotericin B 
appear to operate. For example, in a highly resistant strain of A. terreus it was shown 
that the major sterol in its plasma membrane was ergosterol (Dannaoui et al., 2000). 
Another cause for amphotericin B resistance may be an altered content of (3-1,3 
glucans in the fungal cell wall. These components, which increase the stability of the 
cell wall, influence the access of large molecules such as amphotericin B to the 
plasma membrane sterol. Seo et al. showed that alteration of glucans also led to 
amphotericin B resistance inA.flavus (Seo et al., 1999).
1.4.4. Azoles antifungal compounds
In the 1970s, a new class of antimycotic drugs was developed, the azoles. The first 
azole that was available for systemic use was clotrimazole. However, its use was 
limited largely because of inconsistent concentrations in the blood. Miconazole was 
the first effective azole for systemic infections, but its use was also limited because it 
can only be given intravenously and it offered few advantages over amphotericin, 
aside from lessened toxicity (Prasad and Kapoor, 2005). Recently, ketoconazole is the 
only member of the imidazole class of azole antfungal that is currently used for the 
treatment of systemic fungal infections. Ketoconazole was the first azole to be 
available as an oral formulation and showed consistent blood levels (Utz, 1980). 
Additionally, ketoconazole showed reported activity against Coccidioides, 
Histoplasma, Blastomyces, and dermatophytes. However, in addition to
32
ketoconazole’s rare hepatotoxicity, resistance was described, especially in patients 
with mucocutaneous, oropharyngeal and oesophageal candidosis (Powderly et al., 
1999, Korashy et al., 2007). It now used clinically as an alternative drug for specific 
indications. Itraconazole, a triazole antifungasl, is available for oral and intravenous 
administration. Itraconazole shows broad in vitro activity against Candida spp., but 
also against Aspergillus spp. and dimorphic fungi.
Fluconazole, another triazole that can be administered orally and intravenously, is 
used for the treatment of oropharyngeal and oesophageal candidosis in patients with 
AIDS as well as in neutropenic patients (Ullmann and Comely, 2006). Fluconazole 
has only limited activity against moulds and other filamentous fungi. Use of 
fluconazole in prophylaxis has resulted in a shift of host flora to resistant species. 
Voriconazole, structurally related to fluconazole, shows an activity spectrum similar 
to that of itraconazole. It is active against C. krusei, C. guillermondii, and C. 
lusitaniae (Zaragoza and Peman, 2006, Maschmeyer and Ruhnke, 2004, Tortorano et 
al., 2003). Walsh et al. published a randomized, international, multicenter trial 
comparing voriconazole with liposomal amphotericin for empirical antifiingal 
treatment (Walsh et al., 2002). They concluded that voriconazole is a more suitable 
alternative to amphotericin preparations in antifungal treatment, particularly in 
patients with neutropenia and persistent fever. Voriconazole was approved in the 
United States for limited use in May 2002.
Posaconazole and ravuconazole, two additional triazoles, are currently under 
investigation. Posaconazole has in vitro and in vivo activity against aspergillosis 
(Walsh et al., 2007), cryptococcosis, and coccidioidosis as well as candidosis
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(Gonzalez et al., 2005, Nguyen et al., 1995). Ravuconazole shows in vitro activity 
against dimorphic fungi, such as Coccidioides, Histoplasma, and Blastomyces, as well 
as against Aspergillus, Fusarium, and fluconazole-sensitive and -resistant Candida 
species (e.g., C. krusei), and also against important dermatophytes (Gonzalez et al.,
2005).
Azoles act as ergosterol synthesis inhibitors by binding to and inhibiting the activity 
of CYP51, an enzyme essential in the ergosterol biosynthesis pathway. Ergosterol is 
the most prevalent sterol in the fungal plasma membrane (Loffler et al., 2000). The 
active site of CYP51 contains a Fe-containing haem domain and azoles bind via a 
specific nitrogen atom in the azole ring nucleus to the Fe atom (Lamb et al., 1999). 
Azoles may also target lipids of the fungal plasma membranes and may interact in 
some fungi with another ergosterol biosynthetic enzyme, 3-ketosteroid reductase, an 
enzyme essential in C4- demethylation (Vanden Bossche et al., 1993).
1.4.4.1. Mechanisms of resistance of azoles
1.4.4.2. Alteration of the target enzyme
Alterations in the primary sequence of CYP51, defined by point mutations in the 
CYP51 gene, have been described to be associated with azole resistance. Amongst 
many point mutations only two have been biochemically characterised. White 
described the presence of the amino acid substitution of lysine for arginine at position 
467 (R467K) in C. albicans CYP51 (Lamb et al., 2000, White, 1997). This 
substitution is located near the haem cysteine ligand and thus probably causes 
structural alterations so that the azole binds with less affinity. Another substitution at
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amino acid 464 (G464S) in azole-resistant C. albicans isolates has also been described 
(Sanglard et al., 1998b). Kelly et al. (Kelly et al., 1999) confirmed that this mutation 
results in changes in the haem-binding domain, causes fluconazole resistance through 
reduced affinity probably via perturbation of the haem environment. Fluconazole 
enters the active binding site through an access channel and mutations therein may 
affect the binding of inhibitors.
1.4.4.3. Alteration in ERG3
Altered sterol A(5,6) desaturase (ERG3) is another explanation for azole resistance. In 
azole-sensitive strains treated with azoles, the sterol 14-methyl-3,6-diol accumulates 
leading to a fungistatic effect, whereas in erg3 mutants (due to mutations in the gene 
rendering the enzyme inactive), the substrate of sterol A(5,6) desaturase accumulates, 
which can support growth of the fungal cell. In S. cerevisiae, 120 fluconazole- 
resistant isolates were found to have altered ERG3 activity. It has been shown that 
ERG3 mutations alone can cause azole resistance in S. cerevisiae (Watson et al., 1989, 
Arthington et al., 1991, Kelly et al., 1995). In C. albicans, Kelly et al. demonstrated 
that resistance was caused by defective sterol A(5,6) desaturase in two clinical isolates 
from patients with AIDS, leading to an accumulation of 14-methylfecosterol under 
azole treatment and ergosta-7,22-dienol without treatment (Kelly et al., 1997a). A 
consequence of this mechanism of resistance is that an absence of ergosterol causes 
cross-resistance to amphotericin as discussed previously.
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1.4.4.4. Alteration of drug efflux
It has been demonstrated on many occasions that C. albicans can respond to 
antifiingal challenge by developing specific resistance mechanisms. Several molecular 
studies have identified drug transporters being responsible for resistance in clinical 
isolates (Sanglard et al., 1995, Sanglard et al., 1998a, Magill et al., 2006, Ferreira et 
al., 2005, Prasad and Kapoor, 2005).
Recent genome sequencing data and numerous biochemical and molecular genetic 
investigations have revealed the occurrence of families of primary and secondary 
transporter proteins. Two such families, ATP-binding cassette (ABC) superfamily 
(White et al., 2002) and the major facilitator superfamily (MFS), have been found to 
occur ubiquitously in all fungi. While the ABC family are primary active transporters, 
capable of transporting both small molecules and macromolecules in response to ATP 
hydrolysis (Prasad and Kapoor, 2005), the MFS transporters are secondary carriers 
capable only of transporting small solutes in response to chemiosmotic gradients. 
Although well over 100 families of transporters have now been identified and 
classified, the ABC superfamily and MFS account for nearly 50% of the solute 
transporters encoded within the genomes of microorganisms (Gbelska et al., 2006).
In C. albicans one of the well-documented mechanisms of resistance to azole 
antifungal agents is the upregulation of multidrug transporter genes (Prasad et al., 
1995, Prasad and Kapoor, 2005, Niimi et al., 2006, White et al., 2002). The 
upregulation of multidrug transporter genes leads to the enhanced efflux of azoles and 
therefore results in decreased intracellular concentrations of the drug and hence
36
reduced inhibition of their target encoded by the CYP51. Cdrlp and Cdr2p from the 
family of ABC transporters and CaMDRlp (C. albicans multidrug resistance 1) from 
the family of MFS transporters are the principal mediators of resistance to azoles due 
to transport phenomena. Expression of each of the genes encoding these proteins can 
be upregulated in distinct clinical azole-resistant settings. The transcription of 
CaMDRl, the gene encoding CaMdrlp, is almost undetectable in azole susceptible 
isolates but is much higher in some azole resistant isolates. In contrast, the 
transcription of CDR1, the gene encoding Cdrlp, is detectable in azole-susceptible 
isolates but is increased to higher levels in some azole-resistant isolates.
1.4.5. Glucan Synthesis Inhibitors (Echinocandins)
In vitro data examining the effect of echinocandins against Candida spp. are 
promising and have been developed as clinical therapeutics. Agents of this class are 
fungicidal against both fluconazole-resistant and -susceptible isolates (Joseph et al., 
2007). Isolates of C. parapsilosis consistently have elevated MICs for echinocandins 
to-date, but the relevance of this is unclear (Pfaller et al., 2006). Caspofungin formerly 
identified in the literature as L-743,872 and MK-0991, is a polypeptide antifungal. It 
is a glucan synthesis inhibitor of the echinocandin structural class. Caspofungin 
blocks the synthesis of a major fungal cell wall component, 1-3-p-D-glucan. The 
inhibition of glucan synthesis occurs via inhibition of 1,3-P-glucan synthase (Kurtz et 
al., 1996). The lack of glucan synthesis enzymes in mammalian cells without cell 
walls makes this an attractive target for selective antifungal activity (Maschmeyer and 
Ruhnke, 2004, Cassone et al., 1981).
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1.4.6. Chitin synthase inhibitor
The increase in antifungal resistance and the incidence of deep-seated fungal 
infections in the clinic has led to the development of new agents directed at novel 
targets. Chitin is a major and essential component of the fungal cell wall and is absent 
in the human cell (Odds et al., 1974, Ram et al., 2004, Mellado et al., 2003). Thus, it 
is a very attractive target for designing antifungal agents although efforts over decades 
have not yielded effective drugs targeting the enzyme chitin synthase. Polyoxins and 
nikkomicins are known competitive inhibitors of chitin synthase. There is evidence 
that fungi may adapt to the inhibition of the synthesis of one wall component by 
compensatory production of another component. This again leads to the theoretical 
expectation that a drug that acts on two targets could produce an enhanced and 
desirable antifungal effect.
1.6. Concluding remarks
Candida resistance and its clinical impact have drastically changed in the last few 
years presenting a challenge to understand Candida virulence, prevention and to 
control resistance. Of special importance in the control of fungal infections, 
particularly in the clinic, is a more thorough understanding of CYPs especially as we 
now see huge multiplicity of these proteins in filamentous fungi. The work presented 
herein aims to further the understanding of the biological, genetic and physiological 
aspects of azole treatment on clinical strains, on fungal CYPs (including CYP51) and 
for sterol biology associated with fungi, particularly in Candida species (Flow chart). 
Numerous Candida strains are examined for their drug susceptibility in relation to
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factors that could be important such as sterol composition and drug accumulation. 
The role of a novel CYP56 in C. albicans is probed biochemically and genetically.
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General Materials and Methods
This chapter contains general material and methods applied in this study. 
Materials and Methods used specifically in individual chapters are described in the 
respective chapter.
2. Materials
All chemicals were purchased from Aldrich, Difco, Sigma or Fluka. The 
materials, reagents and solutions used are listed as followed and they were autoclaved 
for 20 min at 121 °C when needed and stored at 4°C.
2.1. Media, Reagents and Solutions Composition
2.1.1. Luria-Bertani (LB) medium and tryptone 1% w/v (Difco)
plates yeast extract 0.5% w/v (Difco)
NaCl 1% w/v 
pH 7
agar 1.5% w/v for making solid media 
ampicillin 100 mg. ml'1
2.1.2. Yeast extract peptone dextrose bacto peptone 2% w/v
(YEPD) yeast extract 1% w/v 
glucose 2% w/v
2.1.3. SOC medium tryptone 2% w/v 
yeast extract 0.5% w/v 
NaCl 10 mM 
KC1 2.5 mM 
MgCh 10 mM
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MgSC>4 10 mM 
Glucose 20 mM
2.1.4. X-Gal stock solution (40 nig.ml'1) (5-bromo-4-chloro-3-indoyl-b-D-galactoside 
(Melford) 400 mg 
Dimethylformamide 10 ml
2.1.5. IPTG stock solution (100 mM) (Isopropyl-b-D-Thiogalopyranoside, dioxin free 
(Melford) 23.8 mg 
1 ml H20 
filter sterilize
2.1.6. Terrific medium bacto tryptone 12 g 
yeast extract 24 g 
glycerol 0.4% 
1LH20
2.1.7. Yeast mineral medium (YM) yeast nitrogen base without aminoacids 6.7 g 
glucose 2%
KH phathlate 20.4 g
amino acid supplement 20 pg.ml'1 uracil and
tryptophan
1LH20
pH 5
filter sterilize
2.1.8. 0.1 M Sodium Phosphate, pH 7.4 13.8 g NaH2PC>4 . H20 up to 100 ml water, filter 
sterilize
26.8 g Na2HPC>4 . H20 up to 100 ml water, filter 
sterilize
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Mix the previous solutions 22.6 ml NaH2P0 4  and 
77.4 ml Na2HPC>4 up to 1L water, filter sterilize
2.1.9. IOx TE 100 mM Tris, pH 7.5
10 mM EDTA, 1L H2O, filter sterilize
2.1.10. 50x TAE, pH 8 Tris.HCl 2 M
sodium acetate 1M
EDTA 50 mM
1L H20, filter sterilize
2.1.11. lOx TBE pH 8.3 Tris.HCl 1 M
boric acid 1M
EDTA 20 mM
1LH20
2.1.12. Li Ac 1M
2.2. Antibiotics
2.2.1. Ampicillin (sodium salt) 100 mg.ml'1 in distilled H2O (Melford, Suffolk,
UK)
2.2.2. Carbenicillin (sodium) 100 mg.ml'1 in distilled H2O (Melford, Suffolk,
UK)
2.2.3. Chloramphenicol 34 mg.ml'1 in ethanol (Sigma)
2.2.4. Kanamycin 10 mg.ml'1 in distilled H20 (Melford, Suffolk,
UK)
2.2.5. Nourseothricin-dihydrogen sulphate 200 mg.ml'1 in distilled H2O (Werner Bioagents,
Jena, Germany)
2.3. Reagents for DNA extraction from Candida albicans
2.3.1. Breaking buffer triton X-100 2%
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SDS 1%
Tris.HCl 10 mM
EDTA 1 mM
NaCl 100 mM
2.3.2. 0 .4M N a2HPO4 10.7 g in 100 ml distilled H20
2.3.3. 0.2 M citric acid 4.2 g in 100 ml distilled H20
2.3.4. EDTA (Na2 dissodium salt) Ethylenediamine-tetra acetic acid 15.2 g in 
distilled H20
2.3.5. 200 mM Citrate phosphate buffer 58 ml of 0.4 M Na2HP0 4  
42 ml of 0.2 M citric acid
2.3.6. Citrate phosphate buffer, Sorbitol 20 mM Citrate phosphate buffer
and EDTA pH 5.6 0.4 mM EDTA 
1.2 M sorbitol 
up to 1L distilled H20
2.3.7. 5 M Potassium acetate 9.8 g potassium acetate in distilled H20
2.3.8. 10% SDS lg in 10 ml distilled H20 
filter sterilize
2.3.9. Zymolyase 20T® (Seikagaku Corporation, Tokyo, Japan)
2.3.10. RNA A 10 mg.ml'1, Sigma, UK
2.3.11. Proteinase K 10 mg.ml'1, Sigma, UK
2.3.12. DTT 1M
2.3.13. Phenol chloroform Sigma, UK
2.3.14. DNA marker 1 kb gene ruler™ DNA ladder (MBA Fermentas; 
St. Leon-Rot, Germany)
2.3.15. DNA loading buffer lOx concentrate
45
3 g glycerol (Fisher) and 25 mg bromophenol 
blue (Sigma) in 10 ml dt^O
2.4. Reagents for Southern blotting
2.4.1. 20X SSC, pH=7 NaCl 3M
Sodium citrate 0.3M
1L distilled H2O
2.4.2. 10% N-lauroylsarcosine (sodium salt 10 % (w/v) in H2O
filter sterilize
2.4.3. Maleic acid buffer
2.4.4. Depurination buffer
2.4.5. Denaturation buffer
2.4.6. Neutralization buffer
2.4.7. Prehybridisation buffer
2.4.8. Hybridization buffer
2.4.9. 2 x Wash solution
2.4.10. 0.5 x Wash solution
2.4.11. Washing buffer
2.4.12. Blocking buffer
maleic acid 0.1 M 
NaCl 0.15 M 
pH 7.5 
HC1 250mM 
NaOH 0.5 M
1.5 M NaCl
1 M Tris-HCl base pH7.5
1.5 M NaCl
5 x SSC, 0.1 % N-laurylsarcosine, 0.02 % SDS, 1 
% blocking reagent
10 ml prehybridisation buffer with 15 pi probe
2 x SSC
0.1 % (w/v) SDS 
0.5 x SSC 
0.1 % (w/v) SDS
0.3 % Tween 20 in maleic acid buffer 
1 % blocking reagent in maleic acid buffer
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2.4.13. Antibody solution
2.4.14. Detection buffer
anti-digoxigenin-alkaline phosphatase 
conjugate 1:5000 in blocking buffer 
0.1 M Tris HC1, pH 9.5, 0.1 MNaCl
2.5. Reagents for Protein studies
2.5.1. Resolving buffer (5 x concentrate)
2.5.2. Stacking buffer (10 x concentrate)
2.5.3. Acrylamide stock solution
2.5.4. Resolving gel
2.5.5. Stacking gel
2.5.6. Protein Marker
1.88 M Tris-HCl (Melford), pH 8.8, stored 
at 4 °C
0.6 M Tris-HCl, (Melford) pH 6.8, stored at 4 °C
30% acrylamide (Amersham;
Buckinghamshire, UK) and 0.2 %
N ’N ’-bis-methylene-acrylamide
(Amersham) stored at 4 °C
3.7 ml of stock acrylamide solution, 2 ml of 5 x 
resolving buffer, 0.2 ml of 10 % SDS and water 
to a final volume of 10ml. The solution was 
mixed prior to polymerisation using 10 pi of 
N,N,N',N'-tetramethylethylene diamine (TEMED 
(Sigma)) and 100 pi of 10 % w/v Ammonium 
persulphate (APS) (Sigma)
1 ml of stock acrylamide solution with
0.6 ml of 10 x stacking buffer and 0.12 ml
of 10 % SDS. Water was added to a final
volume of 6ml and the solution was mixed
prior to the addition of 10 pi TEMED and
100 pi of APS
SDS-PAGE Markers for molecular weights 
200,000 (Sigma)
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2.5.7. Prestained protein marker
2.5.8. Cracking buffer
2.5.9. Electrode tank buffer 
concentrate)
2.5.10. Upper tank buffer
2.5.11. Lower tank buffer
2.5.12. Coomassie Blue stain
2.5.13. Coomassie destain
2.5.14. Transfer buffer
2.5.15. TBS (Tris buffered saline)
Prestained SDS-PAGE standard solution for 
molecular weights 30,000-120,000 (Sigma). 
120mM Tris-HCl, pH 6.8, 20 % glycerol
(Fisher), 10 % SDS,
5 % P-mercaptoethanol (Sigma) and
trace of bromophenol blue (Sigma),
stored at -20 °C
(lOx 0.25 M Tris base (Melford) and 1.92 M
glycine (Fisher) in dH20, stored
at room temperature
lx electrode tank buffer and 0.1% SDS
stored at room temperature
0.5 % electrode tank buffer stored
at room temperature
6.25g Coomassie Brilliant Blue R250,
1.25 L methanol, 175 ml glacial acetic 
acid and dH20  to a final volume of
2.5 L filtered through Watman no.l filter 
paper
1.25 L methanol, 175 ml glacial acetic 
acid and water added to a final volume of
2.5 L
25 mM Tris base, 192 mM glycine, 20 %
(v/v) methanol and 0.025 % (w/v) SDS 
chilled to 4 °C prior to use
20 mM Tris-HCl pH 7.4, 500mM NaCl
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and 0.05 % w/v Tween 20, stored 
at room temperature
2.6. Strains used in this study
Escherichia coli
Strains Genotype Ref.
2.6.1. Escherichia coli 
DH5a“”
F'(|) 8 Od/acZ AM 15 
A(lacZYA- 
arg¥)\J\69 deoR 
recA endAX 
hsdRXlfa, nik+) 
phoA supE 44 A,- thi- 
1 gyrA96 re I AX
Supplied by Novagen, 
(Nottingham, UK)
2.6.2. Escherichia coli 
XL-1 Blue
recAl, endAl, gyrA96, thi-1, 
hsdR17
Supplied by Stratagene (La 
Jolla, California, USA)
Candida spp.
Strains Reference Ref.
2 .6 .5 . Candida albicans ATCC 9 0 0 2 8 s ATCC collection (USA)
ATCC 5 6 5 1 3 s ATCC collection (USA)
ATCC 2 8 5 1 6 s ATCC collection (USA)
I8k
(erg3 fluconazole-and 
amphotericin- resistant mutant)
(Kelly et al., 1997)
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2.6.6. Candida lusitaniae ATCC 200950k ATCC collection (USA)
2.6.7. Candida krusei ATCC 6288“ ATCC collection (USA)
2.6.8. Candida dubliniensis CBS7987s Centraalbureau voor 
Schimmelcultures, Baam, 
The Netherlands
R= fluconazole-resistant, S= fluconazole-sensitive
2.6.1. Clinical strains
Clinical strains used Candida parapsilosis (G1-G10,H1, n=9), Candida krusei 
(9-C, 21-C, 46-B, 53-A, 88-C2, 123-B, 127-D, 129-B, 1-RAO, ATCC 6288), Candida 
lusitaniae (19-A1, 25-B, 75-A, 76-A, 110-A, 121-A), Candida norvegensis (186-A,
3-MASC), Candida valida (1-MBJ), Candida glabrata (G5 and G7). C. albicans 
isolate (1-MAB) was from the oral cavity of a 5-year old HIV1- infected child, who 
had acquired HIV vertically, and was monitored at the Pediatric Immunodeficiency 
Division, State University of Campinas, Brazil. The child started HIV antiretroviral 
therapy in 1999 and never received antifungal therapy. C. dubliniensis isolates of 
IFM 48184 (F6583 isolated from a Japanese patient), 48314 (CBS 7988) and 49192 
(S-34 isolated from a Brazilian patient) were used as references, and isolates 73 and 
390 were obtained from the Brazilian HIV-infected child during 1998 and 1999 (Sano, 
2000). The C. dubliniensis isolates tested were 2-MLA, 3-MLA (grandmother) and 9- 
LPS, 3-LPS (Brazilian HIV-infected child), collected during 2000 and 2001. The 
Brazilian HIV-infected child received highly active antiretroviral therapy (HAART) 
including nelfinavir, zidovudina and 3TC. The HTV-infected child received homecare 
from the grandmother.
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All Candida clinical isolates were from human immunodeficiency virus- 
positive patients. Candida stock isolates were maintained at -80°C, and were grown in 
yeast nitrogen base medium (YNB, Difco) 2% glucose.
Table 2.1. C. albicans strains used in thtD IT 2  study.
Strains Parent Genotype Reference
SC5314 Wild-type strain (Gillum et al.,
1984)
A1-R1-6r SC 5314 dit2A: :SA T1/DIT2 This study
A1-R1-6CS Al-Rl-6* dit2A::FRT/DIT2 This study
A2-S1* A1-R1-6CS dit2A::FRT/dit2A::SAT1 This study
A2-S3As A2-S1r dit2A::FRT/dit2A: F R T  This study
Re-integrant A2-S3As dit2A: :FRT/dit2A: :FRT, This study 
RP10-DIT2
Table 2.2. Plasmids used in the DIT2 study.
Plasmid Size (bp) Reference
pUC19 2686 Yanich-Perron et. a l 1985
pGEM T-easy 3015 Yanich-Perron et. a l 1985
pBlue script 2961 GenBank® 523327
pSFIl 8051 (Wirsching et al., 2000)
CIplO 5198 GenBank accession A181970
CIp20 6200 This study
pSport 4109 modified (Wittbrodt et al., 2002)
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Table 2.3. Primers used in this study for deletion of DIT2 in C. albicans.
Primers Sequence Reference
DITFOR 5 ’ -TTGGCC AAGGAAT ATTTCT G This study
DITREV 3 ’-TGTGCTTTGATGTACCTGTG This study
DIT2F1 5 ’ - ATGCGAGCTC AGTTTGTTACC AAT ATGC AC This study
DIT2R2 3 ’-ATCCGGATCCGCC ATACTATGCC ATTAAGG This study
DIT2KF3 5 ’ -GGCCGGT ACC AGTTT GTT ACC AAT AT GC AC This study
DIT2XR4 3 ’-GGCCCTCGAGAATGGTGGGAAAACTATCTC This study
DITSIIF5 5 ’ -GCCGCCGCGGTTCT AGGTGAGT AT AAAGT G This study
DITSIR6 3 ’-GGCCGAGCTCGCC ATACTATGCC ATTAAGG This study
SAT1 5’-GCCCGACGTCGCActceAGCGTCAAAACTAG-3’ Reuss 2004
SAT2 5 ’-CTAGTGATTTCT ecAGGACC ACCTTTG-3 ’ Reuss 2004
MALI 5’-CATGCAAGCCAGGatCCAATAATGATTGG-3 ’ Reuss 2004
MAL2 5 ’ -GTTC ACTC ATT GTcgacG ATT ATT AGTT AAAC C-3 ’ Reuss 2004
FLP1 5 ’-TTCCGTTATGTGTAATC ATCC Reuss 2004
FLP2 5 ’-CGCTGAGTTTCGAT ATTGTC Reuss 2004
FLP3 3 ’-GTATATGTGCCTACTAACGC Reuss 2004
RT300 5 ’ -GT ACTTG AC AT GCC AT ACT AT GC This study
RT768 3 ’ - AGTTTCGAT AAAGAAAAC AAGA This study
TEM1R 3 ’ -TGGTT ATT CT GAT CCTGTT G This study
ACTIO 5 ’-GCGGAATTC AGAGTCGAC ATT This study
1= SacI; 2= BaniHl; 3=zKpnl; \=Xho; 5=S'arcII, 6=Sacl restriction sites are underlined
2.7. Candida Identification
The isolates were identified according to the standard technique (Sandven, 
1990). They were cultured on com meal agar (Difco, US), supplemented with 1% 
Tween 80, at 25°C for 7 days for chlamydospore formation. Germ tube formation was 
monitored in calf semm (Gibco BR, US) at 37°C for 2 to 4 h. Additionally, the 
isolates were cultured at 30°C for 48 h on chromogenic agar (CHROMagar® - France) 
(Beighton et al., 1995), and tested with the Candida Check kit® (Iatron laboratories, 
Inc., Japan) and ID32C® profiled (bioMerieux, Marcy l’Etoile, France). Differential 
growth test at 45°C was used to distinguish Candida albicans from C. dubliniensis. 
The isolates were maintained on potato dextrose broth containing 25% glycerol (PDA 
Difco, MO, USA) at -80°C.
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2.7.1. Confirmation of C. dubliniensis by polymerase chain reactions (PCR)
The isolates were cultured on potato dextrose agar (PDA Difco, MO, USA) 
slants at 30°C temperature for 48 hours. Extraction of DNA was performed using a 
DNA extracting kit; Gen Torn Kun for yeasts (TaKaRa, Ohtsu, Japan). PCR was 
performed by amplifying a specific sequence of the C. dubliniensis cytochrome b 
gene (Sano, 2000, Biswas SK, 2001). The primers used were Cdub-F (5- 
TTCTCTGTAAGTAATCCTACAATACAGCGT-3') and Cdub-R (5'- 
ACAATTGATGGAGGTGTCACCATTGGGTTT-3'). A positive result was indicated 
by the presence of a 305 base product after resolution by electrophoresis in 1% 
agarose. Comparison of DNA fingerprinting by random amplified polymorphic DNA 
(RAPD) patterns was also undertaken. The isolates were analyzed by RAPD patterns 
generated by PCR using 10 pmole of the primer R28M (5-ATGGATCSSC). An 
annealing temperature of 35°C was used with Taq DNA polymerase (Biswas SK, 
2001, Sano, 2000).
2.8. Propagation of the Escherichia coli
E. coli DH5a strain was used as a recipient for the introduction of plasmid 
DNA. A single colony was propagated in 5ml of LB media supplemented with 100 
(ig.mf1 ampicillin and grown at 37°C on an orbital shaker at 250 rpm in a 60ml sterile 
container (Sterilin) overnight (o/n).
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2.9. Growth of Candida spp.
Candida spp. were grown on YEPD or YM medium. The isolates were 
incubated at 30°C or 37°C for 48 h. The yeast cell growth in liquid culture was 
estimated using a haemocytometer, to measure the concentration of cells.
2.10. Plasmid vectors used in this study
Plasmids used in this study were supplied by Promega (Corp, Southampton, 
UK) or were within the collection in the laboratory. Transformants containing the 
respective plasmids were selected on LB agar medium containing the antibiotic 
needed as illustrated in the map of plasmid (Fig. 2.1-5).
Plasmids Size (bp) Map
pGEM®-T easy vector 3015 Fig. 2.1
pUC19 2686 Fig. 2.2
pSport 4109 Fig. 2.3
pCWori+ 5500 Fig. 2.4
pYEp51 7634 Fig. 2.5
54
p G E M -T  Easy 
Vector
(3015bp)
Fig. 2.1. Map of plasmid containing the restriction sites and antibiotic marker.
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Fig. 2.2. Map of plasmid containing the restriction sites and antibiotic marker.
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Fig. 2.3. pCW Ori+ plasmid containing the tac promoter upstream of a multiple 
cloning site.
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Fig. 2.4. Map of pSPORT 1 containing the multiple cloning site, lad
promoter and antibiotic marker.
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Fig. 2.5. pYEp51 yeast episomal shuttle vector containing the GAL1Q promoter 
to drive heterologous expression.
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2.11. Molecular biological techniques
2.11.1. PCR methodology
Polymerase Chain Reaction (PCR) was used to amplify the different genes of 
interest according to the techniques established by Mullis and Faloona (1987) and 
Erlich (1989). PCR was performed on a Quanta Biotech QB-24 DNA thermal cycler, 
using synthetic oligonucleotides that were purchased from Invitrogen™, (UK). The 
standard PCR was typically carried out in a 200pl PCR tube with 50pl reaction 
volume containing 200pM of each deoxynucleotide triphosphate (dATP, dCTP, dGTP, 
and dTTP) and Sunits of Taq DNA polymerase A (Promega, Corp, Southampton, UK). 
PCR reaction consisted of lpl of the DNA template (100ng.pl'1) plasmid, 5 pi of lOx 
buffer, 5pl MgCL (25mM), lpl dNTPs (lOmM), 2.5pl of the forward and reverse 
primers (10pmol.pl'1), 5pi enhancer, lpl pfx polymerase (5units), 27pl dt^O. The 
conditions were 94°C for 1 minute, then 30 cycles of 94°C for 1 minute, 55°C for 30 
seconds and 72°C for 2 minutes. Occasionally little or no PCR product was detected, 
in this case the optimization of PCR included: 1. DNA template quality -  we checked 
the quality and concentration of the template were checked and also a serial dilutions 
of DNA used to determine the optimal concentration; 2.MgCl2 concentration -  
variation in the concentration ranged from 1.5 to 4mM; 3. Optimal annealing 
temperature -  the temperature depends on the melting temperature of the primers. It 
can range from 45°C to 65°C.
2.11.2. DNA Gel Electrophoresis
A 1% (w/v) agarose gel was prepared in TAE buffer 50ml containing 2pl of 
lOmg.ml'1 stock of ethidium bromide. The gel was placed in a tank (Bio-Rad 
Laboratories Ltd, Hemel Hempstead, Hertfordshire, UK) and filled with TAE buffer.
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0.5fig of a GeneRuler lkb DNA marker (Roche Diagnostic Ltd, Lewes, East Sussex, 
UK) was also included in an additional well. Sample DNA was loaded along with a 
molecular weight standard mixture to aid estimation of the sizes of the sample DNA 
loaded. A constant voltage of 90V was applied on the gel for 30 minutes after which 
the fragments were visualised under ultraviolet light.
2.11.3. Gel Extraction of DNA from Agarose gels
Following agarose gel electrophoresis, DNA fragments of interest were 
isolated using the QIAquick gel extraction kit (Qiagen). The system is dependent on 
the absorption of the DNA fragment onto a silica-based membrane. Prior to this, the 
fragments were excised from the gel using a clean scalpel blade and the gel sizes were 
determined. The gels were melted at 50°C for 15 minutes. The DNA solution was 
then applied onto the columns. The bound DNA was washed with an ethanol based 
buffer and eluted with sterile distilled water.
2.11.4. PCR amplified DNA purification
Following the successful amplification of the gene of interest confirmed by 
agarose gel electrophoresis, the PCR mixtures were cleaned using a GenElute™ PCR 
clean-up kit from Sigma, UK. The buffers, primers, DNA polymerase and dNTPs 
were then removed with an alcohol wash. The double stranded DNA was then eluted 
with sterile distilled water.
2.11.5. DNA Restriction Endonuclease Digestion
Restriction endonuclease digestions were carried out in 20ffi reaction volume. 
The enzymes were obtained from Promega Corp, Southampton, UK or Roche 
Diagnostic Ltd, Lewes, East Sussex, UK. Typically 0.1 -  0.5 jug of DNA was used 
per reaction, with 1 unit of the appropriate enzyme and 2pl of the 10 x buffer to give
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lx dilution of the buffer. The reaction mixtures were gently mixed, centrifuged 
briefly to collect the sample and incubated at the appropriate temperature overnight 
for optimal and complete digestion.
2.11.6. A-tailing and blunt- ending of PCR products
A-tailing of PCR products, prior to “sticky-end” ligation, is necessary when 
proofreading DNA polymerase enzymes are used. The method used was according to 
Knoche and Kephart, (1999). The method uses a non-proofreading DNA polymerase 
and dATP (deoxy adenosine triphosphate) to add poly A tails to the blunt ends of the 
fragment. The PCR product was purified by gel extraction and 6 pi was incubated 
with 1 pi of 15 mM MgCh (Promega), 1 pi of 2 mM dATP (Roche), 1 pi of Taq 
polymerase (Promega) and 1 pi of 10 x Mg2+-free Taq polymerase buffer (Promega), 
for 30 minutes at 70 °C.
Blunt-ending of PCR products was carried out when “blunt-ended” ligation was to be 
carried out. This method uses a proofreading DNA polymerase to remove extended 
bases from PCR-generated DNA fragments. The PCR product was purified by gel 
extraction and 6 pi was incubated with 1 pi of Pfu DNA polymerase, 1 pi of 10 x Pfu 
polymerase buffer and 2 pi of 0.25 mM dNTP, for 30 minutes at 70 °C.
2.11.7. Ethanol precipitation of DNA
DNA samples were desalted and concentrated by ethanol precipitation 
according to the method of Sambrook et al. (1989). Firstly 10 % v/v of 3 M Sodium 
acetate, pH 5.8, was added to the sample (DNA). Then a volume (2 x the volume of 
sample and sodium acetate for DNA precipitation, 100 % ethanol was added and the 
mixture was incubated at -80 °C for 5 minutes. The mixture was centrifuged at 13,000 
rpm for 20 minutes to pellet the precipitated nucleic acid. The supernatant was
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removed and the pellet washed by half filling the tube with 70 % ethanol and inverting 
twice. The sample was centrifuged again for 2 minutes and the supernatant removed. 
Residual ethanol was evaporated in a DNA speed vac and DNA resuspended in dffeO.
2.11.8. Ligation of DNA into plasmid vectors
The DNA used in ligation reactions was either purified from an agarose gel or 
with a PCR purification kit as described previously. About 0 .1  - 0.5pg of insert and 
DNA fragment are used in a reaction volume of 10pl. This volume also contained 1 
unit of T4 DNA ligase and lpl of 10 x ligase buffer (Roche Diagnostic Ltd, Lewes, 
East Sussex, UK). The volume was adjusted to lOpl with sterile distilled water. The 
reaction was incubated at 4°C overnight.
2.11.9. Preparation of competent E. coli cells
Transformations were undertaken using procedures largely based according to 
the method of Cohen et al. (1972). A single colony of bacteria from a fresh plate was 
cultured in 100ml of LB media at 37°C in an orbital shaker (250 rpm). The culture 
was grown to an OD6oo of 0.4 -  0.5. The cells were aseptically transferred into a 
sterile ice-cold tube and placed on ice for 10 -  15 minutes. The cells were then 
harvested at 4000 rpm for 10 minutes at 4°C and the supernatant was decanted off. 
The pellets were resuspended in 10ml ice-cold 0.1M CaCLand stored on ice for 10 
minutes. Cells were then recovered by centrifugation at 4000 rpm for 1 0  minutes at 
4°C. The pellet was resuspended in 2ml of ice-cold 0.1M CaCk for each 50ml of 
original culture, dispensed into aliquots of 2 0 0 pl and stored at -80°C until needed.
2.11.10. Cloning
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The Escherichia coli DH5a competent cells were transformed with various 
plasmids. Transformation was performed by mixing 1 pi of plasmid DNA with 50 pi 
of competent cells (E. coli DH5a) on ice. The cells were kept on ice for 20 minutes 
to allow uptake of the plasmid prior to subjecting the cells to heat shock by incubating 
in a water bath at 42°C for 45 seconds followed by incubation on ice for 2 minutes. 
LB (0.95 ml) was added to the cells and incubation commenced at 37°C, 225 rpm for 
1 hour with the cells being recovered by centrifugation. Selection of transformants 
was achieved by plating out the cells on LB-agar plates containing 0.1 mg.ml'1 
sodium ampicillin or specific antibiotic followed by incubation at 37°C overnight. A 
control transformation was also performed using empty plasmid.
The recombinant colonies were screened by isolation of plasmid DNA from overnight 
cultures in conjunction with restriction enzyme digests. Colonies were grown in 10 ml 
volumes of LB containing 0.1 mg.ml'1 of sodium ampicillin or specific antibiotic 
overnight at 37°C, 225 rpm. The plasmid DNA from 3 ml of overnight culture was 
isolated using a Qiagen Plasmid Purification kit. The plasmid DNA obtained was 
digested with the restriction endonucleases Ndel and Hindlll (Roche) for 2 hours at 
37°C. The digestion products were resolved electrophoretically on a 1% (w/v) agarose 
gel and were visualised by exposure to u.v. light in the presence of ethidium bromide.
2.11.11. Transformation of Candida species by electroporation
Culture of Candida (50 ml) at concentration of 10'4 cells in YPD broth and grow 
overnight at 30°C to an OD600 of 1.6-2. Spin down at 1 K for 10 min. Cells were 
resuspended in 8 ml distilled water and added 1 ml lOx TE and 1 ml 1 M Li Ac, 
incubated at 30°C with shaking 150 rpm for 1 h and 250 pi of 1 M DTT was added 
before incubating for 30 min. Then 40 ml of distilled water was added, cells were
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spun down and washed sequentially in 50 ml of ice cold water and 10 ml of ice cold 
1M sorbitol. The pellet was resuspended in 50 pi 1M and kept on ice and 40 pi of the 
cell suspension taken for each transformation. DNA was added (0.5 to 1 pg) in a 
volume of 5 pi or less to cells, the suspension was mixed gently with the pipette tip 
and transferred mixture to 0.2 cm electroporation cuvette (Sigma-Aldrich 
electroporation). Electroporation was using a Bio-Rad Gene pulser at 1.6 kV, 200Q, 
25 pF and then 450 pi of 1 M sorbitol was added and cells spun down 14,000 rpm for 
1 min. Cells were resuspended in 1ml of YPD and shaking at 200 rpm 30°C for 4 h 
and plated out 50 pi aliquots of transformed cells and controls onto YPD A plates with 
X-Gal, IPTG and antibiotic marker. Antibiotic resistant clones grew after 24-48 h.
2.11.12. Plasmid rescue from Candida species
Cells were grown overnight in selective yeast nitrogen base medium at 30°C. 
Cells were harvested from 1.5 ml of culture in a microfuge tube. The supernatant was 
removed and the pellet resuspended in 200 pi of breaking buffer. Cell suspension was 
added to a screw capped 2 ml tube containing 0.3 g of the glass beads and 200 pi of 
phenol:chloroform:isoamyl alcohol (24:24:1). Cells were disrupted for 1 min in a 
beater/cell disrupter or alternatively vortexed thoroughly for 5 min. The homogenate 
was spun at 14,000 rpm for 10 min (Micro Centaur, Sanyo). The aqueous phase was 
removed and extracted with equal volume of chloroform:isoamyl alcohol (24:1). 
Centrifugation for 2-3 min followed and the aqueous phase was removed to a fresh 
tube. Nucleic acids were precipitated with addition of 20 pi 3 M sodium acetate pH 5 
and 400 pi of ethanol at -20°C and after centrifugation at 14,000 rpm for 10 min, the 
pellet was washed with 70% ethanol and resuspended in 50 pi TE. 1-5 pi of DNA 
was used to transform in plasmid vector.
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2.11.13. Candida chromosomal DNA preparation
50 ml YPD culture was grown overnight at 37°C in 250 ml flask. Cells were pelleted 
in Falcon tube were centrifuge at 2.5 K for 5 min. The supernatant was removed and 
cells resuspended in 5 ml 20 mM citrate phosphate buffer, 40 mM EDTA, 1.2 M 
sorbitol pH 5.6. 15 mg zymolyase 20T ws added and incubated at 37°C with shaking 
for 30-90 min. Protoplasts were harvested by centrifugation at 2.5 K for 5 min 
(Centrifuge Sorvall® Legend TM/T/RT Kendro). The resulting pellet was 
resuspended in 7.5 ml lOx TE and 0.75 ml 10% SDS added. 2.5 ml 5 M potassium 
acetate was then added and the suspension incubated on ice for 30 min. The lysed 
cells are decanted into a 50 ml centrifuge tube and subjected to a clearing spin at 8.5 
K for 10 min, 4°C (Centrifuge Sorvall® Legend TM/T/RT Kendro). The supernatant 
was placed into a fresh Falcon tube and mixed gently with 10 ml ice cold iso-propanol, 
incubated on ice for 5 min and spun at 2.5 K for 5 min. The resulting pellet was dried, 
resuspended in 1ml TE buffer and 100 pi RNase A (10 mg.ml'1) added before 
incubating for 1 h at 37°C. 100 pi proteinase K (10 mg.ml'1) were added and
incubated for 1-2 h at 37°C. Next phenol/chloroform was added and the top phase 
extracted three times. The DNA was precipitated with the addition of two volumes of 
absolute ethanol. The DNA formed a web, which was removed to a fresh eppendorf 
with a pipette tip. The DNA was washed in 70% ETOH for 5 min, dried and 
resuspended in 150 pi TE. For southern hybridisation experiments 10-20 pg of DNA 
was digested with restriction enzyme. The concentration of DNA samples were 
assessed by measuring their absorbance at 260 nm by spectrophometer (FI-Hitachi) 
and calculating the concentration according to following formula 1 unit of A260 = 5 0  
pg DNA.
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2.11.14. Deletant strain construction
Standard molecular biology techniques for DNA manipulations and bacterial 
transformations were used as described in this chapter (Chapter 2.11.10). Once the 
complete DIT2 gene sequence was obtained, the DIT2F and DIT2R primers were 
designed to amplify the entire ORF and PCR-amplified products were purified by gel 
extraction, digested and subcloned between sites Sacl and BamYK in pUC19 plasmid. 
Subsequently a deletion was created in this construct by inverse PCR and attempts 
were made to ligate the caSATl cassette into this deletion, but these ligations failed to 
yield any recombinant plasmid molecules in E. coli. Consequently the strategy was 
altered, and new primers were designed to separately amplify the upstream 5’ 
(DIT2KF and DIT2XR), and downstream 3’ (DITSIIF and DITSIR) regions of the 
DIT2 gene. Firstly PCR-amplified product from upstream of the gene was cloned in 
the pBluescript II plasmid and transformed in the DHSa*"1 E. coli cells. The plasmid 
containing the fragment was digested with Kpnl and Xhol restriction enzymes and 
purified by agarose gel electrophoresis and elution using the Qiagen Qiaex II kit. 
Subsequently this fragment was subcloned in the Kpnl and Xhol sites of the caSATl- 
flipper cassette, provided by Dr. G. Moran, previously digested with Kpnl and Xhol 
restriction enzymes. Similarly the 3’ flanking regions of the DIT2 gene were 
amplified with the primers DITSHF/DITSIIR, digested with Sacll and Sacl restriction 
enzymes and ligated with Sacll and Sacl digested pBluescript II. This fragment was 
then released from pBluescript II by digestion with Sacll and Sacl restriction enzymes 
and gel purification as described previously (Chapter 2.11.3). This purified fragment 
was subcloned into the Sacll and Sacl restriction sites of SAT 1-flipper plasmid
66
containing the DIT2 5’ upstream fragment (Fig. 2.6). Clones from this last 
transformation were purified and digested with Kpnl and Sacl restriction enzymes. 
The fragment thus generated consisted of the SAT 1-flipper cassette flanked by the 5’ 
and 3’ non-coding regions of the DIT2 gene and was used subsequently for C. 
albicans strain transformation to select nourseothricin (Werner Bioagents, Jena, 
Germany) resistant putative gene deletion mutants.
2.11.15. Southern blot analysis
Genomic DNA obtained from strains SC5314, dit2-lk.\FRT  and dit2~ 
1 A: :FRT/dit2-2A: F R T  were digested with restriction endonuclease enzyme in large 
scale (10 pg) for Southern blot analysis. The Southern blotting method followed, and 
DNA probes used to confirm the gene disruption, were prepared by the method 
outlined in the Boehringer Mannhein digoxigenin (DIG) labelled DNA detection 
system.
Probes for the DIT2 gene sequences were made using 15 pi (approximately 1 pg) of 
PCR fragments of DIT2 (from primers DIT2KF and DIT2XR) by random primed 
DNA labelling. The PCR products were denatured, individually, by boiling for 10 
minutes and placing immediately on ice. Once cooled, 2 pi of 10 x DIG labelled 
hexanucleotide mix (Boehringer Mannhein), 2 pi of 10 x dNTP mix (Boehringer 
Mannhein) and 1 pi of klenow fragment (final concentration 100 U/ml; Boehringer 
Mannhein) were added to the PCR product and incubated overnight at 37 °C. The 
labelling reaction was then stopped by the addition of 2 pi of 200 mM EDTA, pH 8.0. 
Genomic DNA samples from the three strains were isolated and digested for 4 hours 
with EcoRl (Promega). The digested genomic samples and PCR fragments were run 
on a 1 % agarose (BHD) gel.
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The gel was washed in 250 mM HC1 for 10 minutes to depurinate the DNA, then 
twice with dt^O  and twice in denaturation buffer (0.5 M NaOH, 1.5 M NaCl) for 15 
minute intervals. After a further wash with water, the gel was neutralised in two 
washes of neutralisation buffer (0.5 M Tris-HCl pH7.5, 3 M NaCl) for 15 minutes 
each time and then rinsed with water.
The DNA was transferred to the nitrocellulose membrane, Hybond™ -N+ 
(Amersham) by capillary action overnight, using 10 x SSC (1.5 M NaCl, 0.15 M 
Sodium citrate, pH 7). The membrane was dried and the DNA crosslinked (Stratagene) 
to the membrane. The membrane was then incubated at 68 °C for 2 hrs in 20 ml 
prehybridisation buffer (5 x SSC, 0.1 % N-laurylsarcosine, 0.02 % SDS, 1 % 
blocking reagent). The probe was hybridised by incubating the membrane overnight 
in 10 ml hybridisation buffer (15 pi probe in 10 ml prehybridisation buffer).
Prior to detection the membrane was washed twice for 15 minutes with 2 x wash 
solution (2 x SSC, 0.1 % (w/v) SDS), and twice for 15 min at 68 °C in 0.5 x wash 
solution (0.5 x SSC, 0.1 % (w/v) SDS). The membrane was then equilibrated in 
washing buffer (0.3 % Tween 20 in maleic acid buffer (0.1 M maleic acid, 0.15 M 
NaCl pH 7.5) for 1 minute and blocked for 1 hour in blocking buffer (1 % blocking 
reagent in maleic acid buffer). The anti-digoxigenin-alkaline phosphatase conjugate 
(Boehringer Mannheim) was mixed in 30 ml of 1% blocking buffer and added to the 
membrane and incubating for 30 min. The membrane was washed twice for 15 min 
with washing buffer (0.3 % Tween 20). 80 pi of Nitroblue tetrazolium salt, 5-Bromo-
4-chloro-3-indoyl phosphate mix added (NBT/BCIP; Boehringer Mannheim) in 10 ml 
detection buffer (0.1 M Tris HC1, pH 9.5, 0.1 M NaCl) and then incubating typically 
for about 5 hours. Finally the membrane was washed with water to stop the reaction.
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2.11.16. Reintegration of DIT2 gene into the homozygous dit2 deletion mutant
To investigate the reversion of the phenotypic characteristics of the dit2A 
double allele mutant, primers were designed for reintegration of the DIT2 gene to the 
homozygous mutant. Primers RT300 and RT768 were designed to allow PCR 
amplification of the promoter region and the entire DIT2 gene. The gene was 
amplified by PCR as previously described (Chapter 2.11.1) using genomic DNA 
template from C. albicans strain SC5314. The resulting PCR-amplified product was 
purified by gel extraction, and subsequently an A-tailing procedure for blunt-end PCR 
fragments (Promega) was performed. This fragment was cloned in pGEM T-easy 
vector for sequencing. Once the gene sequence was confirmed the clone containing 
the gene was digested with Spel and Xbal and subcloned in the plasmid CIp20 
containing the SAT1 nourseothricin resistance marker. The resulting digested product 
was digested with Ncol for DNA linearization within the cloned RP10 gene. The 
fragment was cleaned up using Qiagen Qiaex II kit. Five microliters of this product 
(-500 ng DNA) was used for Candida transformation with the homozygous dit2A 
mutant, the transformation was performed as described previously. Positive clones 
were selected from YEPD plates with 200 pg.ml'1 nourseothricin after 2-3 days of 
incubation at 30°C. DNA from positive clones was isolated by Rapid DNA rescue for 
PCR screening. PCR screens were used to obtain transformants with the desired 
insertion of the DIT2 gene in the chromosomal RP10 locus. Only one single allele of 
the gene was reintegrated. The primers TEM1R and ACTIO were used to identify 
recombinants with integration of the linear plasmid at the RP10 locus.
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2.12. CYP protein studies
2.12.1. Primer designs and PCR conditions
In order to obtain an appropriate CaDit2p heterologous expression system in E. coli 
forward primers were designed and contained the restriction enzyme site Nde I. A 
triplet enconding alanine replaced the second amino acid (phenylalanine) in the 
protein sequence to improve the expression in accordance with Bames-Waterman 
(Barnes et al., 1991). The reverse primer incorporated a Sphl restriction site as well as 
triplets encoding ten 3' histidines residues to facilitate the purification of the 
heterologously expressed CYP protein using Ni2+-NTA affinity chromatography.
The polymerase chain reaction (PCR) was used to amplify the different genes 
in this study in a reaction volume of 50pl. Reactions included lpl of the DNA 
template (100ng.pl'1) plasmid, 5pi of lOx buffer, 5pi MgCh (25mM), lpl dNTPs 
(lOmM), 2.5pi of the forward and reverse primers (10pmol.pl'1), 5pi enhancer, lpl 
pfx polymerase (5units), 27pl dffeO. The conditions were initially 94°C for 1 minute, 
then 30 cycles of 94°C for 1 minute, 55°C for 30 seconds and 72°C for 2 minutes. 
PCR product sizes expected for coding sequence obtained of Dit2 gene was 
approximately 1.5 kb. The products were initially subcloned into pGEM-T Easy 
using T/A overhang, which allowed ease of verification through restriction digest 
analysis. After this the sequence encoding CaDit2p was released after digestion with 
Nde I and Sph I and ligated into a modified pSport expression vector for E. coli 
(Barnes, personal communication). The constructs were transformed into DH5a 
strains for heterologous expression and the vector called pSport-Dit2.
2.12.2. CYP56 expression
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The figures A-D show the DNA sequence of the D1T2 gene locus of C. 
albicans and the corresponding amino acid sequence used in the heterologous 
expression studies. The yellow box in Fig. A and B indicates the DNA and amino acid 
sequence, respectively from the database. The green box corresponds to the gene 
sequence (C) and amino acid sequence (D) of the CaDit2 gene adjusted for E. coli 
expression using the Barnes procedure (Barnes et al., 1991).
(A)
> D i t 2  DNA
ATG TTT CAA CTA TTG AAA TAT ATC TTT ATT GGA GGA TTC ACC TAT TTA CTT
TAT TTA ATT TTG GAG ATA GTT TTC CCA CCA TTC AAT TTC CCT AGA AAT ATT
CCC ACA ATA CCA TTT TAT GTG TCG TTT TTA GGG GCT TGC ACC AAT TTG GAT
CAA GAA GAT ATT TAC AAA CTA TAT CTA CGA GAA AAA TTG GAA AAA TAT GGT
GCT GTT AAA ATG TAC TTT GCC TCG AGA TGG AAT ATT TTA ATC ACT AAA CCA
GAT TTC TTA CTT GAA ATG TTT AAA AAT GAA GAT GTA TTT GCC AAA AGT GGC
AAT CAT GTC AAG ATT CCA AAT TCG GTT TTA GCA ACT TAT ACT GGG GAT AAT
ATC ATT AGT GCT CAT GGA GAA TTA TGG AAA TTA TAC CGA GAT GTT GTT GCC
CAA AGT ATT CAA TTT CCT GAT TTG AAA CCA ATT TCC AAG AAT ACA CAA AAG
TTG TTA CGA TTT CTT GAT AAC GAA ATG GGA TCA GCA AAT CAA GCC ACT ATT
TCA GTG ACA GAT ATA TTA CAG AAA TAT TCC TTG GCC AAT GTT TGT GAA TCT
GTC CTT GGC GTT AAT TTT AAT GTA CTT GAT GAT AAA CAA TCA CTT ATG CAT
GAG AAG ATT AAA TAT GTT AAA CTG CAA ATT TTC AAT CCC ATT TTC TTA AAT
TTC CCT TAT TTT GAC AAT TTC CCC ATT CCA AGC CGA CTC AAG GCA AGA AGA
GAA GTG ATT GGG TTT CGT AAA TGG TAT GGT CAA AGC CTT ATA GAA AAG TAT
AAT TTA CAA TTG CCA AAC TCA GCA GCT ACA AAA TTG GTG GAT TCT TTG ATC
AAA GAA AAA TTG ACA GAA AAA CAA TTT TTG GAT AAT GCC ATA ATT TTA ATG
ATT GCT GGT CAT GAA AAT CCA TTA CTA TTG ATG TTA TCA TTA TTA TAT GTT
GTT TCT AAA TAT CCA CAA GTT CAA GAA TTA ATA CGC AAT GAA ACA GAA ACA
ACA AAA CCT TAC CTT CAT TCA GTT ATT TAT GAA ACT CTA AGA ATG TAT CCA
CCA TTG GGA TTA ATC ATA AAT AGA TGC ACA ACT AGA ATC ACC AAA TTG GGC
AAT ATT GTT ATC CCT AAA AAT GTT TAT TGC GGT TAT AAT AAT TTT GGT ACG
GGA AGG GAT AGA AAT GTC TGG GGA TCA GAT GCA GAT ATT TTC AAA CCA GAA
CGA TGG GGA TTG GAA ATT GAT GAA ATC AAC AAG AAA TTT ACG TTA GCC AAA
AGA TCA GCT GAA TTG CCC GCA TTT CAT GGC AGG AAA AGA GCA TGT TTA GGT
GAA AAA TAT GCA TTG TTT GAA GTT AAA CAA TTT TTA TTG GCA ATT CTA GGT
GAG TAT AAA GTG TCT CTA GAC CCA AAT TGG AAA GAA CAA TTG ACA CCT GCT
GGG CCA ATT AGC CCC TTG CGA TTG AAA TTG AAT TTT GAA AAG CTT ACA GTT
TCC TAA
(B)
> D i t2  P r o t e i n
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M F Q L L K Y I F I G G F
P P F N F P R N I P T I P
D Q E D I Y K L Y L R E K
S R W N I L I T K P D F L
S G N H V K I P N S V L A
E L W K L Y R D V V A Q S
T Q K L L R F L D N E M G
L Q K Y S L A N V C E S V
S L M H E K I K Y V K L Q
D N F P I P S R L K A R R
L I E K Y N L Q L P N S A
L T E K Q F L D N A I I L
L S L L Y V V S K Y P Q V
P Y L H S V I Y E T L R M
T R I T K L G N I V I P K
R D R N V W G S D A D I F
N K K F T L A K R S A E L
E K Y A L F E V K Q F L L
N W K E Q L T P A G P I S
V s *
T Y L L Y L I L E I V F
F Y V S F L G A C T N L
L E K Y G A V K M Y F A
L E M F K N E D V F A K
T Y T G D N I I S A H G
I Q F P D L K P I S K N
S A N Q A T I S V T D I
L G V N F N V L D D K Q
I F N P I F L N F P Y F
E V I G F R K W Y G Q S
A T K L V D S L I K E K
M I A G H E N P L L L M
Q E L I R N E T E T T K
Y P P L G L I I N R C T
N V Y C G Y N N F G T G
K P E R W G L E I D E I
P A F H G R K R A C L G
A I L G E Y K V S L D P
P L R L K L N F E K L T
(C)
> D i t 2  DNA E x p r e s s i o n  
ATG GC^ CAA CTA TTG AAA TAT ATC TTT ATT GGA GGA TTC ACC TAT TTA CTT
TAT TTA ATT TTG GAG ATA GTT TTC CCA CCA TTC AAT TTC CCT AGA AAT ATT
CCC ACA ATA CCA TTT TAT GTG TCG TTT TTA GGG GCT TGC ACC AAT TTG GAT
CAA GAA GAT ATT TAC AAA CTA TAT CTA CGA GAA AAA TTG GAA AAA TAT GGT
GCT GTT AAA ATG TAC TTT GCC TCG AGA TGG AAT ATT TTA ATC ACT AAA CCA
GAT TTC TTA CTT GAA ATG TTT AAA AAT GAA GAT GTA TTT GCC AAA AGT GGC
AAT CAT GTC AAG ATT CCA AAT TCG GTT TTA GCA ACT TAT ACT GGG GAT AAT
ATC ATT AGT GCT CAT GGA GAA TTA TGG AAA TTA TAC CGA GAT GTT GTT GCC
CAA AGT ATT CAA TTT CCT GAT TTG AAA CCA ATT TCC AAG AAT ACA CAA AAG
TTG TTA CGA TTT CTT GAT AAC GAA ATG GGA TCA GCA AAT CAA GCC ACT ATT
TCA GTG ACA GAT ATA TTA CAG AAA TAT TCC TTG GCC AAT GTT TGT GAA TCT
GTC CTT GGC GTT AAT TTT AAT GTA CTT GAT GAT AAA CAA TCA CTT ATG CAT
GAG AAG ATT AAA TAT GTT AAA CTG CAA ATT TTC AAT CCC ATT TTC TTA AAT
TTC CCT TAT TTT GAC AAT TTC CCC ATT CCA AGC CGA CTC AAG GCA AGA AGA
GAA GTG ATT GGG TTT CGT AAA TGG TAT GGT CAA AGC CTT ATA GAA AAG TAT
AAT TTA CAA TTG CCA AAC TCA GCA GCT ACA AAA TTG GTG GAT TCT TTG ATC
AAA GAA AAA TTG ACA GAA AAA CAA TTT TTG GAT AAT GCC ATA ATT TTA ATG
ATT GCT GGT CAT GAA AAT CCA TTA CTA TTG ATG TTA TCA TTA TTA TAT GTT
GTT TCT AAA TAT CCA CAA GTT CAA GAA TTA ATA CGC AAT GAA ACA GAA ACA
ACA AAA CCT TAC CTT CAT TCA GTT ATT TAT GAA ACT CTA AGA ATG TAT CCA
CCA TTG GGA TTA ATC ATA AAT AGA TGC ACA ACT AGA ATC ACC AAA TTG GGC
AAT ATT GTT ATC CCT AAA AAT GTT TAT TGC GGT TAT AAT AAT TTT GGT ACG
GGA AGG GAT AGA AAT GTC TGG GGA TCA GAT GCA GAT ATT TTC AAA CCA GAA
CGA TGG GGA TTG GAA ATT GAT GAA ATC AAC AAG AAA TTT ACG TTA GCC AAA
AGA TCA GCT GAA TTG CCC GCA TTT CAT GGC AGG AAA AGA GCA TGT TTA GGT
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GAA AAA TAT GCA TTG TTT GAA GTT AAA CAA TTT TTA TTG GCA ATT CTA GGT
GAG TAT AAA GTG TCT CTA GAC CCA AAT TGG AAA GAA CAA TTG ACA CCT GCT
GGG CCA ATT AGC CCC TTG CGA TTG AAA TTG AAT TTT GAA AAG CTT ACA GTT
TCC CAT CAC CAT CAC CAT CAC CAT CAC CAT CAC TAG
(D)
> D i t2  P r o t e i n
M A Q L L K Y I F I G G E T Y L L Y L I L E I V F
P P F N F P R N I P T I P F Y V S F L G A C T N L
D Q E D I Y K L Y L R E K L E K Y G A V K M Y F A
S R W N I L I T K P D F L L E M F K N E D V F A K
S G N H V K I P N S V L A T Y T G D N I I S A H G
E L W K L Y R D V V A Q S I Q F P D L K P I S K N
T Q K L L R F L D N E M G S A N Q A T I S V T D I
L Q K Y S L A N V C E S V L G V N F N V L D D K Q
S L M H E K I K Y V K L Q I F N P I F L N F P Y F
D N F P I P S R L K A R P E V I G F R K W Y G Q S
L I E K Y N L Q L P N S A A T K L V D S L I K E K
L T E K Q F L D N A I I L M I A G H E N P L L L M
L S L L Y V V S K Y P Q V Q E L I R N E T E T T K
P Y L H S V I Y E T L R M Y P P L G L I I N R C T
T R I T K L G N I V I P K N V Y C G Y N N F G T G
R D R N V W G S D A D I F K P E R W G L E I D E I
N K K F T L A K R S A E L P A F H G R K R A C L G
E K Y A L F E V K Q F L L A I L G E Y K V S L D P
N W K E Q L T P A G P I S P L R L K L N F E K L T
V S H H H H H H H H H H *
Primers designed for production of PCR derivatives o f CaDIT2 for heterologous 
expression in E. coli. Ten histidine triplets were added in the frame at the 3 end to aid 
the protein purification following expression.
Forward Primer (contains Ndel site and F2 to A2 modification)
>DIT2 Fl exp
CAT CGC C A T  ATG> GCT CAA CTA TTG AAA TAT (30-mer)
Reverse Primer (contains Sphl site and 10-His tag)
>DIT2 R2 exp
ACT GCT <GCA TGC> CTA GTG ATG GTG ATG GTG ATG GTG ATG GTG 
ATG GGA AAC TGT AAG CTT TTC (45-mer)
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2.12.3. Expression of CYP proteins in Terrific Broth (TB) media
Clones containing genes for expression were grown in 10 ml of LB containing 
0.1 mg.ml'1 sodium ampicillin overnight at 37°C, 225 rpm. The overnight cultures 
were used to inoculate 500 ml aliquots of Terrific Broth (TB) containing 0.1 mg.mf1 
carbenicillin. The cultures were then shaken at 200 rpm, 37°C for 5 to 6 hours until an 
optical density of 0.6 was obtained.
After 6h of incubation a-5 amino levulinic acid hydrochloride (ALA) was 
added to assist maximal haem protein production. After 7h of incubation the cells 
were induced for protein expression by the addition of and isopropyl-P-D- 
thiogalactopyranoside (IPTG) to final concentrations of 1 mM, with shaking at 160 
rpm, 28°C overnight. The cells were harvested by centrifugation at 5,000 rpm for 10 
minutes at 4°C (Beckman coulter centrifuge J20XP, rotor type JLA 8.1000). The 
pellet was resuspended in 0.1 M potassium phosphate, pH 7.4 and the cells were 
broken by sonication using a Branson Digital sonifier (32x 15 second bursts on ice at 
power setting 40-60%). The subcellular fractions were isolated by differential 
centrifugation. Cell debris was removed by centrifugation at 14,000 rpm for 20 
minutes at 4°C. The supernatant was subjected to ultracentrifugation at 45,000 rpm 
for 1 hour at 4°C (Beckman coulter ultracentrifuge XL-100K, rotor type 52.IT). The 
pellet contained the membrane fraction and this was resupended in 6 ml of 50 mM 
potassium phosphate, pH 7.4, 20% glycerol on ice using a glass homogeniser. The 
supernatant after centrifugation was the cytosolic fraction, which was kept for 
posterior SDS-PAGE gel analysis. The concentration of cytochrome P450 present was
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determined spectrophotometrically using the reduced carbon monoxide difference 
method of Sato (1964).
2.12.4. Cell breakage using the C5 Emulsifies high pressure homogeniser
Typically 500ml volume of cell culture was harvested by centrifugation 
(Beckman coulter centrifuge J20XP, rotor type JLA 8.1000) at 5000 rpm to pellet the 
cells and then resuspended in a 20ml of 0.1M potassium phosphate (pH 7.4). One 
pass through the homogeniser at 15000-20000 psi ruptured the E. coli cells. The 
homogenate was harvested by centrifugation (Beckman coulter centrifuge J20XP, 
rotor type JA20) at 15,000 rpm for 10 minutes to remove the cell debris and 
afterwards were harvested by ultracentrifugation (Beckman coulter ultracentrifuge 
XL-100K, rotor type 52. IT) at 45,000 rpm at 4°C for lhour all at 4°C to recover the 
microsomal pellet.
2.12.5. Cell breakage using the BL21 (DE3) pLysS cell lysis method
The BL21 (DE3) pLysS (Promega) E. coli strain allows the high efficiency 
expression of proteins under the T7 promoter. It is particularly useful because it 
contains the pLysS plasmid encoding the T7 lysozyme. This enzyme is bifunctional, 
it lowers the background expression of the target protein until IPTG is added and also 
digests the peptidoglycan layer of E. coli cell wall. This occurs upon treatment that 
disrupts the bacterial inner membrane and thus releases the enzyme such as by using 
freeze-thawing of cells. Following protein expression the cells were harvested and 
resuspended in 0.1M potassium phosphate buffer (pH 7.4) and frozen overnight at - 
80°C. The cells were then thawed at 4°C and were harvested by ultracentrifugation 
(Beckman coulter ultracentrifuge XL-100K, rotor type 52.IT) at 45,000 rpm at 4°C 
for 1 hour. Afterwards, the supernatant containing the cytosolic fraction was decanted
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and the microsomal pellet was resuspended in 0.1M potassium phosphate buffer (pH 
7.4) with 20% (v/v) glycerol.
2.12.6. CYP Spectrophotometric assay
Light-absorption spectra were measured using a Hitatchi U3010 scanning 
spectrophotometer. Cytochrome P450 concentration was estimated from reduced 
carbon monoxide (CO) difference spectra according to Omura and Sato (1964), using 
the extinction coefficient of 91 mM'1 cm'1 for the difference in absorbance units 
between 450 and 490nm. The extracts containing CYP were diluted in lOOmM 
potassium phosphate (pH 7.4) containing ImM EDTA and 20% (v/v) glycerol to 1ml. 
The sample was split equally and placed into two cuvettes and the baseline was 
determined between 400-490nm. CO was bubbled into the sample cuvette for 45 
seconds and then both cuvettes were then reduced by the addition of a small amount 
of sodium dithionite. The samples were again scanned between 400 and 490nm to 
determine changes in the absorption at 450nm.
2.12.7. Protein Solubilisation from membrane fractions
Microsomal bound heterologously expressed CYP proteins were initially 
disrupted with Griffiths glass tube homogenisers (Jencons-PLS, Cherrycourt Way 
Industrial. Estate, Bedfordshire). The microsomal suspension was then solubilised in 
0.1M potassium phosphate buffer (pH 7.4) containing 20% (v/v) glycerol and 1% 
(w/v) sodium cholate. The solution was gently agitated and left to stand on ice for 1 
hour with occasional mixing (approximately every 5 minutes). The solution was spun 
at 6,000g- (Centrifuge Sorvall® Legend TM/T/RT Kendro) for 1 minute (and the 
supernatant was clarified by ultracentrifugation at 45,000 rpm for 75 minutes at 4°C 
(Beckman coulter ultracentrifuge XL-100K, rotor type 52.IT). The supernatant was
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dialysed overnight against 5 litres of 25 mM potassium phosphate buffer (pH 7.4) at 
4°C. The dialysed solution was once again clarified by ultracentrifugation at 45,000 
rpm for 60 minutes at 4°C (Beckman coulter ultracentrifuge XL-100K, rotor type 
52. IT), and the supernatant was divided into 0.5 ml aliquots prior to freezing at -80°C. 
The concentration of cytochrome P450 was determined spectrophotometrically using 
the reduced CO method of Sato as before.
2.12.8. Candida CYP purification by affinity chromatography
Ni-NTA agarose (20 ml - Qiagen, Kent, UK) was equilibrated in 50 mM 
potassium phosphate, pH 7.4, 20% (v/v) glycerol (equilibration buffer). The matrix 
was washed three times with 50 ml aliquots of equilibration buffer by followed by 
centrifugation at 4,000 rpm. The equilibrated Ni-NTA agarose matrix was cooled to 
4°C prior to mixing with the solubilised CYP51 extract. The mixture of matrix and 
solubilised CYP51 protein was gently stirred for 2 hours at 4°C. The matrix was 
recovered by centrifugation followed by resuspension in 30 ml of equilibration buffer.
The matrix suspension was packed in a C-16 column (20 cm x 1.6 cm) at a 
flow rate of 30 ml.h'1 at 4°C. The column was washed with 50 ml of 50 mM 
potassium phosphate, pH 7.4, 20% (v/v) glycerol, 0.5 M NaCl to remove non- 
specifically bound protein. CYP51 protein was eluted from the column using 50 mM 
potassium phosphate, pH 7.4, 20% (v/v) glycerol, 0.5 M NaCl, 60 mM L-Histidine at 
a flow rate of 10 ml.h'1 with 1 ml fractions being collected. The fractions collected 
that contained the CYP51 protein were combined and dialysed against 5 litres of 20 
mM potassium phosphate, pH 7.2, 10% (v/v) glycerol overnight at 4°C.
2.12.9. Determination of CYP protein concentrations
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Cytochrome P450 concentration was determined by reduced carbon 
monoxide difference spectra according to Omura and Sato (1964) using the extinction 
coefficient of 91 mM'1 cm'1 for the difference in absorbance units between 450 and 
490 nm. Protein concentration was determined by the bicinchoninic acid method 
(BCA) using bovine serum albumin standards. Spectral determinations were made 
using a UV/VIS spectrophotometer (Hitachi U-3310, San Jose, California).
2.12.10. Concentrating Protein Solutions
Prior to use on sodium dodecyl sulphate polyacrilamide gel electrophoresis 
(SDS-PAGE), protein samples were concentrated using trichloroacetic acid (TCA). 
TCA was added to 3pg of protein to a final concentration of 10% (v/v). Samples 
were then centrifuged at 13,000 rpm for 10 minutes at room temperature. The pellet 
was washed with lOOpl of 0.5% TCA and centrifuged again at 13,000 rpm for 10 
minutes. The pellet was washed with acetone, centrifuged as before and redissolved 
in 15 pi of Laemmli buffer containing SDS loading buffer and 10% (v/v) P- 
mercaptoethanol. The protein samples were heated at 95°C for 5 minutes centrifuged 
for 10 minutes at 13,000 rpm and the supernatant loaded onto the gels.
2.12.11. SDS - Polyacrylamide Gel electrophoresis
SDS-PAGE is based on the fact that the denatured proteins bound to the 
strongly anionic SDS detergent are negatively charged and migrate through the 
polyacrylamide gels in accordance with the sizes of their polypeptides. The 
discontinuous buffer system of Laemmli was the basis of the method used. The 
resolving gel concentration used was 11% (w/v). A constant voltage of 150V was 
applied for 70-80 minutes using the Bio-Rad power pack. Following the successful 
separation of the protein samples, the gel was stained with coomassie brilliant blue R-
250 and destained by shaking in a destaining solution containing methanol and acetic 
acid.
2.12.12. Spectral studies on binding of substrate to CaDit2p
Cytochrome P450 substrate binding spectra was performed according to the 
method of Jefcoate et al., (1969). The substrates (5 mM TV-formyl tyrosine) were 
dissolved in ammonium hydrogen carbonate. 2 nmoles of purified CaDit2p in 1ml of 
potassium phosphate buffer (pH 7.4) 20% glycerol was placed into the sample 
cuvettes and 1ml of buffer was placed into the reference cuvettes. The baseline was 
recorded between 350 and 500 nm. Substrates were added incrementally to both 
cuvette and a difference absorbance spectrum recorded.
The concentration of substrate in each sample after sequential addition of substrate 
solution was calculated as the difference in absorbance between 380 and 420 nm. The 
difference in absorbance between 380 and 420 nm was plotted against the 
concentration of substrate using the programme Profit 5.0.1 (© 1990-1996, Cherwell 
scientific publishing, Quantum Soft, Zurich, Switzerland). Non-linear regression 
using the Levenberg-Marquardt algorithm was used to fit the Michaelis-Menten 
equation to the data, in order to calculate the Ks values. Each substrate-binding 
experiment was performed in triplicate and these were used to calculate the mean Ks 
value for the substrate with CaDit2p. The Hill equation was also applied to determine 
if CaDit2p has more than one substrate binding sites at the same time.
2.12.13. Reconstitution of dityrosine (CYP56) synthase activity in vitro
Dityrosine synthase activity was determined using an in vitro reconstitution 
assay. This consisted of 0.1 to 1 pM of purified yeast Ncprlp (Warrilow et al., 2002),
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5 pM of expressed CaDit2p (Ni-NTA agarose purified), 10 pM.mf1 N- 
formyltyrosine, 80 nM dilaurylphosphatidylcholine and 0.1 M potassium phosphate, 
pH 7.4 in a total reaction volume of 1 ml. The reaction was initiated by the addition of 
NADPH to a concentration of 1 mM prior to gently vortexing the solution to form 
micelles and incubating the assay mixture at 37°C, 200 rpm for 1 hour. The reaction 
was terminated by the addition of 2.5 ml of 1:1 chloroform:methanol followed by 
vortexing for 1 minute at room temperature. The upper phase was isolated by 
centrifugation followed by aspiration, and the lower phase was washed with 1 ml of 
10% ammonium hydroxide and the upper phase isolated. The two upper phases were 
pooled and centrifuged at 16,000 x g for 10 minutes prior to concentration using a 
SpeediVac (Heto Maxi Dry plus) under vacuum at room temperature. The 
components of the concentrated supernatant were separated by TLC as described in 
material and methods (Chapter 2.18.4). A control sample containing dityrosine 
generated by horseradish peroxidase was included. The separated components were 
examined visually under UV light and were isolated from the TLC plate by extraction 
with 10% ammonium hydroxide from scrapings taken from the plate. The separated 
components, including A-formyl dityrosine of both the sample and control, were 
identified by HPLC/MS as described in this Chapter 2.18.5.
2.13. Antifungal susceptibility test
Antifungal susceptibility tests were performed using the broth microdilution 
method according to the guidelines recently published by the National Committee for 
Clinical Laboratory Standards (NCCLS 2002).
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2.13.1. Antifungal agents used in this study
Agents Reference
Fluconazole non-labelled Pfizer (Pfizer Pharm. UK)
[3H] fluconazole Specific radioactivity, STkBq.mmor1, 
Amersham International
Amphotericin B Bristol-Myers Squibb
Nystatin Bristol-Myers Squibb
Voriconazole Pfizer Pharm. Inc. UK
Miconazole Sigma, St. Louis, Mo., USA
Itraconazole Janssen-Kyowa Co., Ltd., UK
Ketoconazole Janssen-Kyowa Co., Ltd., UK
Clotrimazole Sigma, St. Louis, Mo., USA
Imidazole Sigma, St. Louis, Mo., USA
Econazole Sigma, St. Louis, Mo., USA
5-flucytosine Sigma, St. Louis, Mo., USA
ritonavir Abbott, USA
nikkomycin Sigma, St. Louis, Mo., USA
caspofungin Merck, USA
2.13.2. Susceptibility testing
MICs were determined by broth microdilution method of National Committee 
for Clinical Laboratory Standards (NCCLS 2002) (National Commitee for Clinical 
Laboratory Standard, 2002).
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Drugs were tested for antifungal efficacy at concentrations ranging from 16 to 
0.001 (ig.ml"1 for voriconazole, for fluconazole 64-0.001 pg.ml'1, itraconazole 16-0.03 
pg.ml'1, clotrimazole 16-0.03 pg.ml"1, amphotericin 16-0.03 pg.ml'1, caspofungin 16- 
0.001 pg.ml'1, and nikkomycin 64-0.001 pg.ml'1.
The medium used was RPMI-1640 medium (Nissui Pharmaceutical Co., 
Japan), buffer morpholinepropanesulfonic acid (MOPS; Sigma Chemical Co.) and 
adjusted to pH 7.0 (Taguchi et a l 1995). These antifungal reagent-grade powders 
were dissolved in dimethyl sulphoxide solvent (DMSO) to obtain stock solutions of 
12.8 mg.ml'1. A 10-fold serial dilution was performed in RPMI-1640 medium to 
provide a working solution for each drug giving specific final concentration ranges as 
described by NCCLS guidelines (NCCLS 2002). Antifungal agents were serially 
diluted in 96-well microtiter plates (Falcon, Lincoln Park, N J). The isolates were 
subcultured onto PDA slants at 30°C for 24 h. Cell suspensions were prepared in 
RPMI-1640 medium and were adjusted to give a final concentration approximately
2.5 x 103 cells.ml'1. The microdilution plates were incubated at 30°C and the MICs 
were determined visually at 24 and 48 h. The minimal inhibitory concentration (MIC) 
was defined as the lowest concentration of antifungal agent at which 80% inhibition 
of growth (MIC80) compared with that of the growth control well. C. albicans ATCC 
90028 and ATCC 90029 strains were used in each microdilution set to ensure quality
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control. Breakpoints for antifungal susceptibility have been established for Candida 
isolates tested according to NCCLS.
Polyenes Azoles Other
Species AMPHB FLCZ ITCZ KTC 5-FC
C. albicans S S S S S
C. tropicalis S s s s s
C. parapsilosis s s s s s
C. glabrata I S-DD S-DD s
C. krusei I R S-DD to R I-R
C. lusitaniae R S S-DD R
• S = Susceptible to usual doses of this agent (< 1 pg.ml'1 amphotericin B, < 
8pg.m r' fluconazole, ^ O .^ S p g .m f1 itraconazole, < 4 p g .m f1 5-flucytosine 
(5FC))
• S-DD = Susceptibility depends on the dose (fluconazole) or delivery 
(itraconazole) of the drug. Maximal tolerated doses must be used and blood 
levels may need to be checked.
• I = Indeterminate or Intermediate. This category reflects a general lack of 
certainty about the meaning of this MIC.
• R = Resistant to usual doses of this agent (> 64pg.m l1 fluconazole, > 1 pg .m l1 
amphotericin B and itraconazole, (> 32pg.m l1 5FC)
2.13.3. Etest assay
84
The Etest is a susceptibility testing method which involves the placement of a 
plastic strip containing a defined continuous gradient of antimicrobial drug on the 
surface of an inoculated agar. The Etest strips had drug concentrations ranging from 
0.02 to 32 pg.ml'1 for itraconazole and amphotericin B and from 0.016 to 256 pg.ml'1 
for fluconazole. RPMI 1640 with L-glutamine but without bicarbonate was buffered 
with MOPS (morpholinepropanesulfonic acid) at pH 7.0, and agar-BACTO were used 
to prepare Etest RPMI-agar (1.5%) plates. The Etest was performed according to the 
manufacturer’s instructions (AB BIODISK 1993). The inoculum concentration was 
adjusted to 2 x 104 cell.ml'1. A cotton swab was used to apply the inoculum-adjusted 
solution onto the 150 mm diameter RPMI-agar (1.5%) surface so as to obtain even 
growth on the entire agar surface. The plates were allowed to dry approximately 15 
min before the Etest strips were placed with a sterile forceps on the medium surface. 
The plates were incubated for 24-48 hours until growth was clearly seen. The MIC 
was read where the elliptical inhibition zone intersected the scale on the strips and 
compared with Etest reading and interpretation guidelines.
2.14. Accumulation of [3H] fluconazole in Candida clinical isolates
Accumulation of [3H] fluconazole in Candida cells was determined by a filter- 
based assay adapted from Sanglard et. a l (Sanglard et al., 1995). All experiments 
were repeated on three separate occasions. Overnight cultures were grown in YNB 
containing 2% glucose at 30°C, 200 rpm to a density of 109 cells per ml. The cells 
were centrifuged at 4000 rpm for 5 minutes and the pellet resuspended in YNB 
medium to the original cell density. A total of 20 p.1 of [ H] fluconazole (0.154 kBq), 
with a specific activity of 37 kBq.mmole'1, was added to 1 ml of the cell suspension.
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The cells were incubated at 30°C with shaking at 200 rpm. Samples of 100 pi were 
withdrawn at fixed time intervals, and mixed with 0.5 ml of cold YNB medium 
containing 20 pM unlabelled fluconazole placed in a Spin-X nylon membrane 
microfiltration unit (pore size 0.45 pm - Costar, Cambridge). The cells were isolated 
by centrifugation at 9000 rpm for 30 s and then washed with the unlabelled 
fluconazole-YM medium three times. Liquid scintillant was added and the 
radioactivity within the cells was measured using a liquid scintillation analyzer (2500 
TR-TRI carb, Packard Bioscience Company). In other experiments cells were exposed 
to a subinhibitory concentration of sodium azide (NaN3; 0.01 mM) (Moran et al.,
1997) to establish whether [3H] fluconazole accumulation was an active energy- 
dependent process.
2.15. Growth inhibition studies
2.15.1. Antifungal agents
Voriconazole (Pfizer Pharm. Inc. UK), fluconazole (Pfizer Pharm. Inc. UK), 
itraconazole, ketoconazole (Janssen-Kyowa Co., Ltd., UK), miconazole, econazole, 
clotrimazole (Sigma, St. Louis, Mo., USA), imidazole (Sigma, St. Louis, Mo., USA), 
5-flucytosine (Sigma Chemical Co., Ltd., St. Louis, Mo., USA), amphotericin B, and 
nystatin (Bristol-Myers Squibb), and ritonavir (Abbott, USA) were tested at 
concentrations ranging from 0.125 to 64 pg.ml'1.
2.15.2. Cell growth
Single colonies of C. albicans strains were inoculated into 10-ml aliquots of 
YNB (yeast nitrogen broth, Difco) medium containing 2% glucose. These were 
incubated at 30°C for 24 h with shaking at 250 rpm. Cells were harvested by
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centrifugation at 3500 x g  for 5 min, at 4°C, washed twice with YNB medium and 
resuspended in 10 ml YNB medium. Cells densities were adjusted to a final 
concentration of 2 x 103 cells.ml'1 in YNB medium containing 2% glucose. 
Preparation of antifungal drugs and dilution schemes were performed in accordance 
with the National Committee for Clinical Laboratory Standards (NCCLS, 1997). 
Microtitre plates were inoculated with the tested strain under different drug regimes. 
Growth curves of isolates were determined in aerobic batch cultures at 37°C, over 48 
hours using a Bioscreen C Analyser (Groeneveld et al., 2002). Growths were 
calculated as AOD per hour (AOD.hour'1).
2.15.3. Cell wall alteration assays
Various stresses were placed on cells exposed to different agents. Drop tests 
were performed by spotting 106, 105, 104, 103 and 102 cells, ml'1 onto YEPD or YM 
agar plates supplemented with 1.5 M sorbitol, 100 pg.ml'1 SDS, 1 M or 1.5 M NaCl, 5 
mM or 10 mM H2O2 , 0.5 M or 1 M CaCb, 100 pg.ml'1 calcofluor, 100 pg.ml'1 congo 
red, 1 pg.ml'1 itraconazole, 10 pg.ml'1 amphotericin, 2 pg.ml'1 fluconazole, 0.5 pg.ml' 
1 nikkomycin. Other sugars were also tested in the medium besides glucose i.e. 
maltose and galactose, the duplicate plates were incubated 24 h at 37°C and 42°C.
2.16. Sterol extraction
Yeast cells were grown to saturation in YNB medium containing 2% glucose, 
shaking 200 rpm at 30°C. Cells (108 cells.ml'1) were harvested by centrifugation for 5 
min at 3000 g, transferred to stop glass tubes and resuspended in 5 ml of methanol, 3 
ml of 60% KOH and 2 ml of 0.5% (w/v) pyrogallol dissolved in methanol. 
Additionally 50 pi of 1 mg.ml'1 cholesterol was added to the control sample. The
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samples were saponified by heating at 90°C for 2 hours. Sterols were extracted using 
two 5 ml aliquots of hexane followed by evaporation to dryness with N2. The isolated 
sterol fractions were resuspended in 100 pi of toluene and heated at 60°C for 1 h for 
silylation with 20 pi of BSTFA. The sterol samples were analyzed by gas 
chromatography/mass spectrometry using split injections at a ratio of 20:1. Sterol 
identification was determined by comparison of retention times and mass spectra by 
gas chromatography-mass spectrometry (GC/MS) (Joseph-Home et al. 1996).
2.17. Determination of dityrosine content
Determination of dityrosine content of yeast cultures was performed (Rudge et 
al., 1998). Yeast cultures (1x10s cells) were collected by centrifugation, washed 
twice with sterile water, and resuspended in 1 ml of 10% ammonium hydroxide. Cell 
suspensions were maintained at -80°C overnight, thawed, and lysed by repetitive 
vortexing (six times for 30s each) with equal volume of glass beads (425-600 pm, 
acid washed, Sigma) at 4°C. Chloroform:methanol (1:1, 2.5 ml, Sigma), was added, 
and the mixture was mixed for 2 min at room temperature. The upper phase was 
collected after centrifugation, and the lower phase was washed with fresh 10% 
ammonium hydroxide (Sigma). The two upper phases were pooled, and 1.5 ml were 
prepared by centrifugation at 16000 rpm for 10 min at room temperature. Finally, 1 
ml was removed, and the dityrosine content was determined by fluorescence 
spectrophotometry. Fluorescence was measured at room temperature with a 
Fluorescence Spectrophotometer F-2500 (Digilab Hitachi, Tokyo, Japan). 
Measurements were made in a semimicrovuvette. Intensity of emission was measured 
at 420 nm at excitation of 320 nm (Briza et a l 1986).
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2.18. Synthesis of dityrosine standards
2.18.1. Reagents used in the in vitro dityrosine production
All reagents used were of analytical reagent grade purchased from Sigma. N-
carbonate and were kept at 4°C. The working solution of hydrogen peroxide (H2O2) 
was 0.6%. The enzyme solution consisted of horseradish peroxidase (HRP) at 
concentration 3 mg.ml'1 stock solution.
2.18.2. In vitro Dityrosine synthesis
Dimerization of the tyrosine employed the enzyme horseradish peroxidase. 
HRP, a low molecular weight peroxidase, has a heme cofactor, a Fe (III) center bound 
to a porphyrin ring. H2O2 can react with the heme to generate ferryl, which can 
directly or indirectly, via HRP structure, react with the tyrosine residue of the 
monomer to generate phenoxy radicals (Fig. 2.7). After the coupling of two phenoxy 
radicals and tautomerization, the complete dimer is formed (Fig. 2.7). The yield 
during dimerization can be suppressed by the formation of many side products. For 
example, trimers can form from further enzymatic coupling of a dimer and a 
monomer.
Dityrosine Formation
Formyl tyrosine solution (10 pM.mf1) were dissolved in ammonium hydrogen
I I  +  2 h 2o
COOH COOH COOH
Fig. 2.7. Dimerization of the tyrosine employed the enzyme horseradish.
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The dityrosine assays (Amado et al., 1984) were performed in 2 ml containing 
JV-formyl tyrosine solution (2 mg. ml'1) dissolved in 0.1 M ammonium hydrogen 
carbonate, and 0.3 mM H2O2. The reaction was started by adding HRP (10 pg.ml'1), 
the mixture was equilibrated at room temperature for 30 min. Control samples were 
single L-tyrosine or Af-formyl tyrosine, without H2O2 or HRP. The fluorescence 
excitation spectra were collected on a Hitachi F-2500 fluorescence spectrophotometer 
(Hitachi, Tokyo, Japan). The excitation wavelength of dityrosine fluorescence was 
320 nm and relative intensity were measured against a reagent blank. The emission of 
the oxidation product was 400-405 nm. Using vacuum centrifuge (Heto, Maxi Drier, 
UK) the products of reaction were evaporated down to dryness to concentrate the 
product that was stored at -80.
2.18.3. Isolation and purification of dityrosine
2.18.4. Thin-Layer Chromatography assay
TLC was used to characterize the dityrosine synthesised as described above. 
The concentrated samples were resuspended in 100 pi of 10% ammonium hydroxide 
then loaded on 20 cm long silica gel plates (silica gel 60F, Merck, Germany) 
(modified Method Duisburg Essen). The following solvent system was used, n- 
propanolol -  ammonium hydroxide (70:30, v/v). Development of the TLC took 6 
hours at room temperature in a glass solvent tank. The developed TLC plate was air- 
dried and the separated products were visualised by ultraviolet light (254 nm) and 
fluorescence spots were identified. The broad zone of N- formyl dityrosine was very 
well separated from trimer and tetramer of N- formyl dityrosine. The fluorescent zone 
corresponding to 7V-formyl dityrosine was scraped off and, extracted with 10% 
ammonium hydroxide. The extracts were evaporated to dryness and redissolved in
10% ammonium hydroxide. The fluorescence of the extract was examined using by 
Hitachi F-2500 fluorescence scanning spectrophotometer (Hitachi, Tokyo, Japan). 
The fluorescence measurements of the TV-formyl dityrosine were performed at an 
excitation wavelength of 320 nm and relative intensity were measured against a 
reagent blank, the emission of the oxidation product was measurable at 400-405 nm.
2.18.5. High performance liquid chromatography analysis
The samples were analysed by HPLC-MS in multiple reaction monitoring 
mode. The HPLC system used was an Ultimate HPLC pump with FAMOS 
autosampler with an in-house prepared C l8 (Pepmap C l8 stationary phase (Dionex, 
UK)) HPLC column 300|um * 15cm run at a flow rate of 4pl.min'1. The mobile phase 
used was an isocratic mix of 50/50 0.1% formic acid in water / 0.1% formic acid in 
methanol. The HPLC column was connected directly to a LCQ XP DECA ion trap 
mass spectrometer (Thermo Finnigan, UK). It was used in positive ion mode with a 
spray voltage of 3.5kV, Sheath and Auxiliary gas flows of 30% and 10% (arbitary 
units) respectively, a capillary temperature of 200°C and a capillary voltage of 10V. 
The mass spectrometer was set to study the MRM transitions for N-formyl dityrosine, 
and it gave a mass spectrum corresponding to that expected for dityrosine.
2.19. Germination test
Cell suspension at 2 x 103 concentration were prepared in 1 ml RPMI with 20% 
bovine calf serum and shaken 200 rpm at 37°C for 2-4 hours before examination for 
germination microscopically.
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2.20. Chlamydospore formation
Strains were cultured on com meal agar and broth (Difco, US), supplemented 
with 1% Tween 80 and 20 (ig.ml-1 methionine, at 25°C for 5-7 days or on Rice-Agar- 
Tween medium (RAT medium, Biomerieux) before microscopic examination of 
chlamydospore formation. Hyphal formation was induced using 10% calf serum 
(GIBCO BR, USA), or RPMI-1640 at 37°C for 2 to 4 hours. To produce anaerobic 
conditions during hyphal formation, Na2S03 (final 50 mg.ml'1, Sigma, St. Louis, Mo., 
USA) was added to RPMI or minimal medium broth as described before (Watanabe et 
al., 2006). Na2S0 3 absorbs oxygen present in the medium. Airtight anaerobic 
containers (Oxoid) were also used. Hyphal formation was examined by Nikon optical 
microscope and images captured by Nikon 4500 digital camera, at 40x and lOOx.
2.21. Confocal microscope analysis
Three sets of cell culture were performed to investigate the blue natural 
fluorescence presence in Candida yeast form, germination and chlamydospore forms. 
The germination was performed as before and the yeast form was obtained from 
overnight cell culture in YEPD.
Cells were cultured under specific conditions for microscopic visualization of 
yeast-like and hyphal growth. Aliquots of culture were transferred to sterile 
Eppendorf tubes and centrifuged (10,000 x g) for 3 min. Supernatants were discarded 
and each resulting pellet suspended in sufficient 10% (w/v) ammonium hydroxide to 
support effective image composition and reasonable distribution of experimental 
material. Subsequently 7.5 pi of each suspension was dispensed into wells of separate 
multi-spot microscope slides (Hendley, UK), a coverslip affixed and immediately
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viewed with a Zeiss LSM 510 Meta Axiovert facility (Carl Zeiss Gmbh, Heidelberg, 
Germany). Additionally, in a separated procedure cells were stained with 2 pi 
calcofluor (stock 100 pg.ml'1) for 5 min and washed twice with Hepes. Cells were 
dispensed onto microscope slides, dried at room temperature and fixed with 7 pi of 
acetone, finally 2.5 pi of vectashield was added to improve the fluorescence 
visualization. Transmission images were obtained with a 5 mW helium-neon laser, 
wavelength 633 nm, in turn fluorescence images were obtained with a UV 100 W 
lamp, moderated to 30% intensity and filter set FS01. Gain, offset and zoom functions 
were employed to optimize fluorescence image intensity, composition and contrast. 
Slides were viewed with an oil immersion Zeiss Plan-Achromat 63x, 1.4 NA 
objective, 512 x 512 pixel images captured and exported in TIFF format using Zeiss 
laser scanning microscope LSM 510 version 3.2 SP2 software.
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Chapter 3
Characterization of Candida species: 
Susceptibility studies, Drug accumulation 
and Sterol Composition
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3.1. Introduction
The incidence of fungal infections, particularly infections caused by Candida spp., 
has increased considerably during the past two decades. Among the different species 
causing infections, C. albicans has been isolated in more than 50% of clinical cases 
(Nguyen et al., 1996, Melo et al., 2004). Also C. dubliniensis, which is closely related 
to C. albicans phylogenetically, has been isolated in clinics around the world 
(Sullivan et al., 1995, Sano, 2000). In previous investigations, C. dubliniensis was 
isolated from the oral cavities of 27% of human immunodeficiency virus (HIV)- 
infected subjects and 32% of AIDS patients with oral candidosis (Coleman et al., 
1997, Espinel-Ingroff et al., 1999). C. dubliniensis has also been recovered from the 
oral cavities of asymptomatic and symptomatic immunocompetent individuals, 
although to a much lesser extent. C. dubliniensis was first described in South America 
by Rodero et a l (Cuenca-Estrella et al., 2002). Transmission of genetically 
indistinguishable strains of C. albicans between HIV-infected adult partners has been 
reported previously (Muller et al., 1999). Little is known about the transmission of C. 
dubliniensis between children and within families (Muller et al., 1999). The majority 
of C. dubliniensis clinical isolates tested to date are susceptible to several antifungal 
agents (Moran et al., 1997).
Azole antifungals (eg fluconazole, itraconazole) are commonly used to treat C. 
albicans infections. Due to the repeated use of these agents, especially in HIV- 
positive patients with recurrent oropharyngeal candidosis, treatment failures were 
observed to correlate with the emergence of resistant C. albicans strains (Kelly et al., 
1991, Sanglard and Odds, 2002, Kelly et al., 1996). The success of antifungal
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treatments depends on the patient’s status, the type of antifungal agent given, and the 
biological response of the fungal pathogen. Among the different antifungal agents 
available, the class of azoles has been used extensively during the past 20 years and 
their mode of action is through inhibition of CYP51, sterol 14a-demethylase (Ergl lp).
To date, four resistance mechanisms have been suggested in the development of azole 
resistance in C. albicans with varying levels of evidence: (i) the cellular content of the 
azole target encoded by the CYP51 gene can be increased; (ii) the affinity of CYP51 
for azoles can be decreased by mutations in CYP5J; (iii) the ergosterol biosynthetic 
pathway can be altered to suppress the effect of azoles by altering the type of sterol 
accumulating with treatment; and (iv) azole concentration can fail to accumulate to 
the same level inside the cells through altered drug efflux (Sanglard et al., 1998, 
Sanglard and Odds, 2002).
Among these mechanisms, increased drug efflux is the most commonly identified 
mechanism in clinical strains developing azole resistance, although usually 
comprehensive examination of all mechanisms is not undertaken in the literature. This 
mechanism usually involves the upregulation of multidrug transporter genes from at 
least two families, i.e. CDR1 and CDR2 (iCandida drug resistance 1 and 2) of the 
ATP-binding cassette (ABC) transporter family (Prasad et al., 1995, Orozco et al., 
1998, Sanglard and Odds, 2002) and CaMDRJ (Candida albicans multidrug 
resistance 1) of the major facilitator (MF) superfamily (Franz et al., 1998, Sanglard et 
al., 1998, Sanglard et al., 1995). Transcriptional activation of both CDR1 and 
CaMDRl genes as a result of different environmental stresses have also been reported 
(Krishnamurthy et al., 1998a, Krishnamurthy et al., 1998b, Sanglard and Odds, 2002).
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The transcription of CaMDRl, the gene encoding CaMdrlp, is almost undetectable in 
azole susceptible isolates but is raised in some azole resistant isolates. In contrast, the 
transcription of CDRJ, the gene encoding Cdrlp, is detectable in azole-susceptible 
isolates, but is increased to higher levels in some azole-resistant isolates. The 
upregulation of multidrug transporters in the development of antifungal resistance is 
also well described in the baker’s yeast Saccharomyces cerevisiae. Like C. albicans, S. 
cerevisiae possesses ABC transporters or MFS transporters that are able to confer 
resistance to antifungal drugs (Goffeau et al., 1997).
This chapter describes work investigating the prevalence of C. dubliniensis infection 
in a Brazilian family with an HIV-infected child. Additionally, azole susceptibility 
including azole antifungal accumulation in various Candida species, sterol 
composition and the relationship with measurements of inhibitory potency was 
investigated. Some different patterns of azole resistance exhibited by various Candida 
species, investigated here, suggest that more than one mechanism of resistance may 
be active. Therefore a single parameter, such as intracellular drug accumulation levels, 
should be associated with other parameters in the investigation of fungal resistance. 
Further studies including molecular analysis are warranted to further investigate 
whether intra cellular drug accumulation of fluconazole provides supporting data on 
azole sensitivity.
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3.2. Material and Methods
3.2.1. Materials
Chemicals were of analytical grade and are listed in the Chapter 2.13.1.
3.2.2. Strains used in this study
Fluconazole-susceptible strains used were Candida albicans ATCC 90028, ATCC 
28516 and Candida dubliniensis (CBS 7889). The other strains and clinical isolates 
used are listed in the Chapter 2.6.9.
3.2.3 Subjects enrolled in the G dubliniensis study
One HIV-infected child who acquired HIV vertically is being monitored at the 
Paediatric Immunodeficiency Outpatient Service, Medical School, Campinas State 
University. The child’s parents died from HIV. The oral flora from the HIV-infected 
child and family members was investigated. A total of 42 oral isolates were obtained 
from eight family members (Table 3.1).
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Table 3.1.
Characteristics of the eight family members with an HIV-infected child
Name Kindred Age (years) Race Gender
LPS HIV child 5 white Male
MLA Grandmother 55 white Female
LA Aunt 25 white Female
PA Uncle 20 white Male
CA Uncle 21 white Male
CHA Cousin 2 white Male
CAMA Cousin T white Female
JA Cousin 6 mulatto Female
amonths
3.3. Results and Discussion
Different Candida species have been investigated in terms of their antifungal 
susceptibility and drug accumulation within this chapter. Antifungal susceptibility 
exhibited by determined MIC values varied greatly among Candida isolates. The 
intracellular drug accumulation levels, which are also a balance of uptake of azoles 
and active efflux, varied and were species dependent. Non-albicans isolates, such as 
C. krusei, C. lusitaniae and C. norvegensis, exhibited a high intracellular [3H] 
fluconazole concentration in this study (Table 3.2, Fig. 3.1). In contrast C  albicans 
and C. dubliniensis strains exhibited lower intracellular drug concentrations. Most of 
the C. krusei, C. valida and C. norvegensis strains were azole resistant according to 
MIC data. However, all C. lusitaniae and C. dubliniensis isolates were sensitive to 
fluconazole with MICs in the range 0.25 to 4 pg.ml’1.
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Table 3.2.
MICsos, intra cellular [3H] fluconazole accumulation values and total percentage
ergosterol level in Candida species.
Strain MIC8oS (pg.m l1) 
AMPH B FLCZ ITCZ
[3H] 
fluconazole 
(MD ± SD) 
(dpm/109 cells)
Ergosterol
(%)
C. albicans
ATCC 90028* 1 1 0.5 80.5 ± 12.8 93.7
ATCC 28516* 1 1 0.5 73.4 ±6 82.2
1-MAB 8 >64 8 45 ± 4.4 76
(n=3) 1-8 1-64 0.5-16 66 ±8
C. krusei
9C 1 16 4 169.6 ±75.5 71
21 2 8 4 323.4 ±38.9 85
46 0.5 32 4 221.9 ±129.9 32
53 4 64 4 333 ± 128.1 77
88 2 64 8 288.3 ± 169.6 73.4
123B 2 32 4 201.6 ±71.2 79
127D 2 64 4 70.8 ± 15.2 75
129B 2 64 8 168.8 ±62.6 76.7
1-RAO 16 64 4 123 ±33 79
ATCC 6288 0.5 32 0.5 175.5 ±81.8 92
(n=10) 0.5-16 8-64 4-8 227 ± 141.5
C lusitaniae
19-A1 0.25 0.25 0.5 182.1 ±55.8 83.4
25-B 0.5 1 0.5 165.3 ±61.3 78.6
75-A 1 2 2 173.9 ±25.1 69.8
76-A 1 2 2 263.7 ±68.2 72.9
110-A 2 4 4 180.7 ±69.6 74
121-A 1 4 2 243.8 ± 151.3 70
(n=6) 0.25-2 0.25-4 0.5-4 201.5 ± 19.5
C. norvegensis 
186-C 2 64 4 92.3 ± 59.4 80
3-MASC 2 32 2 162 ±47 92.3
(n=2) 2 32-64 2-4 127 ±49.5
Cvalida
1-MBJ 2 64 2 119.4 ±41.2 93
C. dubliniensis 
9-LPS 2 0.5 1 46 ± 11.5 45.4
2-MLA 2 0.125 1 94.6 ±26.1 79.5
IFM 48313 2 0.125 0.125 96.2 ± 17.5 49.5
(n=3) 2 0.125-5 0.125-1 79 ± 18.3
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In addition these isolates have also shown drug accumulation involves an active efflux 
component demonstrated by the effect observed in the presence of sodium azide (an 
agent that blocks ATP-dependent transporters).
Three C. albiccms strains were investigated, among them two reference strains 
that were fluconazole-sensitive and one C. albicans clinical isolate (Table 3.2). The C. 
albicans reference strains were sensitive to all drugs tested and showed 80.5 and 73.4 
dpm/109 cells of intra cellular [3H] fluconazole accumulation, respectively.
The clinical isolate (1-MAB) showed cross-resistance to amphotericin B and 
fluconazole (Table 3.2) with a MIC of 8 pg.ml"1 and >64 pg.ml'1 respectively 
compared to 1 pg.ml"1 and 1 pg.ml"1 in the sensitive isolates. The cross-resistant C. 
albicans clinical isolate was found to accumulate approximately half the amount of 
[3H] fluconazole (44.9 ± 4.4 dpm/109 cells) compared with the reference strains and 
was shown to accumulate approximately 3.5 times more [3H] fluconazole in the 
presence of sodium azide (Fig. 3.3). The altered patterns of fluconazole accumulation 
were not reduced to the same extent in strains containing mutations changing the 
expression of azole drug pumps as reported previously (Odds et al., 2004).
C. dubliniensis and C. albicans are the closest species phylogenetically among 
those studied here in terms of taxonomy and biological characteristics (Moran et al.,
1998). All C. dubliniensis isolates investigated were antifungal-sensitive. Similar [ H] 
fluconazole intracellular concentrations were found between C. dubliniensis (96.2 ±
17.5 dpm/109 cells) and C. albicans (80.5 ± 12.8 dpm/109 cells) reference strains in 
this study (Table 3.2). In contrast one C. dubliniensis clinical isolate showed half the 
amount of [3H] fluconazole intra cellular accumulation (46 ± 11.5 dpm/109 cells) 
compared to the reference CBS strain (Fig. 3.3).
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Antifungal resistance described to date generally involves the emergence of naturally 
resistant species as in C. krusei or the progressive, stepwise alterations of cellular 
structures or functions to block the activity of an antifungal agent to which there has 
been extensive exposure. C. krusei was among the fungal species studied here. The 
reference strain in this study exhibited dose-dependent sensitivity to fluconazole and 
was sensitive to amphotericin B with a MIC of 32 pg.ml'1 for fluconazole and 0.5 
pg.ml*1 for amphotericin B (Table 3.2). Some C. krusei isolates showed higher 
intracellular [3H] fluconazole concentrations and others exhibited lower intracellular 
concentrations compared to the reference strain (Fig. 3.4A). Most of the clinical 
isolates showed MICs values comparable to the fluconazole resistance reported 
elsewhere. Exceptions in the susceptibility testing to antifungal agents were found in 
two isolates (21C and 9C), that showed MICs of 8 pg.ml'1 and 16 pg.ml'1 for 
fluconazole, respectively and hence were more sensitive. Moreover both isolates 
exhibited similar levels of [3H] fluconazole accumulation compared to the reference 
strain. The majority of the isolates, with similar levels of drug accumulation compared 
to reference strains, were azole resistant (high MIC values). One of C. krusei clinical 
isolates (127D) studied here showed low levels of [3H] fluconazole intracellular 
concentrations (70.8 ± 15.2 dpm/109 cells), 2.5-fold less compared to C. krusei 
reference strain and the MIC for fluconazole was 64 pg.ml'1. This isolate was resistant 
to amphotericin B as well as fluconazole (Table 3.2) although efflux is not thought to 
play a role in amphotericin resistance.
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Amongst the strains, C. krusei 53-A and 88-C2 isolates exhibited a high intracellular 
[3H] fluconazole concentration after 30 min of incubation (Fig. 3.4A) when compared 
to the reference strain. After 60 min both isolates showed decreased intracellular 
fluconazole concentrations, less than the reference strain and this could reflect 
differences in efflux mechanisms. Both isolates were fluconazole resistant as 
indicated by MIC data (Table 3.2). In addition, the 53-A isolate showed a high MIC 
value of 4 pg.mr1 for amphotericin B. Hence this isolate shows cross-resistance. The 
C. krusei isolates 21C and 46B after 60 min of incubation with [3H] fluconazole 
exhibited higher intracellular drug concentrations compared to the reference strain and 
this was/ was not reflected in the altered MIC value to the same drug. Although some 
C. krusei isolates exhibited higher intracellular fluconazole concentrations compared 
with C. krusei reference strain, they showed higher MIC values suggesting variation 
in the tolerance of the intracellular fluconazole concentration. All C. krusei isolates 
were shown to accumulate approximately 1.5 times more [3H] fluconazole in the 
presence of sodium azide (Fig. 3 .4B) supporting a role for active drug efflux via the 
ABC transporters superfamily. In general the intracellular [3H] fluconazole 
concentration levels in C. krusei isolates were higher compared to those in C. albicans 
strains (Table 3.2).
Consequently, C. krusei clinical isolates were fluconazole-resistant with high levels of 
intracellular fluconazole tolerance. This general fluconazole resistance phenotype 
observed elsewhere was confirmed with experimental evidence that drug efflux 
mechanisms may play a role. A role for other mechanisms cannot be excluded.
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The C. lusitaniae clinical isolates showed a narrow range of intracellular [ H] 
fluconazole concentration levels (Fig. 3.5). Additionally, all C. lusitaniae isolates 
showed approximately 1.5 times more [3H] fluconazole accumulation in the presence 
of sodium azide (Fig. 3.5). However, the intracellular [3H] fluconazole concentration 
was higher compared to C. albicans, but similar to that of the C. krusei isolates. 
Unlike C. krusei, all C. lusitaniae isolates investigated were susceptible to the 
antifungal agents tested (Table 3.2). However, the literature has reported frequent 
resistance incidences for amphotericin B in C. lusitaniae isolates (Ghannoum and 
Rice, 1999, Noel et al., 2005, Peyron et al., 2002). The study here also included rare 
non-albicans species including C. norvegensis (n=2) and C. valida (n=l) which were 
shown to be azole-resistant.
They also showed slightly higher levels of intracellular concentrations of [3H] 
fluconazole compared to C. albicans (Table 3.2). The exception was a C. novergensis 
isolate, which showed similar levels of intracellular concentrations of fluconazole to 
the C. albicans reference strain.
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In the present work, the ergosterol content in Candida species was also investigated to 
reveal whether mutations in sterol biosynthesic enzymes correlated with amphotericin 
sensitivity and also to identify if the known azole-resistance phenotype of Erg3 
mutants was operating. The predominant sterol observed in most strains was 
ergosterol and the level of this sterol varied between 70-92% of the total sterol 
isolated with only a few exceptions (Table 3.2). The C. krusei reference strain ATCC 
6288 produced 92% of ergosterol. Nine clinical C. krusei isolates were investigated 
and analysis of the sterol content demonstrated that ergosterol was the predominant 
sterol in eight of these isolates. An exception was the C. krusei isolate (46) which 
showed an ergosterol content of only 32% with the concomitant accumulation of 
lanosterol (16% of the total sterol content). Additionally, the MIC value for 
fluconazole of this isolate was 32 pg.ml'1 and intracellular fluconazole concentration 
value was similar when compared to the C. krusei reference strain. On the other hand, 
the MICs for fluconazole varied among C. krusei isolates and showed 5 isolates with 
high MIC > 64 pg.ml'1, 4 isolates with a MIC of 32 pg.ml'1 and one isolate with a 
MIC of 8 pg.ml'1. Interestingly, because isolate (46) accumulated 16% lanosterol 
(Table 3.2) this may indicate some defect in the CYP51 turnover of substrate in the 
sterol pathway.
In the remaining C. krusei isolates the sterol pattern was unaltered comprising 
predominantly ergosterol, although the MICs for fluconazole in general were very 
high. This may suggest that in C. krusei other resistance mechanisms, rather than 
changes in the sterol pathway, are involved. The isolate (1-RAO) revealed cross­
resistance to amphotericin B with a MIC 16 pg.ml'1 and fluconazole MIC > 64 pg.ml'1, 
but surprisingly the sterol profile was unaltered with 79% of ergosterol present. The
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sterol profile, with retention of ergosterol at a high percentage of total sterols present 
in the resistant isolate indicates no mutations of the enzymes involved in the 
ergosterol biosynthetic pathway. Amphotericin is believed to interact with ergosterol 
to mediate fungicidal effects, but no large scale sterol changes of the sort produced by 
polyene resistance in other studies were evident in this resistant isolate (Kelly et al., 
1997, Jackson et al., 2003, Venkateswarlu et al., 1995). However, Kelly et a l has 
previously demonstrated that lack of ergosterol in C. albicans can be the cause of 
cross-resistance to amphotericin B (Kelly et a l, 1997).
The C. krusei isolates in these experiments have shown several different resistance 
profiles. The findings suggest that more than one antifungal resistance mechanism is 
active here. This organism has been described to be intrinsically resistant to 
fluconazole (Ghannoum et al., 1999, Marichal et al., 1995). In the literature there is 
substantial variability in the reported fluconazole MIC for C. krusei (Venkateswarlu et 
al., 1997, Fukuoka et al., 2003). Possibly these differences can be attributed to 
differences in the methodology or strain variations in the mechanism of antifungal 
resistance. Two mechanisms of azole resistance in C. krusei have been described 
previously. Isolates of C. krusei that were resistant to itraconazole exhibited reduced 
drug accumulation, suggesting that resistance to this drug was due to the activity of 
one more drug efflux pump(s) (Venkateswarlu et al., 1996). A second mechanism of 
azole resistance in C. krusei was reduced susceptibility of CYP51 to inhibition by the 
azole antifungal agent (Orozco et al., 1998). In this study, the CYP51 activity in cell 
extracts of C. krusei were 16 to 46-fold more resistant to inhibition by fluconazole 
than was CYP51 activity in cell extracts of two fluconazole-susceptible strains of C. 
albicans. Marichal et a l (1995) has indicated that differences in susceptibility to
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itraconazole and ketoconazole are unrelated to differences in affinity for the C. krusei 
CYP51 (Marichal et al., 1995). The differences in sensitivity of C. krusei isolates 
appeared to arise from differences in the intracellular itraconazole, ketoconazole and 
fluconazole contents.
C. lusitaniae is an emerging opportunistic pathogen recently recognized as an 
important cause of nosocomial infection in severely immunocompromised patients 
(Young et al., 2003). It has been reported that C. lusitaniae strains may be 
intrinsically resistant to antifungal agents (Ghannoum and Rice, 1999). Resistance to 
amphotericin B in yeasts has been considered very rare (Rex et al., 1997, Guinet et al., 
1983). Here six clinical C. lusitaniae isolates from HIV-infected patients were 
analysed and the sterol composition from the strains determined. Prior analysis of the 
isolates in this study has indicated that all clinical isolates were sensitive to 
amphotericin B (Table 3.2), similar data has been reported elsewhere (Favel et al., 
2003, Pfaller et al., 2002). Analysis of the sterol profile of the clinical isolates 
revealed that ergosterol was the major sterol, accounting for 74% of the total sterols 
(Table 3.2). Peyron and collaborators have also reported that ergosterol was the 
predominant sterol in a C. lusitaniae amphotericin B-sensitive isolate (Peyron et al., 
2002). That particular isolate had MIC to amphotericin B of 2 pg.ml'1, which was 
slightly higher than those determined for the isolates tested here. In contrast, the 
amphotericin B-resistant strain reported by Peyron et a l had a different sterol 
composition indicating a defect in the A8—>1 isomerisation step. Amphotericin B is 
believed to interact with ergosterol in the plasma membrane to mediate fungicidal 
effects (Kelly et al., 1997, Jackson et al., 2003, Venkateswarlu et al., 1995), but no 
large scale sterol changes of the sort produced by polyene resistance in other studies
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were evident here. The management of infections due to C. lusitaniae should 
consider the possibility of polyene resistance, but seemingly isolates can exhibit 
sensitive phenotypes and typical ergosterol contents.
Two C. glabrata isolates were studied in which the sterol composition showed 65% 
ergosterol (Table 3.3). Both strains revealed increased amounts of the sterol 
intermediates, but the accumulating sterols observed do not indicate specific mutation 
of the specific enzymes involved in sterol biosynthetic pathway (Table 3.3). These 
isolates were sensitive to antifungal agents (data not shown). C. glabrata has 
emerged as a common cause of disease seen in the outpatient setting and can 
potentially exhibit reduced susceptibility to azole antifungals (Bard et al., 2005, 
Nakayama et al., 2001, Hazen et al., 2005). Consistently, this organism has been 
described to be an intrinsically resistant Candida species similar to C. krusei 
(Nakayama et al., 2001, Melo et al., 2004). The major abundant sterol in C. glabrata 
is ergosterol (Nakayama et al., 2001). This work has shown that amongst two C. 
glabrata clinical isolates the predominant sterol was also ergosterol (Table 3.3). 
Interestingly C. glabrata has ability to uptake exogenous sterol when ergosterol 
biosynthesis is blocked. Specifically, C. glabrata can use cholesterol from the human 
host and thus compensate the azole inhibition of ergosterol biosynthesis. The 
decreased susceptibility to azoles and the requirement of exogenous sterol for growth 
suggest that some C. glabrata isolates may contain defects in ergosterol biosynthesis 
(Bard et al., 2005).
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Analysis of the sterol composition of the C. parapsilosis clinical isolates in this work 
revealed that ergosterol was the predominant sterol in all isolates examined (Table 
3.4). Additionally, all isolates were susceptible to the antifungal agents tested (data 
not shown). Similar results for other C. parapsilosis strains were reported recently 
(Magill et al., 2006, San Miguel et al., 2005, Colombo et al., 2006). Rare non- 
albicans species also included in this study included C. norvegensis (n=2), and C. 
valida (n=l) which were azole-resistant. Surprisingly they revealed an unaltered sterol 
composition (Table 3.2, Fig. 3.6), reinforcing the high diversity of resistance 
mechanism in Candida species. This underlines the explanation for recent emergence 
of non-albicans species causing Candida infection diseases in the clinic.
Several mechanisms have been reported to be associated to resistance to amphotericin 
B and azoles in C. albicans (Ghannoum and Rice, 1999). In this study three clinically 
isolated C. albicans strains were investigated, among them two reference strains were 
fluconazole-sensitive that showed more than 82% of total ergosterol in the cell 
membrane. One C. albicans clinical isolate (1-MAB) was resistant to amphotericin 
and fluconazole. However, the sterol composition indicated normal level to ergosterol 
(Table 3.2). C. albicans seemingly depends solely on endogenous ergosterol 
synthesis and no mechanism of sterol uptake has ever been reported (Kurtz and 
Marrinan, 1989, Nakayama et al., 2000, Tsai et al., 2004). On the other hand Dumitri 
et a l (Dumitru et al., 2004) have reported that anaerobic growth in C. albicans can 
taken place in the absence of exogenous sterol. Ergosterol biosynthesis requires 
oxygen for a number of steps hence the validity of this study is open to question.
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Fig. 3.6. Percentage ergosterol in Candida spp. CK= C. krusei, 
CL= C. lusitaniae, CP= C. parapsilosis, CN= C. novergensis, CV= 
C. valida, CD= C. dubliniensis, CG= C. glabrata, CA= C. albicans.
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Recently, little attention has been paid to the clinical significance of azole-resistance 
in paediatric patients (Muller et al, 2000). The oral Candida isolate (1-MAB) from 
the child in this investigation showed low susceptibility to all azoles tested as judged 
by the MICgos obtained for fluconazole (> 64 iug.mr1), voriconazole (8 pg.ml'1), 
miconazole (>16 pg.ml'1), ketoconazole (>16 fig.mf1), and itraconazole (8 pg.mr1). 
The clinical isolate also showed low susceptibility to amphotericin B (8 pg.mf1) 
(Table 3.5). Caspofungin, a compound active against cell walls of fungi, was a potent 
inhibitor for all strains tested. This class of drug has shown a limited antifungal 
spectrum (Niimi et al., 2006). However because it is not structurally and functionally 
related to the polyenes or azoles drugs, caspofungin cross-resistance was expected to 
be rare (Hernandez et al., 2004). Therefore one approach to increasing the therapeutic 
index of antifungal agents is to use them in combinations for synergistic interactions.
Table 3.5.
Drug susceptibilities of the C. albicans isolates.
MICgos (pg.mf1)
Drug 1-MAB ATCC 90028 erg3
FLC 64 1 >64
VRC 8 0.5 >64
ITC 8 0.5 >64
KTZ >16 1 >64
MCZ >16 1 >16
RT 4 1 -
AMB 8 1 8
CAS 0.03 0.01 0.03
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The clinical isolate, 1-MAB, showed a MIC to ritonavir of 4 i^g.ml"1. On the other 
hand the fluconazole-sensitive strain (ATCC 28516) exhibited a MIC for ritonavir of 
1 jig.mT1. Thus, one could speculate that the long term use of ritonavir, as part of 
HIV therapy, could influence the virulence of the clinical Candida isolates. In spite 
of the recent findings of the unexpected benefit of the protease inhibitors against C. 
albicans secreted aspartyl proteases (Pozio, 2004), further experiments are required to 
establish the value of the HIV protease inhibitors for candidosis treatment.
In the clinical isolate (1-MAB) voriconazole and fluconazole caused 85 % and 65% 
growth inhibition, respectively, at a concentration of 64 pg.ml'1. Amphotericin B at a 
concentration of 8 fig.ml'1 inhibited 62% of cell growth indicating cross-resistance. 5- 
flucytosine was effective at inhibiting cell growth of 1-MAB at a concentration of 
0.25 pg.mf1. 5-flucytosine has been successfully used in combination with 
amphotericin B in the treatment of several deep mycoses (Gonzalez et al., 1996). The 
synergistic effect obtained by this drug combination provides an alternative therapy in 
resistance cases (Hope et al., 2004, Melo et al., 2004, Gonzalez et al., 1996, Martin et 
al., 1992). Our results suggest that 5-flucytosine may be useful in the treatment of 
strains showing cross-resistance to polyenes and azoles although more studies are 
required.
Ergosterol biosynthesis defects are clearly associated with polyene resistance and 
erg3 mutants associated with monogenic cross-resistance. Analysis of the sterol 
profile of 1-MAB revealed that ergosterol remained the predominant sterol (Table 
3.2), accounting for 76% of the total sterols with 4-desmethyl sterols (17%). Varing 
amounts of sterol intermediates (Table 3.6) represent an intrinsic difference between
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the strains unrelated to resistance and similar profiles have been observed elsewhere 
in sensitive strains (Venkateswarlu et al., 1995). The sterol profile with retention of 
ergosterol at a high percentage of total sterols in the resistant isolate indicates no 
mutations of the enzymes involved in the ergosterol biosynthetic pathway. 
Amphotericin is believed to interact with ergosterol to mediate fungicidal effects, but 
no large scale sterol changes of the sort produced by polyene resistance in other 
studies were evident in the resistant isolate (Kelly et al., 1997, Jackson et al., 2003, 
Venkateswarlu et al., 1995).
Table 3.6.
Sterol composition of C. albicans isolates.
Sterol identified
1-MAB
Total Sterol fraction (%) 
ATCC 90028 erg3
Ergosterol 76 93.7 -
Ergosta-7,22 dienol 0.15 - 77
Ergosta-7-enol 0.7 - 22
4-desmethyl sterols 17.3 - -
4-methyl sterols 5.5 - -
Unidentified - 6.3 1
The isolate 1-MAB was found to accumulate approximately half the concentration of 
[3H] fluconazole (44.9 ± 4.4 dpm.109 cells'1) than the reference strains and was found 
to accumulate approximately 3.5 times more [ H] fluconazole in presence of sodium 
azide (Table 3.7). The altered patterns of fluconazole accumulation were much lower 
than those associated with mutations changing the expression of drug pumps 
described elsewhere (Odds et al., 2004).
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Table 3.7.
Accumulation of [3H] fluconazole (dpm.min1) in presence of NaN3 in C. albicans
clinical isolate (1-MAB).
Strains 3[ H] fluconazole [3H] fluconazole + NaN3
(MD ± SD) (MD ± SD)
1-MAB 44.9 ± 4.4 152.6 ±32.8
ATCC 90028 (S)* 80.5 ± 12.8 87.5 ±31.6
ATCC 28516 (S)* 73.4 ± 6 83 ± 8
*Fluconazole-sensitive
The drug efflux mechanisms of azole resistance do not give rise to amphotericin 
cross-resistance - hence the novelty of the findings here. Previously, an example of 
azole and amphotericin cross-resistance not related to a defect in sterol biosynthesis 
was observed in C. neoformans mutants isolated in vitro (Joseph-Home et al., 1996) 
and similar mechanism(s) may be operating in the clinical C. albicans isolate 
examined here. Alternatively two independent mechanisms of resistance may be 
occurring although the probability for such multiple events is much lower. 
Elucidating the genetic cause of the resistance will require molecular analysis. 
Finally we conclude the presence of cross-resistance to antifungal drugs in paediatric 
patients, including azoles not previously used in children, does occur.
Transmission of genetically indistinguishable strains of C. albicans between HIV- 
infected adult partners has been reported previously (Muller et al., 1999). However, 
little is known about the transmission of the isogenic C. dubliniensis strain between 
children and within families. The aim of this study was to investigate the presence of 
C. dubliniensis among Brazilian family members. Oral flora from one Brazilian HIV- 
infected child and his family members was investigated. A total of 42 oral mucosa
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isolates were obtained from eight family members between September 2000 and 
January 2002 (Table 3.1). Yeast isolates were identified by classical methods. These 
methods included chromogenic agar culture, chlamydospore production, germ tube 
formation, Candida Check kit®, ID32C® profile; and the temperature test was also 
used to distinguish C. albicans from C. dubliniensis by its differential growth at 45°C. 
The confirmation of C. dubliniensis identification was performed using molecular 
biotyping.
The oral flora of the family members showed high diversity with several non-albicans 
isolates identified (Fig. 3.7). C. dubliniensis was isolated only in the HIV-infected 
child and in his grandmother. The grandmother has repeatedly refused to be HIV 
tested. The colony forming unit (CFU) quantification was higher for C. dubliniensis 
(CFU=100) in the HIV-infected child than in his grandmother (CFU <30).
C. alb icans 
C.dublin iensis 
C. glabrata
MLA
CA
C. ru g o sa C. parapsilosis
( la} -
C. ru go sa LPS
C. alb icans 
C.dublin iens is  
C .trop ica lis  
C. parapsilosis  
S .c e re v i s a e
CHA
C. ru g o sa  
K loeckera
P .e tc h e  llsii
AM
C. parapsilosis  
P .e tc h e  llsii
Fig. 3.7. Diagram of the species identified amongst the isolates from the family 
members of the HIV-infected child. I iLPS (HIV-infected child); + (HIV-infected 
mother) and ++ (HIV-infected father) both are deceased. Kindred of the HIV-infected 
child (MLA, CA, PA, LA, CHA, JA and CAMA).
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Using classical identification methods it was not possible to identify some isolates 
tested. The primary culture of Candida isolates on CHROMagar showed a dark green 
colony, rough appearance and smaller size in comparison with C. albicans colonies. 
The tested isolates that were identified as C. dubliniensis by PCR appeared as 305 
base pair bands on the gel (Fig. 3.8). The reference isolates had independent band 
patterns after the RAPD-PCR. Isolates 73, 390, 2-MLA, 3-MLA and 3-LPS had 
identical RAPD band patterns (Fig. 3.9), indicating that the clinical follow-up of C. 
dubliniensis might have the same genotype. The other Brazilian C. dubliniensis strain 
(S-34) had a different genotype. The genotypic coincidence among C. dubliniensis 
isolates from the same family members revealed that the grandmother was probably 
contaminated through the HIV-infected child (Fig. 3.9). Further epidemiological 
studies for his environment, such as neighbours, classmates and relatives might be 
required. Recently Milan and collaborators (Milan et al., 2001) reported that 33% of 
Candida spp. colonization with AIDS was through household contacts in contrast 
with 14% in the HIV-negative control (Milan et al., 2001).
Our findings also reveal that transmission through family members is possible and 
perhaps represents a previously under-appreciated factor in families with or without 
HIV infection. Moreover, the asymptomatic members who have not received 
antifungal therapy may also be colonized with resistant Candida species. The 
transmission of C. dubliniensis among siblings, parents and relatives may be through 
the exchange of contaminated commodties, which commonly occurs in the sharing of 
food, utensils, and toys.
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Fig. 3 .8. The gel image of amplification product of the C. dubliniensis specific gene 
cytochrome b. Marker, 1 line; 2, IFM 48184; 3, IFM 48313; 4, IFM 48314; 5, IFM 
49192; 6, 73; 7, 390; 8, 2-MLA; 9, 3-MLA; and 10, 3-LPS.
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Fig. 3.9. The gel image of RAPD fingerprinting patterns of C.dubliniensis isolates. 1, 
Molecular weight marker; 2, IFM 48184; 3, IFM 48313; 4, IFM 48314; 5, IFM 49192; 
6, 73; 7, 390; 8, 2-MLA; 9, 3-MLA; 10, 3-LPS; and 11, molecular weight marker.
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MICs for each antifungal agent were determined and all C. dubliniensis isolates 
investigated were susceptible to the antifungal drugs tested (Table 3.8), with the 
exception of nystatin. C. dubliniensis isolates exhibited MIC values of 0.125 pg.ml'1 
for voriconazole. In a previous study, C. dubliniensis isolates from Brazil reported 
high susceptibility for azoles (Mariano Pde et al., 2003) and similar results have been 
described in the literature (Pinjon et al., 2003, Espinel-Ingroff et al., 1999, Moran et 
al., 1997). Non-dubliniensis isolates from the other members of the family were 
susceptible to all drugs tested (data not shown).
Table 3.8.
MICs for antifungal drugs in C dubliniensis isolates
Drug 3-LPS 2-MLA IFM 48313
MIC (ng/ml)
VOR 0.125 0.125 0.125
FLCZ 0.5 0.125 0.25
ITCZ 1 1 0.125
KTZ 0.03 0.03 0.03
MCZ 2 2 2
CLTZ 0.06 0.06 0.06
AMPH 2 2 2
NYS 16 4 8
Few studies have reported upon the sterol composition of C. dubliniensis isolates 
(Pinjon et al., 2003). In this study sterol profiles of C. dubliniensis isolates (3-LPS, 2- 
MLA and IF 48313) showed percentages of 45.4%, 50% and 49.5% of ergosterol of 
the total sterol content. This contrasts to azole-susceptible C. dubliniensis isolates 
reported in another study in which the ergosterol profile showed 65%, 56% or 60% of 
total sterols (Pinjon et al., 2003). C. dubliniensis isolates from the Brazilian HIV- 
infected child (3-LPS) contained several intermediate sterols (Table 3.9). These 
included cholesta-8,24-dienol (14%) and ergostadienol (11%). In this report C.
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dubliniensis isolates also showed a reduced ergosterol level in comparison to C. 
albicans reference strains (ATCC 90028 and 28516). The ergosterol level has shown 
values above 80% to both C. albicans reference strains (ATCC 90028 and 28516) and 
these results are similar to that described previously (Kelly et al., 1997, Buurman et 
al., 2004). The sterol profile in this work suggests an interesting difference between C. 
dubliniensis and C. albicans as both species are closely related phylogenetically and 
further investigation of the sterol profiles in other C. dubliniensis isolates are required.
Table 3.9.
Sterol profile of C. dubliniensis clinical isolates (3-LPS, 2-MLA)
Total sterol fraction (%)
Sterol Profile 3-LPS 2-MLA IFMa
48313
ATCCb
90028
ATCCb
28516
Cholesta-8,24-dienol 14 13.1 19.1 - 4
Ergosterol 45.4 50 49.5 93.7 80.2
Ergosta-7,22-dienol 3.4 2.8 3.7 - 0.6
Ergosta-dienol 10.9 10.4 9.6 - 3.7
Methylfecosterol 1.5 - 1.8 - 3
Obtusifoliol 4.7 5.6 6.1 - 2.5
Eburicol 0.3 - - -
4,4-dimethylcholesta-dienol 6.6 5.8 - -
Unidentified
a ^ »  J. T1- - __ • _ j  b i7. ’____
12.3 12.3 9.6 6.3 6
Additionally, as these C. dubliniensis clinical isolates showed different ergosterol 
levels, we decided to investigate if the alteration in the function of efflux pumps could 
be detected in these isolates. Using C. dubliniensis isolates from HIV-infected child 
(3-LPS) and his grandmother (2-MLA), cells were incubated in the presence of [3H] 
fluconazole and the intracellular concentration of this compound determined (Fig. 3.3). 
Interestingly, the two clinical isolates were found to differ with regard to fluconazole 
accumulation.
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The isolate from the HIV-infected child was found to accumulate half the amount of 
[3H] fluconazole than the isolate from grandmother and IF 48313 reference strain 
(Table 3.10). It is also true that in the IF 48313 reference strain, ATP-dependent 
pumps were operating but no effect was observed when sodium azide was added. 
However, the isolates from the HIV-infected child and grandmother were found to 
accumulate approximately 1.5 times more [3H] fluconazole in the presence of sodium 
azide. These results indicate that the efflux of fluconazole from these two strains 
involved an active, energy-dependent component, as sodium azide inhibits ATP 
formation required for active transport.
Table 3.10. Accumulation of [3H] fluconazole (dpm/min) in presence of NaN3 in
clinical G dubliniensis isolates
Strains
—3—
[ H] fluconazole 
(MD ± SD)
[3H] fluconazole + NaN3 
(MD ± SD)
3-LPS 46± 11.5 70.3 ± 20.7
2-MLA 94.6 ±26.1 179.4 ±64.7
IFM 48313 96.2 ± 17.5 107.7 ±45.5
The most frequent molecular mechanism of azole resistance recently described has 
been the upregulation of efflux pumps (Odds et al., 2004). Reports have demonstrated 
azole resistance in C. dubliniensis isolates including its ability to rapidly develop 
resistance to fluconazole. This characteristic may partially explain the emergence of 
this species although the sensitivity of the isolates examined here and results of 
fluconazole accumulation studies do not point to any particular change regarding the 
relatively low concentration of ergosterol observed.
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Until the late eighties, clinical resistance to azole antifungals was a rare phenomenon. 
Only a few cases of resistance to ketoconazole were found in patients with chronic 
mucocutaneous candidosis. The spread of AIDS and the widespread prophylactic and 
therapeutic use of the azole compound fluconazole resulted both in the selection and 
induction of resistant strains and in a shift in the nature of the infecting organisms. 
Most azole antifungals such as itraconazole, ketoconazole and fluconazole are active 
against a variety of fungal diseases. However, the concentration required to inhibit 
growth is dependent upon the nature of the infecting species. Physiochemical features, 
such as the hydrophobicity and pKa of a given azole define whether or not it will be 
active or cross-resistant against a given species. Fluconazole is almost inactive against 
C. krusei and A. fumigatus, whereas itraconazole is active against these species. 
Acquired or induced resistance is the most controversial type because, even within a 
given species, organisms may differ in their response to the same azole.
There is controversy over the cause for the increasing incidence of intrinsically 
resistant non-albicans species. The cause might be a selection of these species due to 
the widespread usage of fluconazole. Only a few reports have studied mechanisms of 
resistance in non-albicans species (Venkateswarlu et al., 1996, Nguyen et al., 1996, 
Krcmery and Barnes, 2002, Capoor et al., 2005, Loeffler and Stevens, 2003). 
Development of resistance to azole compounds can lead to cross-resistance to other 
azoles. In the present investigation the intracellular fluconazole concentration levels in 
C. krusei isolates was greater than that of C. albicans. In general non-albicans 
isolates exhibited higher intracellular [3H] fluconazole concentrations and showed 
MICs with varying resistance patterns in most of the isolates in this study. One can 
speculate that in non-albicans species ,the tolerance for high levels of intracellular [3H]
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fluconazole concentrations is higher when compared to C. albicans species. 
However,, no clear correlation of azole drug accumulation and sensitivity in MIC 
have yet been determined. Such data requires to be carefully evaluated and used in 
special conditions such as comparison of genetically matched strains or parent/mutant 
comparisons.
The MIC values obtained for some Candida clinical isolates in this study were diverse 
and in some cases species specific. However, ergosterol levels in the cell membranes 
in most of the isolates were typical of the general expectation for fungi with only a 
few exceptions observed (Fig. 3.6). These exceptions contained relatively large 
amounts of sterol pathway intermediates instead of ergosterol. Further, the pattern of 
intermediate accumulation in strains was not indicative of any particular enzymatic 
defect. However, where it was observed, the reduced levels of ergosterol did not 
adversely effect the growth of the organism observed in these strains. This 
demonstrates the capacity of some strains to grow despite levels of ergosterol being 
half those present in the cell membranes of other strains/species. The mechanisms 
involved in controlling susceptibility to antifungal agents in any given Candida 
clinical isolate still remains unclear. Further work is required to establish the precise 
mechanisms that confer increased resistance to antifungal agents in the particular 
clinical isolates identified in this study. Studies on CYP51 sequence and sensitivity 
would seem a priority as drug accumulation studies did not seem to be implicated and 
other mutations in ergosterol biosynthesis were not detected that would warrant 
further study. Newer technologies such as microarray experiments may also reveal 
insights.
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Chapter 4
ROLE OF DIT2 IN CANDIDA ALBICANS 
GROWTH AND DRUG SUSCEPTIBILITY
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4.1. Introduction
The fungal cell wall is essential for controlling cell permeability, osmotic 
balance, cellular shape and morphogenesis. Studies on the Candida sp. cell surface 
(Shepherd, 1987) have been of particular interest including antigenicity (Calderone 
and Braun, 1991, Smail and Jones, 1984), mechanisms of adherence to epithelial and 
endothelial cells (Calderone and Braun, 1991) and in interactions with the host 
immune system (Smail and Jones, 1984, Smail et al., 1988). Elucidating the 
mechanism(s) of cell wall biosynthesis are critical for our understanding of 
morphogenesis and is an important area of interest for the development of new 
antifungal agents (Hector, 1993).
Amongst many functions, the cell wall contributes to the tolerance of yeast cells to 
damaging environmental agents and stresses. Extensive studies on fungal cell wall 
components have tried to understand the cell wall structure, the order of formation of 
the cell wall and the genes involved in the its formation (Ram et al., 1998, Ruiz- 
Herrera et al., 2006). The cell wall is the outermost structure of yeast cells and it 
provides substantial mechanical strength with a dynamic plasticity, thus guaranteeing 
cell survival in a fluctuating environment. A compromise between rigidity and 
plasticity in this structure at each point of the cell life must be achieved as well as a 
delicate balance between synthesis and degradation.
It is generally believed pathogenic fungi such as C. albicans have a very similar 
polysaccharide structure but differ significantly in their specific protein composition, 
which underscores the importance of cell wall proteins for pathogenesis. However, 
cell wall proteomics of fungi is a highly challenging task due to the complex
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biochemistry of these proteins and their glycosylated condition. The extensive post- 
translational modifications and potential covalent attachment of polysaccharides to the 
polypetide backbone of a large proportion of cell wall proteins makes it a demanding 
task to isolate and identify them. Regarding the genes associated with the Candida sp. 
cell wall, most of our knowledge comes from studies with S. cerevisiae.
Knowledge of the S. cerevisiae cell wall can be summarized as follows: the yeast cell 
wall comprises of a fibrillar network of chitin and 1,3-L-D-glucan to which 
mannoproteins anchor themselves, mostly through 1,6-L-D-glucan molecules. These 
components are synthesized into an elaborate extracellular matrix (Bulawa, 1992). 
This matrix constitutes an organelle that is dynamically engaged with the plasma 
membrane and the underlying secretory organelles (Pryer et al., 1992) along with 
cytoskeletal and cytoplasmic components to maintain cell integrity during growth 
(Cid et al., 1995). The cell surface varies in shape and composition throughout the 
lifecycle of the S. cerevisiae cell; for example, in the budding of vegetative cells, in 
mating projection formation, in cell fusion in haploid cell conjugation, in spore wall 
formation following meiosis and in the specialized cell surfaces and morphogenesis 
seen in pseudohyphal growth (Cid et al., 1995). In view of the complexity of the cell 
wall, the specific number of genes directly or indirectly involved in its biosynthesis 
and elaboration is expected to be large. However, a nearly complete collection of S. 
cerevisiae individual gene-deletion mutants have been identified (Ram et al., 1994, 
Giaever et al., 2002) and approximately 20% of these have been shown to be required 
for cell-wall biogenesis (Lussier et al., 1997). (February 2007, 
http://www.yeastgenome.org/cache/genomeSnapshot.html).
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In general, the Candida sp. cell wall is composed mainly of mannan (linked with 
protein to form mannoprotein), a-glucan, p-glucan, and chitin, which are complex 
polymers of mannose, glucose, and TV-acetylglucosamine, respectively. The content 
and distribution of these components vary with cell age, culture conditions, and 
morphology (Brown et al., 2000, Bogengruber et al., 1998, Ruiz-Herrera et al., 2006). 
The linkages between the glucan, chitin, and mannoprotein are poorly understood but 
presumably play a critical role in maintaining the integrity of the organism.
Different virulence factors are involved in C. albicans pathogenicity, but the role of 
the cell wall in such pathogenicity cannot be overestimated. The cell wall is the 
structure that: (1) first comes into contact with host cells; (2) carries important 
antigenic determinants of the fungus; (3) is responsible for the adherence of the 
pathogen; and (4) establishes a cross-talk with the host, which depends on what has 
been referred to as the ‘glycan code’, which includes modifications in the chemical 
composition and linkages of the cell wall polysaccharides. Microscopic observation of 
thin sections of fungal cells or isolated walls have revealed the existence of several 
layers in the wall, distinguished by their electron density in electron micrographs. 
Depending on the method of analysis, the wall of C. albicans appears to contain from 
four to eight layers (Poulain et al., 1978).
The spore wall in S. cerevisiae is a stratified extracellular matrix that is more complex 
than the normal vegetative cell wall (Klis et al., 2006, Smits et al., 2001). The 
vegetative wall consists primarily of an inner layer (closest to the plasma membrane) 
of P-glucans interspersed with a small amount of chitin and an outer layer of heavily 
mannosylated proteins (Smits et al., 1999, Klis et al., 2006). By contrast, the spore
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walls are formed by the ordered synthesis of different layers: first mannan, then 0- 
glucan, then chitosan, and finally outside of the chitosan is a layer that consists largely 
of cross-linked tyrosine molecules (Briza et al., 1988, Briza et al., 1990, Briza et al., 
1994). This indicates that the assembly of spore walls occurs through a coordinated 
series of steps.
S. cerevisiae has three cytochrome P450 genes: CYP51 (encoding lanosterol 14a- 
demethylase), CYP56 (encoding DIT2 a dityrosine forming enzyme required for spore 
wall biosynthesis), and CYP61 (encoding sterol 22-desaturase). The proposed 
pathway of dityrosine formation in sporulating yeast cells by Briza et. a l (Briza et al., 
1994) indicated that two N-formyltyrosine molecules are covalently cross-linked to 
form dityrosine, and the enzyme responsible for this enzymatic reaction is Dit2p, 
(also named CYP56 in the cytochrome P450 nomenclature 
[http://dmelson.utmem.edu/CytochromeP450.html]). In fact dityrosine is 
biosynthesized in a two-step process that takes place in the cytoplasm of the maturing 
spore. Initially, free L-tyrosine is chemically modified by Ditlp resulting in the 
formation of /V-formyl tyrosine. Secondly, two molecules of /V-formyl tyrosine are 
cross-linked by CYP56 to form LL-A/A^’-bisformyl dityrosine (Briza et al., 1996, 
Felder et al., 2002). NCPR1 was shown to be required for dityrosine formation by 
providing reducing equivalent necessary for CYP56 catalytic activity. The first 
description of dityrosine formation was in 1959 by Gross and Sizer (Gross and Sizer, 
1959), generated by oxidation of tyrosine with hydrogen peroxide and peroxidase. 
Dityrosine is an intensely fluorescent compound and is proposed to result from cross- 
linkage of two tyrosyl radicals (Briza et al., 1986). The oxidation of tyrosine with 
hydrogen peroxide and peroxidase, can lead to phenolic coupling of two phenoxy
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radicals of tyrosine. It was also found that dityrosine cross-links could also be formed 
in vitro by oxidation of structural and non-structural proteins (Andersen, 1964, 
Amado et al., 1984, Felder et al., 2002).
More recently the formation of coupled tyrosine derivatives in proteins has been 
associated with a variety of diseases and disorders which include Alzheimer’s and 
Parkinson’s diseases
(http://www.chemistry.unimelb.edu.au/stafFchutton/research/cah.htmy Non-specific 
formation of cross-linked tyrosine residues has been shown to be a biological marker 
of oxidative stress and plays a critical role in the signalling of protein degradation and 
cellular damage. Dityrosines can also be obtained under a variety of conditions. 
Dimerization of the monomer can occur via oxidative coupling with reagents such as 
VOF3 . Alternatively, dimerization can occur via reductive coupling using potassium 
hexacyanoferrate.
After the first report in 1995 (Smail et al., 1995) of the presence of dityrosine in C. 
albicans, little was known regarding its biosynthesis. The recently completed C. 
albicans genomic sequence revealed a homologue of the S. cerevisiae CYP56 present 
within this genome. Hence, it was of interest to characterise the role of this gene 
product both in the formation of dityrosine in C. albicans as well as its contribution to 
the life-cycle of the organism. This chapter describes experimental results undertaken 
to evalutate the biochemistry of the C. albicans CYP56 and gene knock-out 
experiments to decipher it physiological role. Furthermore, given that cytochromes 
P450 can be drug targets, such as CYP51 in azole antifungal chemotherapy, a 
discovered key role for CYP56 in C. albicans biology may proffer this enzyme as a
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potential drug target for antifungal chemotherapy. Therefore, the role of the CYP56 
gene in C. albicans growth, drug susceptibility and virulence by undertaking gene 
disruption in this diploid pathogen was undertaken as well as its affinity for azole 
antifungal compounds being assessed.
4.2. Materials and Methods
4.2.1. Gene sequence of C. albicans DIT2
In the current assembly (assembly 20) of the C. albicans SC5314 genome 
sequence, the sequence of the DIT2 gene is incomplete at the 5’ end, probably due to 
an unfinished gap. In order to complete the annotation of C. albicans DIT2 gene 
sequence, DITFOR and DITREV primers were designed to amplify the entire DIT2 
gene based on the sequence of the homologous C. dubliniensis DIT2 gene, and are 
listed in Table 2.3. The gene was amplified by PCR as previously described (Chapter 
2.11.1), using genomic DNA template from C. albicans strain SC5314. The PCR 
product was cloned in pGEM T-easy vector for sequencing to reveal the complete 
DIT2 sequence.
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4.3. Results
4.3.1 Deletant C albicans homozygous CYP56 strain construction.
The DNA sequence of the region spanning the gap in the genomic information was 
elucidated using PCR to generate the appropriate DNA fragment. The CYP56 gene 
was then aligned against the deposited C. albicans genomic sequence using the 
computer program Clustal X. The entire CYP56 gene sequence was found to be 1.43 
kb long (Fig. 4.1 and 4.2), similar in length to the C. dubliniensis sequence as 
previously described in chapter 2.
Since C. albicans is diploid, the construction of a homozygous mutant, defective in 
CYP56 in both alleles, required recycling of the resistance marker after insertion into 
the first allele of the target gene in order to allow a second round of transformation to 
inactivate the remaining wild type allele (Fig. 4.2). Consequently, the SAT1 flipping 
method was used, which is a highly efficient and convenient strategy for targeted gene 
disruption in C. albicans (Chapter 2, Fig. 2.6, adapted from Reuss et al. 2004).
A ‘knock-out’ mutant was constructed by using a cassette that contained the antibiotic 
resistance marker nourseothricin and a Candida adapted FLP gene that allowed the 
excision of the cassette following growth on maltose (Fig. 2.6). Two rounds of 
integration and excision were necessary to create the homozygous mutant. The 
structure of the SAT1 flipper cassette consisted of the MAL2 promoter, the Candida- 
adapted FLP gene (grey arrow), transcription termination sequence of the Candida 
ACT1 gene, the main nourseothricin resistance cassette and the FLP recombination 
sequence.
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Figure 2.6 B shows the cassette and the upstream and downstream sequence regions 
of CYP56 to which probes 1 and 2 were designed. The coding region (white arrow) of 
the gene was replaced with the flipper cassette during recombination. The primer pairs 
CYP56KF/CYP56XR and DITSIIF/DITSIR were used to amplify the 5’ and 3’ non­
coding flanking regions of the CYP56 gene using SC5314 DNA template (Fig. 4.3 A). 
Following cloning into pBluescript II, plasmids were then digested with KpnVXhol 
and SaclVSacl restriction enzymes, respectively, to release these inserts for sequential 
ligation to the caSAT1 cassette, and the resulting product was transformed in DH5atm 
E. coli cells. The insertion of both fragments was confirmed by digestion (Fig. 4.3 B). 
The C. albicans wild-type laboratory strain SC5314 was then transformed by 
electroporation with a linear DNA fragment in which the ca&477 cassette containing 
the nourseothricin antiobiotic marker was flanked by 5 'and 3' CYP56 DNA (Fig. 4.4 
A). Transformants were obtained after 2 days of culture on YEPD agar plates 
containing 200 pg.ml'1 of nourseothricin (Fig. 4.4 B). Six resistant colonies were 
picked and used for overnight broth cultures for DNA isolation and PCR screening. 
PCR amplification was performed using the primers CYP56KF which bound 
upstream of the CYP56 coding sequence and FLP1 which bound within the cassette. 
The resulting PCR confirmed that all six colonies exhibited recombination with 
inactivation of one copy of the CYP56 gene and consequently insertion of caSATl 
cassette (Fig. 4.4 C). Thus, the transformants were further inoculated into YEPD 
broth without nourseothricin to allow for FLP-mediated excision of the SAT1 flipper 
cassette.
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The recovery of sensitivity in derivative strains was confirmed from cultures grown 
on YEPD agar plates containing 100 pg.ml'1 of nourseothricin (Fig. 4.4 F and 4.5). 
One derivative strain, A1-R1-6CS, was employed to inactivate the remaining wild- 
type allele using the same procedure of integration and subsequent excision of the 
SAT1 flipper cassette (Fig. 4.4 D), which generated A2-S1R derivative strains. 
However, to allow for FLP-mediated excision of the SAT1 flipper cassette, it was
c
again necessary to grow in broth overnight. The recovery of sensitivity in A2-S3A 
derivative strains was confirmed after culture on YEPD agar plates containing 10 
lig.ml'1 of nourseothricin. Nourseothricin sensitive derivative A2-S3As strains had a 
smaller colony size compared with their A2-S1R parental strains in the presence of this 
concentration of antibiotic (Fig. 4.4 E). Twenty-six colonies were screened by PCR 
analysis using the primers CYP56KF and CYP56SER, and only 2 A2-S3As colonies 
gave a single PCR product of lkb, indicating a homozygous mutant had been 
produced (Fig. 4.4 E). Correct integration was confirmed by Southern hybridization 
with probes from the CYP56KF and CYP56XR upstream region. Southern analysis 
showed that all A2-S3As had excised the SAT1 flipper by FLP-recombination (Fig. 
4.6), inactivating the CYP56 gene. Heterozygous CYP56/cyp56A deletant mutants 
were compared against the double cyp56A/cyp56A mutants and the wild-type strain in 
phenotypic tests.
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4.3.2 Reintegration of wild type CYP56 gene into the cyp56A homozygous mutant.
To confirm that observed mutant phenotypes were indeed caused by disruption of the 
target gene, a functional CYP56 copy was reinserted into the homozygous cyp56A 
mutants. For this purpose PCR amplification of the CYP56 gene was performed using 
wild-type SC5314 genomic DNA as template. Once the isolated CYP56 gene 
sequence was verified as identically matching the genome sequence, CYP56 gene was 
inserted into CIp20 plasmid (Fig. 4.7), which is a derivative of CIplO described by 
Murad (Murad et. a l 2000) containing the SATJ nourseothricin resistance marker (G. 
Moran, unpublished). The linearization of the CIp20 plasmid containing the CYP56 
gene was performed by digestion with Ncol and transformed by electroporation into 
the homozygous A2-S3As derivative strain. By homologous recombination of the 
linearized CIp20 plasmid to the chromosomal RP10 locus (Fig. 4.7), this allowed the 
insertion of the CYP56 gene into the chromosome of the A2-S3As derivative strain. 
The putative re-integrants were sub-cultured in YEPD broth for DNA isolation and 
for PCR screening to confirm their identity. Using primers CYP56KF and RT300 the 
insertion of the intact CYP56 gene was verified in the A2-S3 As derivative strain. Two 
PCR products with sizes of 2kb and lkb corresponding to intact gene and inactivated 
allele, respectively were evident (Fig. 4.8). To verify the correct placement of the 
intact gene, clones were analysed by PCR using primers TEM1R (which binds 
downstream of the RP10 gene) and ACTIO (which binds within CIp20) resulting in 
products of 2kb as expected in a confirmatory study (Fig. 4.8).
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4.3.3 Phenotypic analysis of the cyp56\ homozygous mutant.
4.3.3.1 Antifungal susceptibility testing.
The MICs to various agents was determined by broth methods as illustrated in Table
4.1. The experiments revealed no differences in the MICsos for VOR, FLC, ITCZ, 
CLT, AMB, NYS, and CAS between homozygous cyp56A mutant and wild-type 
strain. Both strains were sensitive with low endpoints for all drugs tested in 
comparison to NCCLS guidelines. MICs were lower for some drugs when minimal 
medium was used in place of RPMI broth (Table 4.1). The only antifungal agent 
which exhibited an altered MIC towards the cyp56A mutant compared to wild-type 
was NIK, for which the homozygous cyp56A strain exhibited a two-fold lower MIC in 
both media tested.
4.3.3.2 Antifungal Etest reading.
Plates containing Etest strips for antifungal susceptibility tests were incubated for 24- 
48 hours in a moist incubator until growth was clearly seen. The MIC was read when 
the elliptical inhibition zone intersected the scale on the strips and compared with 
Etest reading and interpretation guidelines. The strains had insufficient growth after 
24 h of incubation and consequently were read at 48 h. The homozygous cyp56A 
mutant and wild-type strains showed similar susceptibility and endpoint for all the 
drugs tested (Fig. 4.9).
151
Ta
bl
e 
4.1
. 
Su
sc
ep
tib
ili
ty
 
tes
tin
g 
of 
the
 W
T 
an
d 
ho
m
oz
yg
ou
s 
m
ut
an
t
fS
o
<Nun
w W) 
CO I
« E
o oN
bX -
55 -a  
C/5 bJj
4.3.3.3 Analysis of cyp56\ mutant and wild-type strain growth curves in the 
presence and absence of antifungal agents and cell wall alteration assays.
Although MICs demonstrated two-fold differences in susceptibility to NIK in cyp56A 
mutant and wild-type strains, growth curves were investigated as a more sensitive tool 
to examine the effects of deletion of the CYP56 gene in laboratory media. In particular, 
casponfungin and nikkomycin caused slower growth of the cyp56A mutant strain in 
comparison to the wild-type strain in either RPMI or YM broth medium (Table 4.2). 
The remainder of the drugs tested showed no differences on the growth of mutant or 
wild-type strains (Fig. 4.10 A).
To determine the effect of deleting CYP56 gene on the integrity of the cell wall, the 
null mutant was tested for sensitivity to a range of cell wall-perturbing agents and 
other agents whose effects have been associated with altered cell walls. Cell culture 
on YEPD broth supplemented with 1.5 M sorbitol, 100 pg.ml'1 SDS, 1 M or 1.5 M 
NaCl, 5 mM or 10 mM H2O2 , 0.5 M or 1 M CaCl2, 100 pg.ml'1 calcofluor, and 100 
pg.ml'1 congo red, at 37°C for 48 h, did not show changes in the level of sensitivity. 
In order to investigate the effect of glucose on cell growth, cultures of both cyp56A 
mutant and wild-type strains grown on minimal medium with the alternative sugar 
maltose or galactose at 37°C for 48 h. In this condition the homozygous mutant 
showed slower growth compared to wild-type (Fig. 4.10 B). In addition, after 6 h of 
culture the homozygous mutant started to produce hyphae continuously and the wild- 
type strain showed only a budding form. Cell culture in minimal broth medium, 
grown at 42°C for 48 h, also caused an inhibitory effect on growth of the 
homozygous mutant compared to wild-type.
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The susceptibility of cells inoculated on YEPD or YM agar plates supplemented with 
metabolic inhibitors was also investigated. For these studies plates containing 1.5 M 
sorbitol, 100 pg.ml'1 SDS, 1 M or 1.5 MNaCl, 5 mM or 10 mM H2O2 , 0.5 M or 1 M 
CaCh, 100 pg.ml*1 calcofluor, 100 pg.ml'1 congo red, 1 pg.ml'1 itraconazole, 10 
pg.ml'1 amphotericin, and 2 pg.ml'1 fluconazole incubated at 37°C and 42°C were 
investigated. Cells on YEPD agar plates did not reveal any difference in their 
sensitivity of either cyp56A mutant or wild-type strain (Fig. 4.11 and 4.12 A). The 
exception was nikkomycin, which showed an inhibitory effect of 2 fold less (MIC = 
0.5 pg.ml'1) on cyp56A mutant compared to the wild-type strain (Fig. 4.12 B).
In contrast to YEPD medium, cells cultured on YM agar plates did exhibit a mutant 
phenotype. Homozygous cyp56A mutant strains showed a rough colony surface whilst 
the wild-type strain was smooth (Fig. 4.13). Optical microscopy confirmed the 
presence of hyphae in the mutant strain and only yeast cells in wild-type strain grown 
under these conditions (Fig. 4.14). The cyp56A homozygous mutant strain showed 
significantly less growth at 42°C in both YM and YEPD media compared to wild-type 
strain.
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4.3.3.4. Chlamydospore production and hyphal formation.
In commeal broth supplemented with 1% (v/v) Tween 80, wild type C. albicans 
produced abundant chlamydospores after 72 h static growth at room temperature. 
However, the cyp56£s homozygous mutant failed to produce chlamydospores in 
comparison to the wild-type strain (Fig. 4.15 A). This phenotype could be 
complemented by the reintroduction of the CYP56 gene on the plasmid CIp20.
The complemented strain produced chlamysospores in commeal broth, although less 
abundantly and slower (72-96 h) than the wild-type strain. The chlamydospore of the 
wild-type strain revealed a bright fluorescent thick halo when stimulated with UV 
light, in contrast to the cyp56A homozygous mutant which did not produce 
chlamydospores (Fig. 4.15). This fluorescence was also restored in the complemented 
strain (Fig. 4.15 C). Although microscopic features of the germ tube formation were 
similar for both strains, visualization of the effect of Na2SC>3 on hyphal formation 
revealed that the wild-type remained in the yeast form and the mutant was a mixture 
of yeast and hyphal form (Fig. 4.16).
4.3.3.5 Cell fluorescence imagining of cyp56\ mutant and wild-type strains by 
confocal microscopy and fluorescence microscopy.
For fluorescence microscopy, cells were examined using a Nikon Eclipse E600 
epifluorescence microscope. To examine autofluorescence of yeast and hyphae in the 
UV wavelength range, cells were examined using the Zeiss Plan-Achromat 63x, 1.4 
NA objective, 512 x 512 pixel images captured and exported in TIFF format using 
Zeiss laser scanning microscope LSM 510 version 3.2 SP2 software. The cyp56A.
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homozygous mutant exhibited a reduced bluish fluorescence pattern over its surface 
when compared to wild-type strain (Fig. 4.17 A), possibly corresponding to chitin 
which shows autofluorescence. Chitin may also be stained with calcofluor (Fig. 4.17 
C). When both strains were stained with calcofluor localized fluorescent septa areas 
were observed (Fig. 4.17 B). However, the cyp56A mutant strain showed less visual 
fluorescence than the wild-type strain. The chlamydospore of the wild-type strain 
stained with calcofluor revealed a bright fluorescent yellowish thick halo compared to 
the cyp56A mutant strain (Fig. 4.17 B).
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4.3.3.6. Sterol composition comparison of cyp56\ mutant and wild-type strains.
No differences in the sterol composition between cyp56A mutant and the wild-type 
strain (SC5314) were identified with both strains having high level of ergosterol (Fig. 
4.18). Analysis of the sterol composition for both strains in yeast-like form in this 
study revealed that ergosterol was the predominant sterol, accounting for 90% of the 
total sterols present.
4.3.3.7 Synthesis of an authentic dityrosine standard.
Dityrosine is not available commercially and a peroxidase system was used to 
produce a standard for experiments. The enzymatic reaction for dityrosine synthesis 
consisted of JV-formyl tyrosine + H2O2 + HRP, which was optimized in different 
concentration of H2O2 as described in Chapter 2.18.2. The dityrosine synthesized was 
investigated using fluorescence spectrophometry at excitation wavelength of 320 nm 
and emission maximum at 400-405 nm (Fig. 4.19 A). The results were in excellent 
agreement with those published by Briza et. al. (1996). TLC was used to isolate the 
compounds formed as indicated by the arrows in Fig. 4.19 B corresponding to 
fluorescence spots visualized under UV light. The fluorescence measurements from 
the chemical after TLC showed the characteristic spectrum for dityrosine (Fig. 4.19 
C). The dityrosine synthesized was used as a control for identification of dityrosine in 
cell extractions and CaCYP56p enzyme reconstitution assays.
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4.3.3.8 Extraction of Dityrosine from Cells.
Cell walls of yeast and hyphae from wild-type and homozygous mutant strains were 
prepared by vortexing intact organisms with glass beads, centrifugation, and extracted 
with chloroform:methanol. In parallel dityrosine synthesized in vitro was used as a 
control. Dityrosine was not detected in the yeast cell extracts from any strains studied 
by HPLC/MS. Cell walls of chlamydospore from wild-type and homozygous mutant 
strains are still undergoing at the time of submission of this work.
4.3.4 Biochemical analysis of recombinant C. albicans CYP56.
Following heterologous expression in E. coli and isolation of membrane fractions, 
recombinant C. albicans CYP56 was shown to be present in the microsomal fraction. 
Furthermore, a characteristic peak at 450 nm was obtained when the protein was 
reduced in the presence of carbon monoxide (CO) as demonstrated by 
spectrophotometry (Fig. 4.20). Control cells containing empty expression plasmid did 
not exhibit the peak at 450 nm in reduced carbon monoxide difference spectra. 
CYP56 was purified as described previously and exhibited a slight red-brownish band 
during Ni-NTA purification through the Ni-NTA agarose matrix. The purified protein 
was visualized by SDS-PAGE gel showing a molecular mass of 55 kD (Fig. 4.21).
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4.3.5 Spectral studies on CYP56 substrate binding.
In the presence of N-formyl tyrosine, CYP56 produced a Type I substrate binding 
spectrum. The substrate binding was demonstrated using the microsomal enzyme 
system and A-formyl tyrosine as substrate. The substrate affinity of the protein was 
high with a calculated Ks of 26 nM (Fig. 4.22). Furthermore, binding of A-formyl 
tyrosine to CYP56 appeared to be allosteric with an observed Hill number of 1.6, 
suggesting the binding of two substrate molecules in the active site in CYP56.
4.3.6 Reconstitution of CYP56 activity.
In reconstituted enzymatic activity experiments, C. albicans CYP56 and S. cerevisiae 
CPR proteins were incorporated into DLPC micelles prior to the addition of substrate 
and initiation of the reaction with NADPH. TLC was employed for the identification 
of dityrosine bands produced in the reaction. Additionally, HPLC methods also 
permitted the separation of N- formyl dityrosine from substrate produced in this 
reaction. When reconstituted into DLPC micelles, CYP56 catalyzed the conversion of 
A-formyl tyrosine into N- formyl dityrosine (Fig. 4.23). Controls in which NADPH 
was omitted did not produce dityrosine. The mass spectrum of the generated authentic 
dityrosine had a molecular ion of m/z 315. The reconstitution assay revealed that 
CYP56 fraction converted A-formyl tyrosine through to the oxidation product N- 
formyl dityrosine (m/z=315) in the presence of CPR and NADPH. The retention time 
of this molecule under the HPLC conditions used was 21 min'1 (Fig. 4.24).
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4.3.7 Bioinformatic analysis of C. albicans CYP56.
The available resolved CYP crystal structures show that the general overall CYP 
tertiary fold is preserved during evolution from bacteria through mammals (Nelson, 
1999, Kelly et al., 2001). At the same time, there are variable regions that appear to be 
associated with recognition and binding of structurally diverse substrates and redox 
partners (Podust et al., 2001). Using BLASTP 2.2.14 NCBI we have performed the 
alignment of CYP56 between C. albicans and S. cerevisiae consisting protein lengths 
of 477 and 489 amino acids respectively. They were found to be 46% identical as is 
shown in the Fig. 4.25.
The regions corresponding to I helix, K helix and the active site (involving at its base 
the binding of haem to a cysteine residue in red) are in the box marked with the 
consensus sequence (Fig. 4.25). The I Helix is thought to be central to catalytic 
function of CYP’s (Gotoh, 1993) and is thought to play a part in proton delivery and 
dioxygen binding (Poulos et al., 1987). The amino acid sequences of the haem 
binding sites were HGRKRAC and HGGRRAC for C. albicans and S. cerevisiae 
respectively, therefore showing only two amino acids varying. However the location 
of a cysteine residue was conserved for both as expected for active cytochromes P450 
in order to provide the fifth ligand for the haem.
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4.4. Discussion
After the first report of the presence of dityrosine in C. albicans in 1995 (Smail et al., 
1995), few studies have addressed the contribution of dityrosine related to the biology 
of this organism. This was surprising since the cell wall of C. albicans is of active 
interest as a target for new drugs and because of its role in pathogenicity and 
immunogenicity. The role of the novel CYP56 gene present in C. albicans in growth 
and drug susceptibility was investigated here.
Sequencing of the C. albicans genome (Nantel, 2006) has allowed advances in the 
study of functional genomics, leading to a better understanding of the role of specific 
genes in the biology and virulence of this pathogenic fungi. A widely accepted and 
direct approach to assess the physiological function of a gene is to inactivate the gene 
by targeted mutagenesis. In this present study this has been achieved by using the 
SAT1 flipping method (Reuss et al., 2004) which is a highly efficient way to construct 
a homozygous knock out mutant in the diploid C. albicans. The DNA sequence of C. 
albicans CYP56 gene sequence was revealed and using genomic DNA template from 
C. albicans strain SC 5314 and primers designed from the full-length C. dubliniensis 
CYP56 gene sequence available in the database (Dr. G. Moran, data unpublished), the 
gene isolated and a deletion construct produced. Subsequent deletion of the CYP56 
gene from the C. albicans genome allowed the characterisation phenotypically and 
biochemically of the homozygous cyp56k mutant against the wild-type strain, 
especially in terms of features associated with the cell wall, viability, natural 
fluorescence associated with the presence of dityrosine and sensitivity to antifimgal 
drugs.
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Susceptibility testing for the drugs tested revealed no important differences in the 
MICs values for cyp56A mutant and the wild-type strain. The Etest data reinforced the 
similarity in the MIC results for both strains. Although the MIC endpoint values have 
not shown remarkable difference, when the cell growth kinetics were investigated 
differences between homozygous cyp56A mutant and wild-type strains were observed. 
However, one exception was nikkomycin which showed a 2 fold lower MIC for the 
cyp56A homozygous mutant compared to the parent strain. The slower growth at sub- 
inhibitory concentrations of casponfungin and nikkomycin in the cyp56A homozygous 
mutant strain was clear and reproducible between experiments. Considering 
caspofiingin is glucan synthase inhibitor and nikkomycin is a chitin synthase inhibitor, 
and both contribute to cell wall structure, the results from this study suggest an 
alteration of glucan and chitin structure in the cyp56A homozygous mutant strain. 
Hence, dityrosine may play a key role in cell wall arrangement or possibly have a role 
in the order of layer deposition in the cell wall. Chitin and glucan composition of the 
mutant should be investigated in future studies. It is known structural composition of 
the cell wall varies according with form. Ruiz-Herrera and collaborators (Ruiz- 
Herrera et al., 2006) have indicated in their work that hyphae showed 6% chitin 
composition whilst yeast forms only 2%. In the case of glucan, this was 56% in the 
hyphae and 60% in the yeast form.
The deletion of CYP56 had a profound effect on chlamydospore formation in C. 
albicans. This was not surprising due to the essential nature of dityrosine in the 
formation of the spore wall in S. cerevisiae. The cyp56A mutant failed to form 
chlamydospores in commeal broth, whereas the wild-type formed abundant spores.
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Interestingly, the wild-type spores had thick walls that fluoresced strongly under 
stimulation with UV light. This fluorescence was paler and more intense than the 
natural blue chitin fluorescence seen in hyphae and yeast cells in the same cultures. It 
is tempting to speculate that this fluorescence in chlamydospores is due to the 
presence of dityrosine. Although dityrosine may also be present in yeast cells, we 
observed little difference in the levels of fluorescence between wild-type and mutant 
yeast cells. This was probably due to the background levels of blue fluorescence from 
chitin in the cell wall. Further experiments will be required in order to determine if 
dityrosine is present in the yeast wall and if the CYP56 gene is expressed during 
vegetative growth. The increased susceptibility of cyp56A mutant yeast cells to 
nikkomycin suggests some role for dityrosine in this growth form.
Yeast cells normally form smooth, white dome-shape colonies, however at low 
frequency, C. albicans can reversibly convert a variant colony shape, i.e. wrinkle, in 
which the colonies are composed of a mixture of yeast and filamentous cells. In our 
study this phenomenon was expressed in the cyp56A mutant strain grown in minimal 
medium agar. However this was also seen in minimal medium broth wher the cyp56A 
mutant strain had shown hyphal production in contrast to wild-type strain that 
exhibited only a yeast-like form. Here the deletion of CYP56 gene suggested that it 
has switched a possible hyphal formation regulatory system or expression of genes 
associated with hyphal formation under the conditions of growth investigated.
The ability to switch between yeast and hyphal morphologies is often suggested to be 
relevant for virulence (Sudbery et al., 2004). Filamentous growth allows cells in a 
starving colony to extend its borders and forage for nutrients. Different responses are
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exhibited by the cells when deprived of nutrients: for example, glucose depletion 
favours growth arrest, whereas ammonium depletion favours filamentous growth. On 
the other hand both wild-type and cyp56A mutant strains during the first five hours 
shaking in minimal medium have shown hyphal formation, but after 6 h of incubation 
the wild-type reverted to yeast-form and the cyp56A mutant strain produced hyphae 
continuously. To investigate the hyphal production of the cyp56A mutant in 
anaerobic conditions, Na2S0 3  was added to RPMI medium. After 24 hours the wild- 
type has shown only yeast forms during growth compared to the cyp56A mutant 
which exhibited a mixture of yeast and hyphal form (Fig. 4.16). The CYP56 re­
integrant strain showed reversal of the phenotypes observed in the homozygous 
cyp56A mutant. The susceptibility of the reintegrant to nikkomycin and caspofungin 
was similar to the results shown by wild-type strain. A similar result was found for the 
hyphal production phenotype among reintegrant and wild-type cultures. The ability to 
produce chlamydospores was also recovered by the reintegrant strain.
Overexpression of CYP56 was achieved in E. coli and CYP56 was localised in the 
microsomal and cytosol fractions, with a characteristic Soret peak at 450 nm when the 
protein was reduced in the presence of carbon monoxide (Fig. 4.20). The enzymatic 
activity was also confirmed in catalysing C-C bond linkage for the first time in vitro. 
Finally the substrate A-formyl tyrosine bound to CYP56 with an affinity typical of a 
natural substrate for a cytochrome P450. Binding two substrate molecules per CYP56 
was important as this P450 was predicted to be involved in coupled two substrate 
molecules together.
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In conclusion, CYP56 is not essential for growth in C. albicans. However, in this 
work the null CYP56 double allele mutant exhibited phenotypes that implicated 
associated endogenous functions to cell wall structure. The increased sensitivity of 
the cyp56£s mutant to two different cell wall inhibitors may reflect the ability of this 
organism to compensate for the absence of the deleted gene possibly by shifting other 
components of the cell wall composition. Among other phenotypes, activating the 
hyphal form of growth in the mutant was an unexpected phenotype. Additionally, the 
absence of chlamydospore production by the cyp56A mutant strain indicates that 
CYP56 is essential during chlamydospore formation and implicates a possible key role 
for dityrosine in this specialized cell wall structure. Chlamydospores have been 
isolated recently from AIDS patient and have also been associated to Candida 
virulence (Nobile et al., 2003) and this could be an important characteristic of 
dityrosine requirement and involvement as a pathogenicity factor.
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CHAPTER 5
General Discussion
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Historically C. albicans has been the most common fungal pathogen. 
However, in recent years there has been a shift in the spectrum of Candida infections 
(Nguyen et al., 1996, Melo et al., 2004). Several factors might be responsible for the 
emergence of non-albicans species (Mujica et al., 2004, Mullen et al., 2003) and this 
has also altered the focus of studies on azole mode of action and resistance. There is 
an increasing population of severely immunocompromised patients who are at risk for 
developing infections. Particularly vunerable are those receiving chemotherapy and 
the increased use of antifungal agents may select for non -albicans spp. that exhibit 
decreased susceptibility to these agents. Prophylactic use of fluconazole has been 
associated with resistance in C. albicans and linked to the emergence of C. krusei and 
C. glabrata infections..
The failure of antifungal agents to treat certain patients with Candida infections is 
well recognized (Salavert Lleti et al., 2006, Tortorano et al., 2003). Several factors 
contribute to therapeutic failure including severity of the underlying illness, impaired 
host immune function, persistent infection or retained intravascular catheters or 
prosthetic devices. Antifungal resistance also involves the emergence of naturally 
resistant species or progressive, stepwise alterations of cell structure(s)/function(s) to 
avoid the activity of an antifungal agent to which there has been extensive exposure. 
Over the past decade, significant advances in in vitro antifungal susceptibility testing 
have been made with the development of a standardized, broth based testing 
methodology that demonstrates reproducibility (National Commitee for Clinical 
Laboratory Standard, 2002).
The rise in severe fungal infections has prompted the development of new antifungal 
agents with novel modes of action. Because of their eukaryotic nature, fimgal cells
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have a restricted set of specific targets that do not overlap with their mammalian 
counterparts (Miura et al., 2003). However, the cell wall is a structure that is essential 
for the fungus and absent from the mammalian host, and so it presents an attractive 
target for the development of new antifimgals (Orozco et al., 1998). Various 
antibiotics have been reported to interfere with the formation of fungal cell walls. For 
example, nikkomycins are inhibitors of chitin synthesis, echinocandin interfere with 
glucan metabolism and tunicamycin is an inhibitor of the glycosylation of 
mannoproteins (Elorza et al., 1987). One potential new target studied in this project 
was the cytochrome P450 undertaking dityrosine formation in C. albicans that could 
be an azole-based target, but it was found to be a non-essential gene.
Additionally, part of the present study investigated different Candida species in terms 
of antifungal susceptibility and associated mechanisms of resistance. Antifungal 
susceptibility, demonstratable by significant increases in MIC values varied greatly 
among different Candida isolates. The intracellular drug concentration levels, which 
also reflect a balance of azole uptake and active efflux, also varied and were species 
dependent. Other Candida spp. such as C. krusei, C. lusitaniae and C. novergensis 
exhibited a high intracellular [3H] fluconazole concentrations. However no significant 
correlation with MIC values or ergosterol content was found suggesting this 
measurement has questionable value. Tolerance to high level of concentrations of 
fluconazole exhibited by some non-albicans isolates can partially explain resistance 
but overall the data supported the multiplicity of antifungal resistance mechanisms.
Variation in ergosterol levels compared to the total sterol content were also observed 
in the strains studied. Altered ergosterol levels did not adversely effect the growth
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observed in one C. krusei strain. This demonstrates the capacity of some strains to 
grow despite significantly reduced levels of ergosterol being present. In many 
circumstances resistance can lead to the understanding of specific mechanisms of 
action of different antifungal drugs. The mechanisms involved in controlling 
susceptibility to antifungal agents observed in many of the strains studied here still 
remain unclear.
The main causative agent of oropharyngeal candidosis is C. albicans (Odds, 1988). 
Infection by C. albicans generally involves adherence and colonization of 
superficial tissues (Felk et al., 2002, Kretschmar et al., 1999, Lo et al., 1997). 
During this process, budding yeast cells are able to transform to hyphae and 
penetrate deep into the tissue (Odds, 1985). C. albicans produces hyphal growth 
under a wide range of conditions, including growth in blood serum, at 37°C, and at 
neutral pH (Sudbery et al., 2004). Upon return to favourable conditions, the 
morphological program can be reversed. The control of the cytoskeleton and cell 
cycle are both critical elements of the transition from yeast-hyphal form and vice- 
versa. Understanding the biology of the different specialized cell type may be 
crucial in determining strategic points in terms of the development of fungicidal or 
fungistatic target(s) in the cell. Hyphal formation is considered to be necessary for 
virulence. Several antifungal susceptibility tests such as microdilution (NCCLS), 
agar diffusion (Hewitt, 1981) and flow cytometry are designed to work primarily 
with yeasts and yeast-like fungi. However, for filamentous fungi or hyphal invasion, 
these standard antifungal susceptibility tests do not accurately determine the 
effectiveness of a drug as an antifungal agent.
192
Understanding the processes affecting the yeast to hyphal balance was illuminated in 
studies on the C. albicans CYP56 presented herein. Disruption of this gene caused 
growth to be altered compared to the parental strain grown under the same conditions. 
It is generally believed that pathogenic fungi such as C. albicans, have a very similar 
polysaccharide composition but differ significantly in their cell wall proteins, which 
underscores the importance of such cell wall proteins involved in pathogenesis. This 
may not be the case for the presence of dityrosine, which is absent in vegetative S. 
cerevisiae but may be present in C. albicans (the subject of ongoing work in the 
laboratory). The spore walls in S. cerevisiae are formed by the ordered synthesis of 
the different layers: first mannan, then P-glucan, then chitosan, and finally outside the 
chitosan layer is a layer that consists largely of cross-linked tyrosine molecules (Briza 
et al., 1988, Briza et al., 1990, Briza et al., 1994). Dityrosine was first identified in 
the spore wall of S. cerevisiae in 1986 (Briza et al., 1986, Briza et al., 1994). In 
contrast the first report of the presence of dityrosine in C. albicans was in 1995 
(Smail et al., 1995). In the present study CYP56 was investigated regarding its 
contribution to the biosynthesis of the cell wall in C. albicans. It was demonstrated 
that the CYP56 null mutant was not essential for growth. However, interesting 
phenotypes associated with the biosynthesis of the cell wall structure and antifungal 
susceptibility were observed. The hypersensitivity of the cyp56A mutant to two 
different cell wall inhibitors suggests an accentuated vulnerability of the targets of 
these agents through a possible alteration in the cell wall composition. The activation 
of the hyphal form in the cyp56A mutant when the parent strain grew in a yeast form 
was an unexpected phenotype. The phenotypes described here suggest an important 
role for dityrosine in maintaining cell wall integrity in vegetative cell growth. 
Additionally, a further phenotype of the mutant indicated an essential role for CYP56
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in the formation of chlamydospores. Chlamydospores develop from hyphal cells, so 
the precise basis of this fundamental alteration in cell biology requires further study, 
although one can speculate.
One distinct property of C. albicans is its ability to produce chlamydospores, an 
ability shared only with the closely related species C. dubliniensis. Chlamydospores 
are large, highly refractile cells with thick cell walls that form on the ends of 
elongated suspensor cells attached to the hyphae and, occasionally, to pseudohyphae 
(Odds, 1994). They are rich in RNA content (Vidotto et al., 1996) and in some cases 
can germinate (Sudbery et al., 2004). Under nutrient poor, oxygen-limited conditions 
and at low temperatures chlamydospores can be induced (Calderone and Fonzi, 2001). 
In commeal agar, which is the typical inducing medium used in vitro, both light and 
glucose inhibit chlamydospore formation (Nobile et al., 2003). Chlamydospores have 
been found in the lung of AIDS patients (Chabasse et al., 1988), and thus may be 
relevant to infection. The genetic requirements for chlamydospore formation are of 
interest for several reasons. Chlamydospores are the output of a developmental 
process. It is unclear why the C. albicans genome has so many genes without close 
homologues in other organisms but the possibility that they play a role in C. albicans 
specific processes, such as chlamydospore formation, may explain their presence. 
Some conserved regulatory pathways respond to well-defined signals, so 
identification of chlamydospore regulators may reveal the specific external signals 
that govern their formation. Finally, because chlamydospores form under growth 
conditions that are not routinely employed for C. albicans cultivation in the laboratory, 
their genetic requirements may reveal unique functional relationships, biological roles 
or regulatory signals that govern activity of known gene products.
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The fungal cell wall is essential for maintaining the osmotic balance of the cell as well 
as contributing to its physical strength. The macromolecular components of the cell 
wall for the majority of fungi include chitin, a or p-glucan and mannoproteins 
(Coluccio et al., 2004, Ruiz-Herrera et al., 2006, Miura et al., 2003, Smail et al., 1995). 
These components may vary in composition depending on the phase of the cell cycle, 
environmental conditions and the developmental stage of the organism. C. albicans is 
found as a yeast form when growing saprophytically but often adopts a hyphal form 
when it colonises tissue. The transition from one cellular form to the other is 
associated with changes in the composition of the cell wall polymers (Murgui et al., 
1986). The linkages between the glucan, chitin, and mannoprotein in the C. albicans 
cell wall are poorly understood but presumably play a critical role in maintaining the 
integrity of the organism. Although S. cerevisiae contains only 2-3% of chitin in its 
cell walls, the synthesis of this polymer seems to be essential for cell growth and 
survival (Selvaggini et al., 2004). Since cell wall components are crucial for fungal 
cell development, chitin and glucan biosynthetic steps have been attractive targets for 
the development of novel antifungal inhibitors (Cassone, Mason et a l , 1981; 
Maschmeyer e Ruhnke, 2004). Hence, the biosynthesis of dityrosine in the C. 
albicans cell wall may yet bring novel insights regarding the understanding of C. 
albicans cell biology and possibly identify a novel drug target. Although the 
production of dityrosine is not essential for growth and azole antifungal susceptibility 
was unaltered in the cyp56A mutant, synergistically altering the susceptibility of C. 
alicansi to other drugs could be a route to combined drug therapy.
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To assess the structure/function of CYP56, overexpression of the protein was obtained 
in E. coli and CYP56 was found to be located in the membrane fraction. For fungal 
CYP to exert its catalytic activity it requires a source of reducing equivalent usually 
provided by P450-reductase (CPR). CPR is a microsomal-bound flavoprotein which 
transfers electrons from NADPH to the CYP molecule allowing the molecular 
scission of atmospheric dioxygen. Accordingly, reconstitution of CYP56 required its 
insertion into a lipid micelle together with a CPR, in this work S. cerevisiae CPR. 
When reconstituted into DLPC micelles, CYP56 catalyzed the dimerisation of N- 
formyltyrosine in the biosynthetic reaction proposed by Briza (Briza et al., 1996). 
Here we demonstrated in vitro for the first time the proposed pathway of dityrosine 
biosynthesis in Candida albicans.
CYP enzymes constitute a superfamily of haem-thiolate containing proteins and are 
involved in metabolism of both exogenous and endogenous compounds. The 
alignment of C. albicans and S. cerevisiae CYP56 revealed 46% homology. C. 
albicans is closely related to S. cerevisiae and it was of interest that it has CYP56 as 
well. S. pombe is more distantly related, perhaps branching from yeast 500-1000 
million years ago. Both CYP51 and CYP61 are found in all three species, but CYP56 
is present only in S. cerevisiae and C. albicans. It seems probable that CYP56 
evolved from CYP51 or CYP61 and that the ancestral yeast may have had only the 
two CYPs and not three. However it is also possible that S. pombe has lost DIT2 
during ascomycete evolution.
Drug resistance in Candida spp. including C. albicans and other fungi has given an 
important impetus to the detailed investigation of specific mechanisms of resistance
196
to assist in selecting the appropriate antifungal agent to treat refractory fungal 
infection(s). The availability of molecular genetic tools has led to a rapid enrichment 
in our understanding of the mechanisms by which antifungal resistance emerges and 
spreads. This will also be an important route for the development of novel, potent and 
safer agents in the future. Once the diversity of resistance mechanisms is established, 
the identification of new resistant determinants in pathogenic fungi may also give the 
opportunity to define new targets for the design of alternative and effective antifungal 
agents as outlined in the present thesis.
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